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2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a highly lipophilic polyaromatic 
hydrocarbon and a persistent environmental contaminant. In the human epidermis, TCDD 
causes enhanced proliferation and altered, accelerated differentiation. However, 
epidermal differentiation, mediated by calcium (Ca), opposes and attenuates proliferative 
signaling, driven by the epidermal growth factor receptor (EGFR). Using a monolayer 
cell culture model, confluent NHEKs were treated with high Ca (1.8 mM) or TCDD (10 
nM). EGFR down-regulation, signaling, and proliferation were then examined to assess 
the proliferative capacity of differentiating skin versus pathophysiological, TCDD-
mediated differentiation. We found that while Ca and TCDD caused marked (~50% and 
~30%) loss of [
125
I]-EGF binding, the effects of this down-regulation differed. ERK 
activity decreased 45% in Ca-treated cells and increased 300% in TCDD-treated cells. 
Utilizing ligand-specific ELISAs to interrogate cell-secreted EGFR ligands which might 
drive ERK activity, we found that Ca increased transforming growth factor-alpha (TGF-
α) secretion, while TCDD increased TGF-α and EREG secretion relative to basal cells. 
Amphiregulin (AREG) increased with time in all treatments. Inhibiting ligand secretion 
with the MMP inhibitor, batimastat, or action with ligand-specific neutralizing antibodies 
in TCDD-treated cells reduced the increased ERK activity to basal levels but could not 
rescue ERK activity in Ca-treated cells. Similarly, in TCDD-treated NHEKs, 
neutralizing AREG or EREG reversed EGFR down-regulation, and removal of TGF-α 
further reduced biotin-EGF binding. In Ca-treated cells, neutralizing EGFR ligands had 
no effect on EGFR down-regulation. We then investigated how these treatments 
 vi 
influenced proliferative capacity of cell populations through dsDNA quantitation and 
EdU labelling. We found that while Ca-treatment led to ~15% fewer cells than basal they 
still retained an equal (~5%) amount of EGFR-dependent proliferating cells. Conversely, 
TCDD-treatment led to equal cell numbers relative to basal cells, both of which were 
reduced following ligand neutralization. However, TCDD-treatment led to a significant 
increase in the population of proliferating cells (~8%) relative to basal.  Taken together, 
our data suggests that in Ca-treated cells, EGFR down-regulation is ligand-independent 
and correlated with a loss of proliferative signaling capacity while TCDD-treated cells 
down-regulate the EGFR in a ligand-dependent manner, and that TGF-α retains a 
population of surface-associated receptors which may drive increased proliferation.   
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PREFACE 
This dissertation is presented in four chapters including two manuscripts. Chapter 
One introduces the current research and frames the experimental question and approach. 
Chapter Four ties together results and conclusions from Chapters Two and Three. The 
second chapter, entitled “Calcium causes ligand-independent EGFR down-regulation,” 
contains the manuscript which is in preparation for submission to the Journal of Cell 
Science. Chapter Three entitled “Role of EGF Receptor ligands in TCDD-induced EGFR 
down-regulation and cellular proliferation” is published in Chemico-Biological 
Interactions volume 253, 23 April 2016. Both manuscripts are written in the format 
which aligns with the guidelines set forth by their respective journals. Chapters One, 
Four, and the Appendix are referenced in accordance to the guidelines of the journal 
Endocrinology. 
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Rationale for this Study 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) causes seemingly contradictory 
phenotypes of epidermal hyperproliferation and  accelerated, though altered, keratinocyte 
differentiation (1-5). Previous findings from our lab show that this occurs through an 
epidermal growth factor receptor (EGFR)-dependent mechanism which can be attenuated 
by the use of an EGFR-inhibitor or an EGFR-specific neutralizing antibody (6). The 
literature is divided as to how this phenomenon occurs; several studies suggested that 
TCDD stimulates the synthesis and release of EGFR ligands (7-9) while others suggested 
that the EGFR is instead activated in a ligand-independent way, such as through 
transactivation by phosphatidylinositol-3 kinase (PI3K)- activated phospholipase Cγ 
(PLCγ) (10) or through the non-receptor tyrosine kinases (RTK) such as c-src (11, 12). 
However, work from several laboratories show that TCDD and calcium (Ca), the 
physiological modulator of keratinocyte differentiation, cause EGFR down-regulation 
from the cell surface (13-15). EGFR down-regulation, which would attenuate signaling 
seemingly contradicts the requirement for epidermal growth factor (EGF)-like ligands 
and EGFR activation in TCDD-induced proliferation (14).  However, data supporting a 
hyperproliferative role of TCDD in keratinocytes has been equivocal, dependent upon 
endpoint, treatment protocol, and which cell lines have been used (13, 14, 16).  
In this study, we sought to clarify the role of the EGFR and its ligands in mediating the 
TCDD-induced proliferation of normal human epidermal keratinocytes (NHEKs) by 
addressing the following questions: 
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1. What causes the down-regulation of EGFRs observed in Ca differentiated 
or TCDD-treated NHEKs? 
2. Is the loss of EGFRs associated with a reduction in (or the loss of) EGFR 
signaling capacity? 
3. What role do individual EGFR ligands play in EGFR down-regulation and 
proliferation in Ca- or TCDD-treated cells? 
While the literature suggests that crosstalk exists between the aryl hydrocarbon receptor 
(AhR) which binds TCDD, other cellular signaling pathways, and the EGFR (12, 17, 18), 
our work shows that TCDD enhances the secretion of transforming growth factor-α 
(TGF-α) and epiregulin (EREG) while maintaining an environment of high amphiregulin 
(AREG). We further found that neutralization of all three ligands is required to  reduce 
cell number but that neutralization of singular EGFR ligands have unique effects on loss 
of surface-associated EGFR and keratinocyte proliferation.  
Literature Review 
Human exposure to 2,3,7,8-tetrachloro-p-dioxin 
TCDD is a ubiquitous environmental contaminant that is not produced 
intentionally but persists in the environment due to its lipophilicity and production as a 
byproduct in industrial and natural combustion processes in the presence of chlorinated 
waste products (19). TCDD is also a product of pulp bleaching in paper production and is 
thus found as a contaminant in paper products including, alarmingly, some feminine 
hygiene products and diapers at very low levels (20). TCDD is also created during the 
production of some herbicides (19). Agent Orange is the most prominent example, but it 
has also been produced in other milder pesticides (19)—though many of these have been 
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discontinued since by the Environmental Protection Agency (EPA).  Due to heavy 
regulation of TCDD-producing industries, exposure to high levels of TCDD is 
uncommon (19) though lower level exposure is not. 
TCDD is a highly toxic and lipophilic chemical which tends to concentrate and 
persist in the food chain, particularly in fish. It follows that the major source of exposure 
to TCDD and related compounds is dietary (Table 1). The average person carries a 
TCDD load of 32 parts per trillion in his or her fat in a steady state (21). Regardless, 
these levels, even in the most extreme situations are well below the United States 
Department of Agriculture’s reference dose (20, 21). Nevertheless, its persistence in the 
body can prolong the effect of even a low dose of TCDD. In a study of Agent Orange-
exposed Vietnam War veterans, TCDD was found to have a half-life of 7.1 years (95% 
c.i. of 5.2 – 8.6 years) in the human body--much longer than in most laboratory animals 
(22).  However, TCDD half-life can be much shorter (1-3 years) in patients exposed to 
very high levels (>100,000 pg/g lipid weight) (23) and over 10 years for patients exposed 
at low levels (<50 pg/g lipid weight) (22).  This phenomenon was observed following the 
poisoning of Viktor Yushchenko, but also observed in highly exposed individuals from 
European occupational or accidental exposures (23). Researchers hypothesized that this 
was due to a higher concentration of activating metabolizing enzymes in the skin or liver 
(23).  By a similar rationale, a meta-analysis found that half-life could also be 
dramatically reduced in patients who were regular smokers, owing to the smoke’s 
induction of cytochrome P450 1A1 (CYP1A1) (24). TCDD has also been shown to have 
a shorter half-life in individuals with a lower percentage of body fat, owing to a smaller 
reservoir for TCDD storage (25) , as well as for patients who are under 18 at time of 
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exposure due to rapid growth and turnover of lipid stores, breastfeeding women, and 
individuals on drugs used to mobilize fats (23, 24).  However, weight loss post-exposure 
did not affect serum levels of TCDD (24).  
The preceding information reveals how difficult it is to quantify TCDD’s relative 
toxicity in the human body. The National Institute for Occupational Safety and Health 
(NIOSH) has not determined a relative exposure limit or an immediately danger to life 
and health limit, nor has Occupational Safety and Health Administration assigned a 
permissible exposure limit  (19). However NIOSH notes TCDD to be an occupational 
carcinogen (19).   Even in animals, the LD50 varies between 500 ng/kg body weight in 
guinea pigs to over 1.1 mg/kg body weight in Siberian hamsters (26). Within strains or 
even sexes of rats, fold-level differences can exist (26, 27) and studies in NHEKs in vitro 
 
Table 1. Average dietary TCDD exposures (21) 
Food [TCDD] (pg/g) Average daily TCDD intake 
pg/person/day 
Ocean fish 500 8.6 
Freshwater fish 70 -- 
Meat 35 6.6 
Cheese 16 0.31 
Milk 1.8 0.20 
 
 
show an order of magnitude in individual variation of EC50 (0.45 nM – 1.41 nM) of 
TCDD  in four donor cell lines (28). LD50 has not been determined in humans due to the 
paucity of lethal dose exposures to TCDD, though it appears to be on the higher end of 
the interspecies range presented above (23, 29). Still, regulatory bodies maintain that 
even low level exposures can be harmful. While the effect of chronic, low level exposure 
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to TCDD is difficult to parse, several large scale accidental or intentional exposures have 
brought TCDD into the public eye and helped elucidate the effects of TCDD on human 
health in vivo.  
Large-scale exposures since World War II 
Food contamination: Dioxins and other polyaromatic hydrocarbons (PAHs) 
bioaccumulate in fatty tissue in animals, but there have been several incidences over the 
past few decades involving excessive contamination from dioxins or other PAHs such as 
polychlorinated biphenyls (PCBs) or polychlorinated dibenzo-furans (PCDFs). The most 
famous case occurred in 1968 in the Japanese Kyūshū province. Rice bran oil was 
contaminated by PCBs, affecting 14,000 people, and over 400,000 birds who died of 
respiratory distress. In humans, a disease called Yusho disease was identified, marked by 
skin and eye lesions, irregular menstruation in women, weakened immune responses, and 
cognitive defects in children. In 1979, Taiwanese rice bran oil was similarly 
contaminated, causing many of the same symptoms and referred to as YuCheng illness 
(30). These, as with most environmental contaminations, were of a mixture of PCBs and 
PCDFs compared to laboratory based studies which tend to use TCDD (30).  However, 
victims in the Yusho and Yucheng group have been closely monitored for the past four 
decades for outcomes on reproductive health, cancer incidence, skin manifestations of 
PCDF intoxication, and metabolic syndromes (31). One difference between the two 
exposures is that a coplanar PCB in the Yusho incident appears to be linked with thymic 
atrophy and decreased androgen metabolism, contributing to reproductive effects 
observed in exposed women (32). Women were also more strongly affected in the 
Yucheng cohort with increased risks of diabetes, chloracne, or hypertension compared to 
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a control population (33).  As recently as 2008, a dioxin contamination of Irish pork 
caused a worldwide recall, though fortunately the European Union recognized this before 
it caused a global health crisis. About 10% of the population of Ireland was exposed to 
meat thought to have been contaminated  through animal feed (34). It is too soon to see if 
chronic health problems have arisen from these exposures, but early data indicate TCDD 
has not been elevated in breast-milk of first time Irish mothers, though some increase in 
PDCFs was observed (35). 
Seveso, Italy: On July 10, 1976, a factory in Seveso, Italy, 9 miles north of Milan 
exploded. The factory produced 2,4,5-trichlorophenol, an intermediate for 
hexochlorophene, an antibiotic used in toothpaste and soaps, and for 2,4,5-
trichlorophenoxyacetic acid, an herbicide (36). TCDD was created unintentionally as a 
byproduct of this reaction and of the 6 tons of chemicals released. 1 kg of TCDD was 
distributed over an 18 km
2
 area, in some areas as high as 100 ppm (36). Within days, 
3,300 animals, mostly poultry and rabbits were found dead, and over the next two years 
80,000 animals were slaughtered to prevent bioaccumulation within the food chain. Over 
5,436 humans lived within an area with soil concentrations > 5 µg/m
2
 (36). This 
represents the largest scale human exposure in a residential population to date and the 
cancer and disease incidences of these exposed populations has been extensively 
followed in the nearly 40 years since. (37).  
Love Canal, New York: From 1942 until 1953, Love Canal, NY was used as a 
dumping ground for waste from the Hooker Electrochemical Company, the US military, 
and the city of Niagara Falls. Here, Hooker stored 55 gallon drums of industrial waste, 
including “caustics, alkalines, fatty acids and chlorinated hydrocarbons from the 
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manufacturing of dyes, perfumes, solvents for rubber and synthetic resins (38, 39)." After 
1953, the canal was paved and sodded over, and sold to the Niagara Falls City School 
District for $1 (U.S.). They built a school and surrounding community on the site (39).  
Love Canal represents persistent exposure like Seveso. Twenty years later ground water 
testing showed the presence of dioxins at ~53 parts per billion as a result of seepage from 
the dump into the sewer. Further research showed an increased incidence of miscarriages 
and birth defects in children born in Love Canal (40, 41). Infants born to exposed 
mothers were also more likely to be preterm, at a low birth weight, and had a skewed 
male:female ratio (41).  Children born and raised in Love Canal suffered increased 
incidences of epilepsy, cognitive disorders, eye problems, and skin rashes (38). Nearly 
1/3 of the population showed high white blood cell counts and chromosomal damage, 
considered to indicate increased likelihood of leukemia (42) and after 30 years, one study 
found a slightly elevated incidence of bladder and kidney cancer in former Love Canal 
residents, though the sample size was too small to draw definitive conclusions.  No 
increase in all-cause mortality was observed (43, 44).  
Times Beach, Missouri: Times Beach, Missouri was a town of around 2000 
people located 17 miles south of St. Louis and the site of another mass exposure to 
TCDD (45). In 1972, the City of Times Beach paid a subcontractor to pressure wash 
2400 feet of dirt roads within the town. This subcontractor who owned a trucking and oil 
business, had also held contracts for waste disposal for the Northeastern Pharmaceutical 
and Chemical Company, Inc., a company that manufactured hexachlorophene from 2,4,5-
trichlorophenol (the same chemical manufactured in Seveso). This subcontractor used the 
same trucks to carry dioxin contaminated wastes as he did to pressure wash the roads and 
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over the next four years, he sprayed an estimated 160,000 gallons of toxic waste on the 
roads (45). In 1983, dioxin concentrations on the roads were still measured at 0.3 ppm 
(46). Interestingly, the public health ramifications of Times Beach were minimal at best 
as no cases of chloracne, the hallmark condition of dioxin exposure were observed (47). 
In fact, a 1991 EPA report questioned whether the Times Beach evacuation had really 
been necessary (48) and in 1997, Times Beach was removed from the list of superfund 
sites needing cleanup (47). Further, soil samples as of November 2012 indicate that 
Route 66 State Park in Times Beach now poses no threat to park visitors or workers (47, 
49).  
Viktor Yuschenko’s poisoning: The most public instance of dioxin in the news 
was the 2004 poisoning of Ukrainian presidential candidate Viktor Yushchenko. 
Yuschenko was admitted to hospital in early September 2004 with acute pancreatitis, and 
over the coming months developed a disfiguring skin condition, identified by doctors as 
chloracne (23). In December 2004, serum samples from Yushchenko confirmed a level of 
108,000 pg/g lipid weight laboratory-grade TCDD-- more than 50,000 times that of the 
general population (23).  Over the next three years, a team of doctors monitored 
Yushchenko’s blood, urine, feces, skin, sweat, and material extracted from skin lesions 
for levels of TCDD and its metabolites, as 2,3,7-trichloro-8-hydroxydibenzo-p-dioxin 
(OH-TriCDD) and 1,3,7,8-tetrachloro-2-hydroxydibenzo-p-dioxin (OH-TCDD) wherein 
they were able to make several determinations about TCDD metabolism and secretion in 
humans (23). Doctors found that most TCDD was excreted fecally, a similar finding to 
observations in rodents (27). They also found that most excreted TCDD was 
unmetabolized, particularly in the skin and serum, though fecal samples contained the 
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highest concentration of metabolites (23). Further, Sorg et al. discovered a high 
concentration of TCDD in samples removed from TCDD-induced skin lesions, 
suggesting a new mechanism for TCDD elimination (23). In Yushchenko, researchers 
found TCDD to have a half-life of 15.4 months, much shorter than expected even with 
his high initial serum levels. Some of this accelerated metabolism was attributed to 
frequent surgery and biopsying as well as to pharmacological interventions which 
enhanced cytochrome P450 1A2 (CYP1A2) expression and dioxin metabolism, and 
mobilized lipid turnover, depleting the reservoir for dioxin, such as Olestra and Orlistat 
(23).   
Molecular and genetic actions of TCDD 
 Epidermal hyperproliferative disorders are frequently caused by genetic and 
idiopathic factors, and chemicals have also been shown to replicate this disease 
phenotype.  2,3,7,8-tetrachlorodibenzo-p-dioxin (Figure 1) is the most potent congener in 
a class of polychlorinated dibenzodioxins (19) and binds to a receptor known as the AhR 








The AhR is an ligand-activated transcription factor and serves as a basic helix-
loop-helix transcription factor containing a Per-Arnt-Sim domain (bHLH/PAS) which 
binds polyaromatic and halogenated aromatic hydrocarbons (51). In its unliganded form, 
the AhR is cytosolically bound to several proteins including heat shock protein 90 
(Hsp90) (50). Upon ligand binding (Figure 2), the nuclear localization signal on the AhR 
is exposed, allowing the AhR to migrate to the nucleus where it partners with ARNT, the 
aryl hydrocarbon receptor nuclear translocator (52).  The AhR-ARNT heterodimer binds 
DNA at 5-7mer sites identified as xenobiotic response elements (XREs) with a consensus 
sequence of TnGCGTG (with n indicating any base) (53). Although this is the  
most clearly understood mechanism of AhR activation, very few genes have been 
confirmed to be controlled directly through an XRE. A computerized search of the human 
genome discovered 72,318 putative XREs and found further that XREs were more 
heavily concentrated in coding regions of DNA compared to non-coding regions, and 
were most concentrated within 1.5 kb of the transcription start site (TSS) (54). Canonical 
genes induced following AhR activation include cytochrome P450 1A1 and 1B1 
(CYP1A1 and CYP1B1) (52, 54) both of which been confirmed as XRE-dependent in 
mouse, and CYP1A1 has been confirmed in rat (54-56). CYP1A1 and CYP1B1 are 
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Figure 2. Canonical and non-canonical mechanisms of  AhR-mediated 
activation A. TCDD-dependent activation of AhR through AhR/ARNT binding at 
an XRE sequence leads to upregulation of target genes (53, 63) B. TCDD-dependent 
estrogenic activity through AhR/ARNT/Estrogen Receptor α (ERα) at an estrogen 
response element (ERE) or estradiol (E2) dependent activation via E2 classical 
pathway lead to an upregulation of c-myc (64). C. TCDD-dependent anti-estrogenic 
activity through AhR/ARNT binding to inhibitory XRE (iXRE) sequences, blocking 
ERα homodimer binding to ERE sites leading to a downregulation of c-myc (64). D. 
Xenobiotic metabolism may create estrogenic metabolites, antiestrogenic 
metabolites, or ROS. Sod1 removes ROS from the cell. (18). 
D
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members of the cytochrome P450 protein family of monooxygenases that are involved in 
xenobiotic and drug metabolism, a logical target for the AhR (52). CYP1B1 in particular 
hydrolyzes PAHs and 17β-estradiol (57, 58).  Genes involved in metabolism, lipid 
synthesis, and response to reactive oxygen species (ROS) are also directly regulated by 
the AhR including: aldehyde dehydrogenase 3 family member A1 (Aldh3a1), NAD(P)H 
dehydrogenase, quinone 1 (Nqo1), glutathione S-tranferase alpha 2 (GSTA2), UDP 
glucuronosyltransferase 1-6 precursor (Ugt1A6) were verified as XRE-mediated in rats 
(54, 59).  Superoxide dismutase 1 (Sod1) converts superoxide radicals to molecular 
oxygen and hydrogen peroxide (H2O2) which can then be broken down by catalase. 
Catalase is critical in the cellular ROS response and has been shown to be XRE-mediated 
in humans and in rats, presumably to aid in neutralization of ROS generated as xenobiotic 
metabolites (60, 61).  Nevertheless, XRE-mediated genes directly related to keratinocyte 
differentiation are still largely undescribed. In mice, the EGF receptor ligand EREG is 
regulated by an XRE, though this finding has not been replicated in humans (9). Finally, 
work from our lab has shown Filaggrin (Flg), a marker of keratinocyte differentiation, to 
be likewise regulated by an XRE 1400 bp upstream of its TSS (18). 
Increasingly, there has been discussion of non-canonical mechanisms of action of 
the AhR, particularly those pertaining to its endocrine disrupting actions (Figure 2B-C). 
TCDD and many planar hydrocarbons in its class can have anti- or pro-estrogenic effects 
which may be tissue- specific (62). In porcine ovarian cells, TCDD was shown to affect 
estrogenic signaling and oocyte maturation at the level of steroidogenesis through 
inhibition of P450 cholesterol side chain cleavage enzyme (P450SCC) and aromatase 
(63), fundamental steps in estrogen synthesis. This finding was echoed in rainbow trout 
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where TCDD inhibited P450SCC and steroidogenic acute regulatory protein (stAR) (64). 
Aluru et al. also showed that TCDD-exposed trout produced less cortisol following an 
adrenocorticotrophic hormone (ACTH) challenge, suggesting TCDD exposure may 
decrease glucocorticoid production and diminish stress responses (64).  The AhR can 
directly bind the ERα, and the AhR/ARNT/ERα can either signal through estrogen-
regulated genes in the absence of E2 or bind inhibitory iXREs located near EREs, 
conformationally blocking the binding of ligand bound ERα  (65, 66). 
The AhR can function as a mediator of inflammation in several ways: directly, 
through XRE-mediated induction of inflammatory cytokines involved in Th17 cell 
differentiation, particularly (interleukin) IL-22, IL-23, and IL-1A, as well as the retinoid-
related orphan receptor (RORα) (67, 68). This may also be due to the ability of AhR to 
bind nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) (69, 70). 
This likely evolved as lipopolysaccharide (LPS) binds the AhR, however, pathologically, 
it leads to a hyperinflammatory feedforward loop that explains dioxin’s role in persistent 
inflammation in vivo (70, 71). AhR binding to NF-kB also serves as a mechanism of cell 
cycle inhibition wherein AhR sequesters NF-kB, attenuating its role in DNA-synthesis 
(72). AhR can also inhibit cell cycle progression by sequestering pRb which 
preferentially binds to the liganded Ahr (66, 69).  Finally, AhR can alter cellular sex 
steroid signaling by functioning as a ligand-dependent scaffolding molecule within cullin 
4b E3 ubiquitin ligase complex which targets these hormones for degradation (73).  
Overall, the AhR has a variety and wide ranging subset of cellular and tissue 
responses from hormonal, to inflammatory, to proliferative. While it is likely that some 
effects of TCDD on epidermal differentiation are mediated through canonical, XRE-
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mediated routes, it is possible that cofactor competition, or non-canonical mechanisms 
are mediate TCDD-accelerated epidermal differentiation.     
Health risks of TCDD exposure 
As discussed above, population-wide acute or chronic exposures to TCDD have 
given researchers insight into target tissues for PAHs. TCDD intoxication produces or 
contributes to a variety of diseases in four major categories: 1) immunotoxic and 
inflammatory, 2) oncogenic, 3) reproductive and developmental, and 4) skin (74). 
 Immunological effects: The immune system is complicated and intrinsically tied 
to tissue homeostasis throughout the body, however there is evidence that the immune 
system is a site of toxicity for TCDD. Prolonged dioxin exposure causes thymic atrophy 
in rats (27), a response also recognized in YuCheng victims (32). It is suggested that an 
AhR-mediated loss of NF-kB signaling which is required for normal medullary thymic 
development is involved in this thymic atrophy (70, 75). Lacking a competent thymus, 
the patient has difficulty with T-Cell maturation, which TCDD further compounds. 
Individuals exposed to PAHs in utero show poor notch1-induced T cell differentiation, 
predisposing them to T-acute lymphocytic leukemia (T-ALL) (76). Further, TCDD 
promotes Th17 maturation in a seemingly direct, XRE-mediated manner (68) which is 
linked to increased inflammation and autoimmunity. Nude mice, which congenitally lack 
T cells, are less sensitive than their immunocompetent littermates (77). These changes in 
immune cell function cause an increased susceptibility to infection and a hypersensitivity 
to LPS (78). While it was originally thought that this enhanced susceptibility was specific 
to gram negative bacteria, it has also been shown to increase rates of infection, morbidity, 
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and mortality from gram positive bacteria (79), viruses (80, 81), parasites (82, 83), and 
even establishment of transplanted neoplasms (84). 
Oncogenic effects: TCDD is classified as a known human carcinogen, (19). 
While victims of the 1976 Seveso disaster showed increased incidences of metabolic 
disorders and blood cancers (85), a meta-analysis of TCDD-exposed populations show an 
increased risk of cancer in general as opposed to a specific type (86, 86). However when 
these findings were applied to Agent Orange-exposed military veterans or smaller 
occupational groups, the all-cancer risk was not supported (87). In animal models, mice, 
rats, and hamsters exposed to TCDD reliably developed tumors in multiple organ systems 
(88). In fact, TCDD-induced tumor development in these rodent models increased in a 
dose-dependent manner (88).  
Others suggest that TCDD functions not as a direct mutagen, but as a tumor 
promoter, leading to more tumors following tumor initiation studies (89, 90). Interspecies 
variability in sensitivity and LD50 as well the ethical inability to perform these same 
experiments in humans outside of cell culture leave these opposing hypotheses 
unanswered (26, 91). In female rats, the LD50 is twice that in males (45 µg/kg to 22 
µg/kg, respectively) (88). This makes prediction of toxicity dose based upon exposure 
level imprecise. The toxic equivalency factor which quantitates the potency of a ligand is 
established based upon toxicity in male rats and fails to take into account interspecies or 
interstrain pharmacogenomic differences in rodents, but also population level variance in 
sensitivity for humans exposed to admixtures of PAHs in large or, even small, scales 
(92).   
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Where the evidence for TCDD-mediated oncogenesis is somewhat stronger is in 
the offspring of acutely TCDD-exposed parents. In rats exposed in utero exposure are 
predisposed offspring to mammary cancer by increasing the numbers of terminal end 
buds. Additionally, mice exposed to TCDD in utero are predispose to T-ALL as a result 
of desensitizing them to notch1-signaling which drives T cell development (76), and 
children of Agent Orange exposed veterans have increased incidences of 
rhabdomyosarcoma (93). 
Reproductive and developmental effects: One of the most common fears 
regarding endocrine disrupting chemicals is that they will mimic estrogen in males, 
feminizing them. However endocrine disrupting chemicals can function in a variety of 
ways including : 1) inhibition of aromatase which converts testosterone to E2; 2) 
antagonism or agonism of the ERα which can be anti- or pro-estrogenic; 3) agonism or 
antagonism of the androgen receptor; 4) agonism of the AhR which can inhibit or activate 
ERα; 5) interaction with steroid binding proteins; and 6) altering hormone metabolism 
(94) . Effects have been seen on male reproductive health and hormones: PCB exposure 
in the YuCheng incident has led to decreased serum androgen and gonadal testosterone 
synthesis in male patients (32). TCDD exposure in rats leads to decreased epididymal 
sperm count through an apoptotic rather than anti-spermiogenesis mechanism (95, 96). 
Other works in rats and hamsters confirmed lowered sperm count and demonstrated 
decreased sex organ size and reduced semen quality, in the presence of normal levels of 
androgens.   However, it is in the hypothalamic-pituitary-gonadal (HPG) axis of women 
where TCDD has its most marked effects. 
 17 
TCDD can lower fertility in both males and females (97, 98). However, in 
women, TCDD also increases the risk involved in a pregnancy. Pregnant women suffer 
from higher incidences of miscarriage following TCDD exposure (41) and enhanced 
placental inflammation which, if insufficient to cause a miscarriage, can lead to preterm 
birth or incidences of endometriosis (99). TCDD can be detected in the breast milk of 
lactating mothers who have been exposed to high levels of TCDD (35). Further, twenty 
years after the Seveso incident, researchers observed a strongly elevated incidence of 
breast cancer in 900 women exposed to high levels of TCDD (100). However at thirty 
years, this was no longer significantly different than the population at large (37).  
The risks of TCDD exposure in utero and in newborns are greater still. Following the 
Seveso incident, 30 pregnant women in Zone A nearest the site had induced abortions, 
and 4 women who had been pregnant during the incident spontaneously miscarried (100).  
Of these, no gross morphological, or obviously fetotoxic effects were observed, though 
the spontaneous abortions showed structural abnormalities (100). The small number of 
embryos, often incomplete structurally, is not sufficient to rule out a damaging effect of 
in utero exposure (100). More, observations from Love Canal support this hypothesis. 
What initially drew attention to the contamination in Love Canal was a higher rate of 
miscarriage, as well as a higher rate of birth defects (101), matching a finding previously 
observed in mice where in utero exposure caused cleft palate (102, 102) . Learning and 
cognitive disabilities were seen in children raised in Love Canal or exposed in utero to 
contaminated rice bran oil (31, 41). Children born in Love Canal were more likely to be 
low birth weight or premature (41). But these observations were all made in very small 
populations, making definitive conclusions difficult. 
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Dermatologic effects: The hallmark symptom of TCDD exposure in humans is 
chloracne (74). Chloracne is characterized by hyperproliferation and altered 
differentiation of the interfollicular epithelium as well involution and hyperkeratinization 
of the pilosebaceous unit which is comprised of the hair follicle and sebaceous gland 
(74). Comedones on the interfollicular epidermis contain a higher concentration of TCDD 
than unaffected skin, directly linking chloracne to the disease (23). Interestingly, 
chloracnegenesis seems inversely proportional to cancer, perhaps due to increased 
secretion of TCDD through dermal lesions leading to a shorter window of exposure. In a 
report studied twenty years after the Seveso incident, no individuals who developed 
chloracne shortly after the explosion subsequently developed cancers (85).  
As chloracne is one of the most common morbidities of humans following TCDD 
exposure, the skin becomes an ideal model in which to study TCDD biology.  TCDD 
causes a variety of effects on the skin, upregulating genes involved in epidermal 
differentiation, including 24/60 of the genes on the Epidermal Differentiation Complex, a 
region on chromosome 1q21 (18). In mice, TCDD exposure caused epidermal barrier to 
form one day earlier in utero in what has been shown to be a Flg-dependent manner (5). 
TCDD has been shown to upregulate Flg mRNA in an XRE-dependent manner (1) and 
this upregulation is blocked by stimulation of the EGFR (6). TCDD has been shown to 
accelerate barrier formation through the increased synthesis of barrier lipids (103).  In 





The Structure of Human Skin  
Skin is the body’s largest organ (Figure 3A), and provides the first line of defense 
against external threats.  It also plays an important regulatory role against desiccation 
(105). The epidermis, comprised of highly stratified squamous epithelial cells, provides a 
physical and watertight barrier (105). It is interspersed with tissue- specific macrophages, 
called Langerhans cells, sensory receptors called Merkel disks, and melanin-producing 
cells called melanocytes (106) which collectively provide a physical, biochemical, and 
adaptive barrier (107).   
The epidermis also plays an important role in vitamin D synthesis following sun 
exposure (108). Sunlight causes the conversion of 7-dehydroxycholesterol (7-DHC) in 
the membrane of keratinocytes and dermal fibroblasts to to cholecalciferol (vitamin D3). 
Cholecalciferol is hydroxylated in the liver to make 25-hydroxyvitamin D3 (25(OH)D3). 
25(OH)D3 is further hydroxylated in the kidney by 1-alpha-hydroxylase to form 1,25-
dihydroxy-vitamin D (1,25-(OH)2D3). This end product, calcitriol, regulates Ca intake 
enterically and the release of Ca from the mineralized matrix of bone. Melanocytes 
embedded in the epidermis counterbalance this vitamin D production by absorbing excess 
Ultraviolet B (UVB) and preventing 7-DHC activation (109). Skin color is dependent 
upon  the inherited density and clustering of granular melanosomes in melanocytes (with 
caucasian skin having fewer often in clusters while darker skin has more diffusely 
distributed  melanosomes (110)),  UVB radiation  also causes branching of dendritic 
shaped  melanocytes and the increased trafficking of melanin-containing melanosomes, 
to decrease ultraviolet (UV) light-induced damage to DNA. This also causes a induced 
darkening of the skin, such as tanning or photoaging (108, 110)  
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The same cells that give rise to the epidermis also gives rise to the pilosebaceous 
units, comprised of hair follicles and sebaceous glands (106), or in hairless regions, 
sebaceous glands which cover all of the body except the soles of the feet and hands (111). 
The sebaceous gland secretes sebum, a waxy substance comprised of triglycerides, 
squalene, wax esters, and other lipid metabolites (112). Sebum serves to lubricate and 
further waterproof the epidermis as well as acidifying the skin to a pH between 4.5 and 
6.2 which serves as a barrier against bacteria, viruses, and dermal contaminants (113). In 
high temperatures, sebum emulsifies sweat from eccrine sweat glands (also embedded in 
the epidermis) to further cool the body (114). Hair follicles and sebaceous glands are 
maintained by stem cells located in in the follicular bulge (115).  Epidermal hair serves a 
thermoregulatory and sensory function.  
Below the epidermis lies the dermis: a highly vascularized and innervated layer 
comprised of fibroblasts, adipocytes, and macrophages in an extracellular matrix (ECM) 
comprised of collagen, elastin, and a loose reticular extrafibrillar matrix consisting of 
proteoglycans and glycosaminyoglycans (105, 115). Within the dermis are blood vessels 
and capillary beds which provide oxygen to epidermal keratinocytes, and a variety of 
sensory neurons for pressure, temperature, and pain (115).  Below the dermis lies the 
hypodermis, which stores subcutaneous fat that further stabilizes body temperature and 
can be broken down to provide energy (115).  
The Structures of the Epidermis 
Stratum Basale: Within the epidermis, a single layer of cuboidal basal cells sits 
in contact with the basement membrane of the dermis via hemi-desmosomal structures 




Figure 3. Human skin and accessory structures, the epidermis, and the cornified envelope. A) The human skin is derived from the 
mesoderm embryonically and is comprised of multiple layers. The superficial epidermis provides a defensive epidermal barrier and 
prevents desiccation. The dermis provides structural support to the epidermis as well as vascularization and innervation for pressure, 
temperature and pain. Below the dermis lies the subcutaneous layer which is primarily used for fat storage (115). B) The epidermis is 
comprised of keratinocytes and contains melanocytes, and skin-specific macrophages known as Langerhans Cells. As keratinocytes 
lose contact with the basal lamina (BL) and move from basal to suprabasal layers. they undergo terminal differentiation as they move 
from the stratum basale (SB) through the stratum spinosum (SS) and stratum granulosum (SG) towards the stratum corneum (SC) 
where they express layer-specific markers of differentiation (left).  C) In the stratum corneum, cells extrude lamellar bodies containing 
ceramides, fatty acids and cholesterol outside the cell. The membrane of the mature, anucleate keratinocyte (corneocyte) has also 
undergone structural changes including the cross-linking of small proline-rich proteins (SPRR) to membrane proteins such as loricrin 
(Lor) and involucrin (Ivl). Corneocytes have also undergone keratinization where keratins 1 & 10 are crosslinked and bundled together 












also provides juxtacrine signals that maintain the basal cells in a proliferative, 
undifferentiated state (107). The stratum basale contains pockets of proliferative cells that 
asymmetrically divide to maintain the epidermal stem cell population and produce a 
population of transit-amplifying daughter cells (TACs) which migrate superficially into 
the suprabasal layers (117, 118). TACs are an undifferentiated population of cells 
transitioning between multipotent stem cells and differentiated cells (119).  These 
daughter cells are already expressing markers of the earliest phases of keratinocyte 
differentiation, keratin-5 and -14 (K5, K14) and p63 (119).  
Stratum Spinosum: Suprabasal keratinocytes become increasingly differentiated 
as they move towards the stratum corneum, the uppermost layer of the epidermis (107). 
As cells progress towards the epidermal surface through the stratum spinosum and 
granulosum to the stratum corneum (Figure 3B), they undergo profound morphological 
changes and consist of populations of cells transitioning between multipotent stem cells 
and differentiated cells. They begin to express markers of differentiation. In the stratum 
spinosum, cells have lost contact with the basal membrane and begin to increasingly rely 
upon on transitional desmosomal contact and tight junctions (TJs) with other 
keratinocytes for juxtacrine signaling and maintenance of differentiation status (105). TJ 
proteins such as claudins 1, 4, and 7, as well as occludins and zona occludens protein 1 
(ZO1) are expressed in the stratum spinosum (105). These TJs serve to enhance 
epidermal barrier function in the case of disruption of the stratum corneum (120) and 
mice defective for occludins or claudins die from excessive water loss shortly after birth. 
In addition, aberrant expression of claudin-4 and occludin have been linked to epidermal 
diseases such as psoriasis vulgaris, ichthyosis, and lichen planus (121). Cells within the 
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stratum spinosum also change their protein expression. These proteins, including k1 and 
k10, envoplakin (Evpl), periplakin (Ppl), 14-3-3δ, and members of the S100 family of 
Ca
2+
 binding proteins [S100a7, S100a8, S100a9 and S100a10 (122-125)], are important 
in barrier structure and function and serve as markers of keratinocyte differentiation 
(Table 2).  
Stratum granulosum: As cells progress into the stratum granulosum, cell 
morphology progresses towards a more squamous phenotype, exemplified by flat, scale-
like cells, and an increased cytoplasm: nucleus ratio. High extracellular Ca (>1 mM) 
leads to the formation of keratin-rich cytoskeletons linked and stabilized at desmosomes 
through desmoglein 1 (Dsg1), a desmosomal cadherin (126, 127). Dsg1 inhibits EGFR 
signaling in the stratum granulosum and firmly commits cells to terminal differentiation 
(128). Higher extracellular Ca further raises intracellular Ca mediated by the Ca receptor 
(CaR) whose expression is regulated by 1,25-(OH)2D3  (123, 129). The CaR activates 
PLC signaling, particularly PLCβ and PLCγ1 which ultimately leads to the upregulation 
of several markers of differentiation and cornified envelope (CE) precursors such as 
transglutaminase 1 (Tgm1) and Flg (11). Increased intracellular Ca is required for the 
redistribution of signaling molecules such as protein kinase C (PKC)-α and calmodulin to 
the membrane (130), metalloproteinase and Tgm1 activation (131-133), and is correlated 
with the expression of markers of differentiation such as Flg (a protein that bundles 
keratins (1, 107, 134)) and two Tgm substrates involucrin (Ivl) and loricrin (Lor) (135). 
Stratum Corneum: Within the stratum corneum (Figure 3C), terminally 
differentiated cells undergo nuclear degradation as part of a specialized program of cell 
death called cornification (136). While cornification leads to nuclear and DNA 
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degradation as is typically seen in apoptosis, it is a slower and Ca-dependent process 
wherein organelles are lysed but DNA is not fragmented. Further, cells remain 
metabolically active, though mitotitically inactive until eliminated by desquamation 
(137).  Corneocytes (fully differentiated, anucleate cells of the stratum corneum). 
 
Table 2. Epidermal markers of differentiation by layer 
Epidermal Layer Gene markers Reference 
Stratum corneum Lor, Flg, SPRR, Ivl, Cnfn (121) 
Stratum granulosum Ivl, Tgm3, Tgm5, Claudins, 
Desmogleins, Desmocollins, Cdsn 
(105, 119) 
Stratum spinosum K1, K10, Tgm1, Evpl, Ppl (105) 
Stratum basale K5, K14 (105, 118, 138) 
Basal lamina α6β4 Integrin, Lama5 (105, 118, 138) 
Abbreviations: Loricrin (Lor), Filaggrin (Flg), Small proline-rich protine protein  
(SPRR), Involucrin (Ivl), Cornifelin (Cnfn), transglutaminase (Tgm), Corneodesmosin 




undergo changes in membrane lipid composition and Tgm1-mediated cross-linking of 
membrane associated proteins, predominantly Lor, Ivl, and keratins to form a structure 
known as the CE (107, 137). Interestingly, extracellular Ca drops in the stratum corneum, 
an event that precedes the extrusion of lamellar bodies from the cytoplasm and formed in 
the stratum granulosum (139). The specialized lipids contained within these lamellar 
bodies help to form a watertight matrix in which a multi-layered physiochemical barrier 
of mitotically inactive, insoluble cells lie within a matrix of specialized membrane lipids 
similar to “bricks and mortar” in a wall (105).  
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The stratum corneum is continuously lost through desquamation allowing 
keratinocytes from the suprabasal layers to take their place (107). The stratum basale 
maintains this population of cells through the continued production of TACs from the 
epidermal stem cell population maintained therein, (115, 140).  The average turnover of 
the normal epidermis occurs in 40-56 days in vivo in humans and 8-10 days in murine 
skin (141); However, this turnover time can be shortened with disruption to epidermal 
barrier as in the case of wound healing (142, 143).  
The signals governing keratinocyte differentiation versus proliferation are tightly 
regulated through the interplay of mitogenic cell-basal laminar interactions and factors 
such as growth factors and inhibitory micro-environments with increased extracellular 
Ca, decreased EGFR signaling, and loss of basal-laminar interactions. Further, 
toxicological or pharmacological interventions can modify epidermal homeostasis. As  
such, altered proliferation and/or differentiation are implicated in many dermatological 
conditions, such as psoriasis (142, 144, 145). Epidermal turnover occurs every 28-45 
days in the presence of increased inflammation leading to the development of 
characteristic thick, pruritic plaques and lesions (142). Desmosomal connections or 
cytoskeletal components are frequently altered or lost in common epidermal diseases 
(Table 3). 
Ca as a physiological regulator of epidermal differentiation 
As discussed above, Ca is an important modulator of epidermal differentiation. 
Within the epidermis, Ca is lowest in the stratum basale, increases steadily reaching its  
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Flg Dry skin overall with patches of itchy, red, swollen, cracked skin. 
More common in children 











Severe hyperkeratosis and greatly accelerated epidermal 
proliferation. Reduced lipid transfer across the membrane leads to 









Genetic Tgm1 Extensive scaling of the skin with hyperkeratosis (156, 157) 
Pemphigus Autoimmune Dsg1, Dsg3 Epidermal acantholysis forming painful, non-pruritic blisters 
beginning in the mouth (pemphigus vulgaris) or the scalp, back, 







Thickened epidermis and loss of stratum granulosum. Plaques 




peak in the stratum granulosum and then dropping again within the stratum corneum 
(146, 147). As cells similarly progress from basal to suprabasal epidermal layers, high 
extracellular Ca can cause genomic and non-genomic effects (148) such as increases in 
expression of markers of differentiation [e.g.  Ivl, Lor, and Tgm1 protein within hours 
(149)], and increased cornification at 1-2 days (150). High extracellular Ca has also been 
shown to have non-genomic effects on cellular homestasis such as redistribution of 
desmoplakin (DP), a desmosomal protein that  anchors intermediate filaments in 
desmosomes to the membrane (141) and increases in cell-cell adhesions (15), both of 
which are important in establishing and maintaining epidermal barrier (115, 159, 160). 
Ca is also required for the activation of differentiation-related Tgm1 which crosslinks 
proteins in the CE (107) as well as for the activation of several metalloproteinases 
essential for migration through the epidermis (131, 133, 161).  Ca increases the protein 
phosphotyrosine content in keratinocytes, activating the non-RTKs fyn (12) and src (11, 
162). Through the use of signaling defective mutants of src and fyn, Xie et al. showed 
that these non-RTKs as well as PI3K can phosphorylate PLCγ1 which is required for 
keratinocyte differentiation in a PI3K-dependent manner (10, 11).  
The cause of this epidermal Ca gradient is not entirely clear however it has been 
shown to be integral to the epidermal barrier formation and differentiation processes 
(139). Disruption of the epidermal barrier leads to disruption of the epidermal Ca 
gradient, and that re-establishment of this gradient precedes barrier restoration (139, 147). 
Further, diseases which disrupt the epidermal barrier, such as psoriasis, or experimentally 
induced essential fatty acid deficiency show corresponding loss of this Ca gradient (167, 
168). In utero, the Ca gradient is established alongside fetal barrier formation (146). 
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However, mechanistically this barrier is poorly understood. The epidermis is replete with 
membrane-associated Ca transporters which could export Ca released from the 
endoplasmic reticulum (ER) to the extracellular compartment (169). Elias et al. showed 
through the artificial re-establishment of barriers in barrier-disrupted tissues exposed to 
cold that energy-free, passive mechanisms such as transcutaneous water flow were 
sufficient to establish this Ca gradient (139). In fact, studies in two-photon microscopy 
showed that the majority of this extracellular Ca originated in the intracellular 
compartment, having been released from the ER or Golgi into the cytoplasm (170). 
Concentrations of extracellular Ca that promote epidermal differentiation are 
associated with increased intracellular Ca (163, 164) produced by Ca binding to the CaR 
and inducing a conformational change that leads to Gαq-dependent activation of PLCγ 
(165). PLCβ then cleaves phosphatidyl-inositol 4,5-bisphosphate (PIP2) in thecellular 
membrane to form the second messengers inositol trisphosphate (IP3) and diacyl-glycerol 
(DAG). (10). DAG activates PKC (166) and IP3 releases Ca from intercellular stores 
(165). Intracellular calcium can also be elevated through the opening of Ca-gated 
outwardly rectifying chloride channels which depolarize the cell causing voltage-gated 
Ca channels in the ER to release Ca into the cytoplasm  (234-236).   
Elevated Ca causes genomic effects (125) such as increases in expression of 
markers of differentiation (149), and morphological changes such as cornification (150). 
High extracellular Ca also has  non-genomic effects on cellular homestasis such as 
redistribution of DP, a desmosomal protein that anchors intermediate filaments in 
desmosomes to the membrane (140) and increased cell-cell adhesions (15), both of which 
are important in establishing and maintaining epidermal barrier function (115, 159, 160). 
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Ca is also required for the activation of differentiation-related Tgm1 which crosslinks 
proteins in the CE (107) and the activation of matrix metalloproteinases (MMPs) which 
cleave membrane-associated ligands and are required for cell motility (171).    
The EGF Receptor:  A target for regulation by TCDD and Ca 
It would be easy to argue that TCDD builds upon the differentiation-inducing 
mechanisms similarly affected by increased intracellular Ca. However, keratinocyte 
commitment to differentiation is represented not only by genetic, structural, and 
morphological changes to the cell, but also by the attenuation of EGFR signaling, a 
common regulatory target for both Ca and TCDD. Within the epidermis, the EGFR is the 
major driver of epidermal proliferation (172). Studies have shown that EGFR signaling is 
strong in basal keratinocytes and is inhibited by Ca in suprabasal layers (173).  This is 
accompanied by the decreased staining and [
125
I]-EGF binding capacity observed in the 
suprabasal layers of the epidermis (174-176) and  indicates that keratinocyte 
differentiation is dependent upon both enhanced extracellular Ca and attenuation of 
EGFR signaling (177, 178).  Secretion of EGFR ligands, such as TGF-α, AREG, or 
EREG, are frequently enhanced  in hyperproliferative skin disorders such as psoriasis or 
atopic dermatitis (145, 179, 180) and experimental overexpression of EGFR ligands can 
replicate psoriatic phenotypes (176, 181). Further, juxtacrine signaling by surface-
associated EGFR ligands maintains differentiated keratinocyte phenotypes while MMP-
mediated cleavage of these ligands drives keratinocyte migration in wound healing (182).  
 Work from our lab has shown that EGF, the prototypical ligand for the EGFR, 
upregulates nearly 3000 genes in keratinocytes, many involved in processes of epidermal 
disease (172). Further, pretreatment with EGF decreases the expression of markers of 
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keratinocyte differentiation in vitro and enhances transepithelial water loss (TEWL) 
indicative of impaired barrier function and dedifferentiation (172).  Pre-treatment with 
EGF inhibited TCDD-induced increases in expression of markers of keratinocyte 
differentiation, suggesting EGFR signaling is important not only in promoting 
keratinocyte proliferation but in suppressing differentiation (6). 
Structure and Function of the EGFR: The EGFR is a 170-kDa protein that is a 
member of the ErbB family of Type I RTKs in which each ErbB possesses different 
ligand affinities and subtly different downstream signaling events (183).  All four ErbB 
receptors are structurally related and have three domains: an ecto-domain, a 
transmembrane domain, and a C-terminal intracellular tyrosine kinase domain (184). The 
receptors, while structurally similar, have very different sequences: the EGFR and ErbB2 
are the most closely related with 49% identity (64% similarity). In contrast EGFR/ErbB3 
have 37% identity (53% similarity) and EGFR/ErbB4 have 28% identity (49% 
similiarity) (184). The tyrosine kinase domain is the most conserved between receptors 
(39-81% identity) and the C-terminal domain (CTD) the area of lowest identity (12-30%) 
(184) (Figure 4).  
Work in keratinocytes addressing ErbB signaling tends to focus on the EGFR. 
Keratinocytes also express ErbB2, and ErbB3 both in vivo and in vitro (185). The EGFR 
is expressed most strongly in the stratum basale and stratum spinosum where cells are 
actively proliferating, but is also present in the upper layers of the epidermis (185, 186).  
ErbB2 and ErbB3 are found in multiple cell lines and embryonic skin at low levels (185, 
186). Stoll et al. identified ErbB2 in the cytoplasm of keratinocytes in the stratum basale, 









Figure 4. Phosphotyrosine sites on the ErbB receptors and their effector 
molecules. The scaffolding and adaptor molecules Shc and Grb2 can bind on 
multiple sites across all four receptors, while other signaling and effector 
molecules show far more specific receptor recognition. The E3 ubiquitin ligase 
Cbl which leads to receptor ubiquinylations only recognizes phosphorylated 
EGFR and PI3K binds on ly ErbB3 and ErbB4 . Src/Csk and STAT5 recognize 
ErbB3 and EGFR respectively. The adaptor proteins Crk and Nck recognize 
phosphotyrosine residues on ErbB4 and are thus not relevant to epidermal ErbB 
signaling in skin (186). SH3BGRL, an SH3/SH2 domain containing protein, and 
protein tyrosine phosphatase 2C (PTP-2c) bind EGFR and ErbB2. Figure adapted 













human skin and A431 keratinocytes in vitro (185). However, in the MD-MBA breast 
cancer cell line which expresses higher levels of ErbB2, smaller, cuboidal “basal-like” 
cells expressed a mixture of surface and punctate intracellular ErbB2, suggesting that the 
relative amount of ErbB receptors present in a system can drive alterations in cellular 
localization and recycling of active ErbB receptor (185). Similar observations were made 
regarding EGFR in vivo or in EGFR-overexpressing A431 cells in vitro (185).  ErbB2, 
which lacks a ligand binding domain but possesses a constitutively active tyrosine kinase 
domain, has been shown to enhance tumor promotion by phorbol esthers in murine 
epidermal overexpression models (187). Further, due to its suprabasal expression, 
ErbB1/ErbB2 heterodimers are thought to play a role in ligand-induced differentiation 
while signaling through ErbB1 homodimers functions to drive proliferation and migration 
(185).  This may reflect the tendency of ErbB heterodimers to recycle causing a more 
persistant EGFR signal as opposed to the shorter signaling induced by EGFR 
homodimers. ErbB3’s role in skin is poorly understood but it does appear to be important 
in melanocyte development, and plays a role in melanoma progression (188). ErbB4 has 
not been shown in the epidermis, keratinocyte monolayer or organ culture, or 
keratinocyte cell lines (185).  In normal human keratinocytes in monolayer culture, 
ErbB2 and ErbB3 receptor numbers increase as cells become confluent, suggesting that 
ErbB2 and ErbB3 serve to maintain tissue structure and differentiation but also allow for 
a rapid response to wound regeneration wherein the loss of cell-cell contact changes 
EGFR signal from predominantly juxtacrine activation by membrane bound pro-EGFR 
ligands to paracrine activation by soluble ligands. (189). 
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Across the ErbB family, phosphorylation of tyrosine residues in the CTD recruits 
signaling and adaptor proteins to the receptors. This allows signaling molecules as well as 
scaffold and adaptor proteins to interact with receptors via their SH2 or phosphotyrosine-
binding (PTB) domains (190). The low degree of sequence identity within the CTD of 
ErbB receptors, contributes to distinctive signaling activity associated with each ErbB 
receptor and ErbB receptor dimers (Table 4). The EGFR has several sites which 
associate with Grb2, Stat5, and Shc, as well as sites for c-Cbl, a ubiquitin ligase which 
target receptors for internalization (191). ErbB2 interacts primarily with Shc leading to 
Ras-dependent extracellular signal-related kinase (ERK) activation, but also protein 
kinase A (PKA) (192). In murine models and human skin cancers, elevated ErbB2 is 
strongly linked to tumor promotion and neoplasm, respectively (187, 192, 193) while 
ErbB3 and ErbB4 are the only members of the ErbB family that can interact with the p85 
subunit of PI3K (191, 194).  
Upwards of 20% of the EGFR protein is N-glycosylated, which targets it to the 
plasma membrane where it exists as an inactive monomer, or transiently, as a dimer 
(184). Localization of the EGFR to the membrane increases its effective concentration 
and makes dimerization more likely (195). However, evidence also exists to support the 
presence of pre-formed dimers which dissociate upon ligand binding (196). Though these 
preformed homo- and heterodimers are thought to be largely inactive (197), their 
existence allows for more rapid activation of ErbB receptors and a higher degree of 
phosphorylation of cellular ERK and Akt following EGF challenge (198). Over half of 
the EGFR found in caveolae exist in their unphosphorylated state, but the readily 
available pool of potential dimer partners and effector molecules enhances receptor   
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Table 4. Common ErbB phosphorylation sites.  
  EGFR   
Site Phosphorylated by EGFR Recruits Activates Reference 
Y845 Src Stat5, P38 Ras, Stat5 (211-213) 
Y992 Auto/transphosphorylation PLCγ, SHC Stat3, PKC, Erk, Vav2 (212, 214) (215-217) 
Y1045 Auto/transphosphorylation c-cbl Ubiquitinylation (208, 208, 208, 218, 
219) 
 
Y1068 Auto/transphosphorylation Grb2, JNK Ras, Stat3, c-Jun, AP-1 (212, 218, 220, 221) 
Y1086 Auto/transphosphorylation Grb2, SH2 Stat3, MAPK, Pak1 (212, 216, 217) 
Y1148  Shc MAPK, Stat1, AP-1 (212, 215, 222-224) 
Y1173 Autophosphorylation Shc MAPK, PLCγ, Shp2 (212, 215, 222-
224)(225) 
S1046/7 Cam Kinase II P38 c-Cbl independent 
internalization  
(225-227) 
S1070 Cam Kinase II c-Cbl Internalization & 
ubiquitinylation 
(209, 225, 226) 
ErbB2 
Site Phosphorylated by ErbB2 Recruits Activates Reference 
Y877 Src  Stat3, PKA (192) 
Y1112 Auto/transphosphorylation c-cbl Ubiquitinylation & degradation (228, 229) 
Y1221/2 Auto/transphosphorylation  Shc, ErbB2 (190, 223, 230-232) 
Y1248 Auto/transphosphorylation  ErbB2 (230, 231) 
T686 PKC  Internalization (233) 
S1113 Calmodulin Kinase II (CaMK II)   (234) 
ErbB3 
Site Phosphorylated by ErbB3 Recruits Activates Reference 
Y1289  PI3K PI3K, Akt (194) 
Abbreviations: Mitogen activated protein kinase (MAPK), Y= tyrosine, S=serine, T=threonine, Calmodulin Kinase II (CaMK II) 
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responsiveness by facilitating dimerization and transactivation at the membrane rafts 
(199).  
 Upon ligand binding, receptor dimerization is induced by changes in 
conformation of the ligand-bound ectodomain and the exposure of the dimerization loop. 
While all 10 dimeric configurations of ErbB receptors are possible, some heterodimers 
are preferred (175, 200). ErbB2 lacks a ligand-binding domain, resulting in the 
constitutive exposure of its dimerization domain and making it the preferred dimerization 
partner for the all ErbBs (201). More, EGFR/ErbB2 heterodimers decrease EGFR 
degradation while EGFR homodimers are sorted more rapidly to the lysosome for 
receptor degradation (202, 203). Receptors dimerize and transphosphorylate one another 
(204) which allows signaling molecules, scaffolds, and signal inactivators to bind via 
SH2 and PTB domains. 
Following dimerization, phosphorylation of two regions of the CTD targets the 
EGFR to clathrin-coated pits where it is rapidly internalized into endosomes (203, 205-
207). From here, ligand either remains bound to the receptor and the ligand-receptor 
complex is degraded, or it is released and the receptor is recycled to the surface (Figure 
5; 202). EGFR homodimer sorting to the lysosome is directed by multiple mono- 
ubiquitinylation (208, 209). While the process is not fully understood, receptor 
endocytosis appears to be cholesterol-dependent and concentrated at lipid rafts (202, 
206).  Clathrin-mediated endocytosis, conversely, leads to a higher rate of EGFR 
recycling to  the surface prolonging the ability of EGFR to signal (210). This non-clathrin 
endocytosis drives receptor sorting to lysosomes and is more likely to attenuate EGFR 












Figure 5. ErbB subtypes and ligand specificity, signaling, and trafficking.  
The top left portion of this figures shows the four ErbB receptor subtypes 
(ErbB1-4) and differential ligand specificities. ErbB2 lacks a ligand binding 
domain and ErbB3 lacks a tyrosine kinase domain (2, 184). Ligand binding 
promotes dimerization, phosphorylation, and ubiquitinylation of the ErbB 
dimer. This targets it for association with effectors promoting ErbB-mediated 
signaling as well as targeting the dimer for internalization in clathrin-coated pits 
(52, 118, 203, 234). In endosomes, ligand identity and dimer composition direct 












Heterodimers of EGFR/ErbB2 or EGFR/ErbB3 tend to dissociate from the ligand 
regardless of ligand identity and are recycled back to the surface giving heterodimers a  
stronger and more persistent signaling capacity than EGFR homodimers (202). However, 
while receptor dimer pairs and method of endocytosis can dictate receptor degradation or 
recycling, ligand can also play a role. EGF causes downregulation of EGFR homodimers 
while other ligands, such as TGF-α, direct recycling of the receptor to the surface (205, 
235). 
Location-Dependent EGFR Signal Transduction and Down-regulation: 
EGFR signaling activates pathways involved in proliferation, cell survival and migration 
and its activity must be inhibited in the course of normal keratinocyte differentiation 
(175, 236). Although phosphorylated EGFRs in endosomes have lost access to ligands, 
these receptors can still signal,  While EGFRs cannot associate with or activate PLCγ or 
PI3K whose substrates are located in the plasma membrane (199, 222),  the receptors 
remain phosphorylated and associated with the scaffolding protein SHC (src homology 2 
containing containing transforming protein 1), the adaptor protein Grb2 (cytoplasmic 
growth factor receptor bound protein 2 ), or the guanine nucleotide exchange factor SOS 
(son of sevenless homolog 1), all of which allow ERK signaling to be propagated (237).  
These changes in location-dependent signal transduction can have profound 
effects on keratinocyte cell fate. EGFR signaling is canonically considered to be 
proliferative in keratinocytes, and ERK activation is also linked to keratinocyte 
proliferation and hyperproliferation in disease states (238-240). Previous studies have 
shown that PLCγ activation is required for keratinocyte differentiation (11) and that 
distribution of PLCγ is frequently altered in hyperproliferative skin conditions such as 
 38 
psoriasis or seborrheic keratosis (241). PLCγ can be directly activated by EGFR-
dependent phosphorylation and is also activated in a PI3K-dependent manner involving 
Ca-, c-src-, and cadherin-dependent mechanism (11, 242). PI3K sits upstream of PLCγ in 
keratinocytes but can also signal through Akt to promote keratinocyte differentiation and 
prevent cell death (242). As discussed previously, ErbB3 is the only ErbB receptor in 
keratinocytes with a binding site for PI3K, a pro-differentiation signaling cascade in 
keratinocytes (191).  Thus through differentiation-induced changes in ErbB receptor 
complement that cause a suprabasal increase of ErbB3, the EGFR could switch from pro-
proliferative signaling to pro-differentiation signaling, dependent upon context. 
MAPK/ERK pathway: Five members of serine/threonine MAPKs have been 
classified to date: ERK 1/2, c-Jun amino terminal kinases (JNK), p38, ERK 3 and 4, and 
ERK5 (243). Each MAPK pathway consists of a MAPKK kinase (MAPKKK) that 
activates a dual specificity MAPK kinase (MAPKK) which in turn activates a mitogen-
activated protein kinase (MAPK) by phosphorylation of tyrosine and threonine residues. 
The ERK signaling cascade is one of the primary mitogenic pathways in the epidermis, 
and a pathway that can be activated by all receptor tyrosine kinases.  Activation of the 
ERK pathway is initiated by phosphorylation of growth factor receptors including those 
for EGF, platelet derived growth factor (PDGF), insulin-like growth factor 1(IGF1), 
fibroblast-derived growth factor (FGF), and dermally-secreted keratinocyte growth factor 
(KGF / FGF7) (244).  
In the ERK 1/2 pathway (Figure 6A), EGF-like ligands activate the EGFR, 
inducing dimerization and transactivation of ErbB dimer pairs. The phosphorylation of 
tyrosines such as Y1068 and Y1086 on EGFR, recruit Grb2 via its SH2 domain (217, 
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220). The SH3 domains of Grb2 bind the guanine nucleotide exchange factor, SOS, 
which activates a membrane-associated GTPase, Ras (244). Activated Ras interacts with 
a downstream effector, Raf, the MAPKKK of the RAS-RAF-MEK-ERK pathway (243). 
Raf then phosphorylates the dual specificity kinases MAPK/ERK kinases (MEK), MEK1 
and 2, which in turn activate ERK 1/2 (243).  
Phosphorylated ERK that is not associated with scaffolding molecules can move 
into the nucleus where it is a major modulator of cellular proliferation and involved in 
entry into the G1 phase of cell cycle (245). Activated ERK phosphorylates over 80 
downstream effectors including nuclear substrates and transcription factors such as AP-1, 
c-Myc, c-Fos, STAT3, and Pax6. ERK also phosphorylates cytoskeletal and membrane-
associated proteins such as CD120A, Syk, and Calnexin which alter keratinocyte 
cytoskeletons to allow suprabasal migration (246). The localization of ERK signaling can 
also influence which interacting partners are able to interact with the receptors. With the 
loss of juxtacrine signaling in wounding, EGFR dimers can be internalized, and signal 
through ERK at the level of the endosome (237, 247). Conversely, the loss of cytosolic 
phosphorylated ERK through nuclear localization can attenuate signaling through 
cytosolic proteins maintaining suprabasal phenotype of keratinocytes in the case of an 
intact epithelium (238). Cytosolic ERK drives cytoskeletal changes and motility (248).  
Changes in ligand-stimulated EGFR activation following wounding and desmosomal 
interruption stimulate cytoskeletal changes, allowing for migration of keratinocytes 
across the wound (182, 240). ERK can also lead to activation of other proteins which lead 
to cytoskeletal or transcription factor phosphorylation such as Rsk2 and MSK1 (249).  
 40 
In the epidermis, the ERK pathway plays an important role in regulating normal 
epidermal homeostasis, as well as keratinocyte proliferation and viability (238). Increases 
in ERK activity associated with activating mutations of Ras or Ras over-expression occur 
in the majority of human squamous cell carcinomas (SCC) and is a key player in the 
development of murine SCC models (238). In the epidermis, Ras is activated in basal 
layers to drive proliferation while the Ras protein is lost suprabasally (250). Within the 




Figure 6. Signaling Pathways downstream of the EGFR. The EGFR upon 
activation will dimerize and is capable of interacting with several downstream 
pathways involved in cell proliferation, differentiation, and survival. Three 
prominent pathways are (A) RAS/RAF/ERK (B) PLCγ and (C) PI3K. PKC 
which is stimulated indirectly by EGFR activation also provides feedback 







pathway in basal layers leads to epidermal hyper-proliferation and thickening, as well as 
impaired differentiation (250).   
Phospholipase Cγ/Protein Kinase C: PLCγ is a membrane-associated enzyme 
that cleaves PIP2 into IP3 and DAG. While both function as second messengers 
interacting with downstream pathways, DAG remains membrane- associated while IP3 
diffuses into the cytosol where it interacts with IP3 receptors in the ER and releases 
calcium into the cytosol.  Ca, along with DAG activate classical PKCs (α, β, and γ) while 
DAG alone is required for activation of novel PKCs (ε, η, δ, and θ) (251). PKC is a 
serine/threonine kinase which has a number of substrates and is capable of 
autophosphorylation (252). PKC is thus activated by and linked to increased intracellular 
Ca and phosphorylates the EGFR on T654, which causes its downregulation (253, 254).  
PKC (Figure 6B) is also linked to Ca-driven structural changes such as enhanced 
desmosome formation (252). PKC α is activated by DAG and Ca and phosphorylates DP, 
a required part of the desmosome which anchors intermediate filaments to desmosomal 
plaques (255). DP phosphorylation by PKCα is required for desmosomal formation (256), 
but loss of PKCα seems to be necessary for the dissolution of desmosomes preceding 
epithelial-mesynchymal transition (EMT) in wounding (257). 
In the normal epidermis, membrane-associated PLCγ co-localizes with the EGFR 
only in the basal compartment. In contrast, suprabasal expression of PLCγ is common in 
many epidermal hyperproliferative diseases such as psoriasis, seborrheic keratosis, and 
the margins of second degree burns (241). However, PKC co-localizes to desmosomes in 
murine and human epidermis and serves to maintain epidermal barrier function in the 
intact epidermis (130, 250). The expression and activation of certain isoforms, 
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particularly PKCη, but also PKCα and δ, have been shown to be necessary for the 
expression of differentiation markers such as Lor, Ivl, SPRR-1, and Flg as well as the 
initiation of the differentiation process (258, 259).   
Phosphoinositide-3 Kinase signaling: There are three classes of 
phosphoinositide-3 kinases (260). The most commonly studied are class I PI3Ks which 
are targets for activation by RTKs and G-protein coupled receptors (GPCRs) (260). Class 
I PI3Ks phosphorylate PIP2 to PIP3 at the cellular membrane while classes II and III are 
less well understood and thought to be involved in vesicular signaling (261, 262). Class I 
PI3Ks are heterodimeric molecules comprised of a 110 kDa catalytic subunit and an 85 
kDa regulatory subunit containing a p110-binding region as well as two SH2 sites (260). 
Class I PI3Ks are activated by ErbB3 and ErbB4 (261).  
Evidence shows that PI3K/Akt is activated by the EGFR or c-Src in early 
epidermal differentiation both in vivo and in vitro (185, 242). However, the role of PI3K 
in epidermal homeostasis is complicated and seems to be highly context dependent. In the 
best understood scenario, PI3K signaling promotes cell survival by stimulating Akt-
driven inhibition of pro-apoptotic genes (242). Epidermal PI3K also activates PLCγ 
through the non-receptor kinases fyn and src, suggesting that PI3K is involved in 
epidermal differentiation (262).  However the role of PI3K may not be so much of an on-
off switch, as a context-dependent pro-survival and differentiating signal.  
While PI3K deletions in mice cannot be studied as they are early embryonic lethal 
(263), mice lacking phosphatase and tensin homolog (PTEN) which inactivates PI3K 
signaling, display a “shaggy bear” phenotype characterized by wrinkly skin and fur 
symptomatic of hyperkeratosis, hyperproliferation, and hypergranulation. These data 
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suggest that an unregulated increase in PI3K promotes aberrant proliferation (263), a 
hypothesis supported by data in the HaCaT human keratinocyte cell line where PI3K 
overexpression leads to increased invasiveness and epidermal thickening in organotypic 
culture (263). In addition, constitutive activation of PI3K inhibits the expression of 
markers of differentiation while driving hyperproliferation, leading to disorganized, 
hyperplastic, and poorly differentiated tissue (263, 264). 
This contextual signals driving differentiative and anti-apoptotic responses as 
opposed a proliferative, migratory role in the epidermis makes sense, within the context 
of wound healing and EGFR internalization. While both the p110 α and β catalytic 
subunits of PI3K are strongly expressed in the skin, the basal activation of Akt in normal 
skin is limited to the hair follicle sheath, the basal layer of neonatal murine epidermis, 
and extensively in the wounded epidermis where it stimulates cytoskeletal rearrangement 
to allow for EMT and keratinocyte wound infiltration (242, 263). Wounding leads to a 
rapid increase of phospho-Akt, particularly during the inflammatory phase of wound 
healing, but also leads to the upregulation of the p110 γ catalytic subunit of PI3K perhaps 
suggesting that enhanced Akt phosphorylation reflects an upstream increase in PI3K 
activity (263).  
Although the role of PI3K is still emerging, it appears to inhibit apopostis while 
maintaining a degree of epidermal plasticity for the skin’s healing response (242, 263). 
Stimulation of PI3K is tied to differentiation, both through location and ErbB receptor 
subtype. Due to its colocalization with membrane phospholipids, Class I PI3K is 
associated with signaling from the membrane (261). It clusters to TJ and desmosomal 
structures at the membrane and thus readily activates and is activated by ErbB receptors 
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colocalized to these same structures. Activation of PI3K by juxtracrine-activated EGFR 
at desmosomes can serve as a presence/absence indicator of cell-cell contact which is lost 
following desmosomal disruption. This leads to enhanced activation and altered PI3K 
signaling upon disruption or wounding (10, 260, 265). Further, only ErbB dimer pairs 
containing ErbB3 or ErbB4 can signal through PI3K (183). However, ErbB4 is not 
expressed in the epidermis suggesting that EGFR-ErbB3 dimers drive PI3K signaling in 
the epidermis (185).  
EGFR Ligands 
EGF and its family of ligands (Table 5) are formed as membrane bound-
promolecules containing one or more EGF-like domains (176). Of the 11 ligands in the 
EGFR ligand family, the EGFR recognizes the most ligands including  EGF, TGF-α, 
betacellulin (BTC), heparin binding EGF-like growth factor (HB-EGF), epiregulin 
(EREG), amphiregulin (AREG), and epigen (EPGN) (266). In addition, BTC, HB-EGF, 
and EREG bind to ErbB4 (175, 267). ErbB2 possesses no ligand-binding domain and 
thus recognizes no EGF-like ligands while neuregulins (NRG) 1-4 bind to ErbB3 and 
ErbB4 (268). Since EGFR signaling promotes proliferation, cell survival, and migration 
its signaling capacity must inhibited in the course of normal keratinocyte differentiation 
(175, 236).  The epidermis contains EGFR, ErbB2, and ErbB3 which can recognize all  
EGFR ligands and signal through EGFR/ErbB2 and EGFR/ErbB3 heterodimers as well 
as EGFR/EGFR homodimers (197).  
EGFR ligands in the skin auto-induce their own mRNA as well as cross-induce 
that of other EGFR ligands (279-281). For TGF-α, this occurs through a PKC-dependent 
stabilization of the TGF-α transcript that increases the half-life of its mRNA in primary 
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Role in the epidermis  Reference 
AREG 11.3 EGFR 4.2
4
 NC Epidermal proliferation, wound healing, 
inflammatory response, over-expression  
causes psoriatic-like lesions 
(211-213, 
269) 




 NC hair follicle development and hair cycle, 
but KO or over-expression models have no 
skin phenotype 
(269) 
EGF 6.2 EGFR 1.8
3
 NC Used historically in skin literature, but not 
produced in the epidermis 
(3, 175, 270) 
EPGN 7.9 EGFR 2678
3
 +3.77-fold Causes sebaceous hyperplasia in utero (111, 271) 
EREG 6.0  EGFR UNKN +2.02-fold Loss of EREG causes chronic dermatitis-
like phenotype 
(272) 




 NC Involved in wound healing and 
keratinocyte migration 
(182, 273) 
TGF-α 5.2 EGFR 8.8
2
 +1.71-fold Elevated in many hyperproliferative skin 




Abbreviations: No measured binding (NMB), No change (NC). 
1
molecular weight of pro-ligand 
2
solubilized full length EGFR in 
A431 cells 
3
As competitive binding experiments for EGFR ligands are performed in a heterogeneous system, Kd have been calculated 
from IC50 utilizing the Cheng-Prusoff equation (276):  𝐾𝑑 = 𝐼𝐶50 (
(1+[𝑐𝑜𝑚𝑝𝑒𝑡𝑖𝑡𝑜𝑟])
(𝐾𝐷𝑐𝑜𝑚𝑝𝑒𝑡𝑖𝑡𝑜𝑟)
)⁄   for 50 pM [125I]-EGF (277) 4or 645 pM [125I]-
EGF (278). 
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keratinocytes (8, 282, 283).  In other systems, such as the transformed colon epithelial 
LIM1215, auto-induction occurs through an EGFR-dependent transcriptional mechanism 
(282). In both cases, inhibition of the EGFR or PKC reverses the increase in TGF-α 
mRNA (282). Similar increases in BTC mRNA levels were observed in RIE-1 
gastrointestinal cells, however increases in secreted AREG and HB-EGF were only 
partially explained by a transcriptional mechanism (283). AREG and HB-EGF were also 
found to be elevated in cell lysates and conditioned medium before other EGFR ligands 
suggesting a role in promoting synthesis of other EGFR ligands (283). This suggests that 
increased cleavage as opposed to, or in conjunction with, increased synthesis drives 
increase of some ligands.  
EGFR ligands are released at different times, to different degrees, and have 
differential downstream effects following ErbB receptor activation (284). In 
keratinocytes, AREG is strongly proliferative, and in conjunction with HB-EGF, can 
account for around 70% of proliferation in monolayer keratinocytes grown in the absence 
of EGF (285). However, in mammary cell lines, AREG was the only assayed EGF-like 
ligand that failed to induce proliferation or increase ErbB3 phosphorylation (284). Other 
ligands, such as TGF-α, are not observed at a high level in normal skin, but are elevated 
in response to toxin exposure or epidermal disease (7, 274, 282).  Overall, AREG, HB-
EGF, TGF-α, and EREG are secreted by normal keratinocytes or upregulated in 
epidermal hyperproliferative diseases (196). 
Competition assays show that EGFR ligands possess markedly different affinities 
for the EGFR. However, these data must be interpreted cautiously, as most assays have 
used [
125
I]-EGF instead of iodinated forms of the ligand in question (270, 278). In 
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addition, each ligand possesses a different functional EC50 for proliferation, cell motility, 
and the EGFR signaling pathways they activate. While all EGF ligands in keratinocytes 
bind exclusively to the EGFR (176, 286), each ligand preferentially stabilizes differing 
ErbB dimer pairs which can have implications in endocytic sorting and receptor 
downregulation (176, 286).  ErbB2, the preferential dimer partner for EGFR, raises the 
EGFR’s affinity for TGF-α and HB-EGF (270), making ligand binding to EGFR/ErbB2 
dimer pairs more likely than EGFR homodimers.  Further, the presence of a heparin 
binding domain like that possessed by AREG and HB-EGF lowers the affinity of these 
ligands for the EGFR (288) though enhances acid-resistance to the low pH in lysosomes, 
directing receptors to degrade as opposed to TGF-α which dissociates at a low pH and 
leads the receptors to recycle (287).  
EGFR ligands are produced and trafficked to the cell surface in a membrane-
associated pro-form (171). From the membrane, ligands can signal directly with 
neighboring cells in a juxtacrine manner or can be cleaved by Ca-dependent 
metalloproteinases to interact with receptors on the same (autocrine) or neighboring 
(paracrine) cells (Figure 7)  (171, 269). This provides a mechanism for changes in EGFR 
signaling following disruption of cell-cell contact in wounding, and as a mechanism of 
altering EGFR signaling in differentiation (182, 289). Juxtacrine signaling does not allow 
for receptor endocytosis as the membrane-tethered ligand prevents internalization (171). 
This keeps the EGFR at the surface where it can signal through PI3K and PLCγ (289, 
290). Overall EGFR signaling represents a highly evolved system with a high degree of 
combinatorial complexity. In the epidermis, four ligands are secreted which can activate 
three ErbB receptors, producing five functional dimer pairs.  These dimers can signal  
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persistently at the cell surface, or inside the cell, and can activate a number of different 
downstream signaling pathways . This allows for the temporal and spatial control of 
EGFR signaling that is critical for epidermal homeostasis but still not fully understood 
(291). 
EGF—the prototypical EGFR ligand: As the nomenclature suggests, EGF is 
the prototypical EGFR ligand and the first EGFR ligand identified (205, 292, 293).  EGF 
has a high affinity for the EGFR and upon binding, induces dimerization and lysosomal 
degradation following internalization (204, 294). EGF is the best understood EGFR 
ligand and its frequent use has led to the preferential development and availability of 
tools specific to this ligand. These facts have led to a historical tendency to use EGF as an 






Figure 7. Mechanisms of EGFR activation for EGF-like ligands. Pro-
AREG (or another EGF-like ligand) exists in a membrane-bound form wherein 
it can activate EGFRs on neighboring cells in a (A) Juxtacrine manner, or, 
following cleavage by MMPs or ADAMs, diffuse in its cleaved form to 












295). Choi et al. (8) identified TGF-α in conditioned medium and then used [I
125
]-EGF to 
study TGF-α induced EGFR downregulation. However, differences in affinity, structure, 
and endosomal sorting of ligands and receptors create a false equivalency, particularly in 
the epidermis which does not produce soluble or membrane bound EGF (3, 176). Further, 
EGF binds to and down-regulates EGFRs differently than other ligands such as TGF-α 
which causes rapid receptor cycling, or AREG which causes slow recycling (287).   
Amphiregulin (AREG): In humans, AREG expression is controlled by two 
copies of the AREG gene, AREG and AREGB which are found on chromosome 4q13.3 
and flanked by BTC on the 3’ end and EPGN on the 5’ end (296). These genes produce a 
1.4 kb, six exon product which is translated into a 252 amino acid pro-form of AREG 
(296). This pro-AREG contains five major domains, including a signal domain (aa 1-19), 
an N-terminal domain (aa 20-101), an EGF-like domain (aa 102-184), a transmembrane 
domain (aa 199-221) and a cytoplasmic tail (aa 222-252) (297). Pro-AREG is cleaved by 
a disintegrin and metalloproteinase (ADAM)17, ADAM15, and MMP1(298-301). 
Proteolysis results in a 98 amino acid soluble AREG with a molecular mass of 11.3 kDa.  
AREG is typically referred to as a low affinity ligand for the EGFR, even though its IC50 
in competitive binding assays is within the same order of magnitude as most other ligands 
(278). This description appears to arise from the observation that AREG is far less potent 
than EGF in stimulating receptor phosphorylation or colony formation, in some cases 
requires 300 times as much ligand (270, 278). AREG, like EGF, remains associated with 
the EGFR in the late endosome. While it does not target the EGFR for lysosomal 
degradation, it does cause a slower recycling of the EGFR back to the cell surface (~30 
minutes) compared to TGF-α (2-5 minutes) (287).  
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TCDD does not affect AREG production in the skin but does increase its 
production in murine ureters (104) and by tobacco smoke in human oral mucosal cells 
(302) . When experimentally overexpressed in murine skin, AREG caused a psoriatic 
phenotype characterized by epidermal thickening and severe, early-onset psoriasis when 
overexpression was targeted to suprabasal keratinocytes (181, 303). In the latter case, 
AREG overexpression was involved in the induction of synovitis, suggestive of a 
mechanism of psoriatic arthritis, a common co-morbidity to psoriasis (181, 304).  In 
humans, AREG is an autocrine growth factor for keratinocytes, enhancing ErbB1-
mediated ERK signaling and proliferation (145, 182, 240).  
In cultured human keratinocytes, AREG mRNA expression was 19 times greater 
than any other EGFR ligand and soluble AREG was present at 7.5 times the 
concentration of any other EGFR ligand. AREG drives keratinocyte proliferation in an 
EGFR and CTD-dependent manner (182, 297, 305). Further, AREG is upregulated in 
human epidermal diseases such as psoriasis and squamous cell carcinomas of the 
epidermis, reinforcing its role in hyperproliferative conditions (306). 
Heparin Binding EGF-like Growth Factor (HB-EGF): In humans, proHB-EGF 
is a 21 kDa protein first isolated from macrophages (289, 307) and biochemically 
characterized by Iwamoto (289, 307).  Structurally similar to AREG, HB-EGF is found 
on the minus strand of chromosome 5q23 which encodes an 87 amino acid protein 
comprised of five exons (279). Interestingly, Pro-HB-EGF is unique among EGFR 
ligands in that it serves as a receptor for the diphtheria toxin. (308).  Pro-HB-EGF is 
targeted to the cell membrane where it can signal in a growth-inhibitory juxtacrine 
manner at points of cell-cell contact. However, when cleaved by MMP-3, MMP-7 (309, 
 51 
310) or MMP1 it becomes soluble and stimulates keratinocyte motility (298). HB-EGF is 
a low affinity ligand containing a heparin binding domain (311) and it is heavily O-
glycosylated. Like AREG, HB-EGF possesses a heparin-binding domain that makes it 
acid resistant and less likely to dissociate in the late endosome (287). However, unlike 
AREG, HB-EGF leads to EGFR downregulation by targeting endocytosed receptors to 
the lysosome for degradation rather than slow recycling (203, 312)  
Experimentally induced injuries lead to MMP-mediated cleavage of HB-EGF, 
producing its soluble form.  Soluble HB-EGF stimulates not only proliferation like 
AREG, but is also involved in migration and EMT (182, 313). In human skin, pro-HB-
EGF is responsible for cell-cycle inhibition and maintaining an epithelial phenotype 
(288). When HB-EGF is cleaved, the soluble HB-EGF enters the extracellular space and 
the CTD of HB-EGF enters the cytoplasmic where it alleviates transcriptional repression 
of cell cycle by promyelocytic leukemia zinc finger protein (PLZF). In fact, localization 
of the CTD correlates with cell cycle phase: cytoplasmic in early G1, nuclear in S phase 
(preceding late S phase transport of PLZF), and near centrosomes during cytokinesis. In 
this manner, cleaved HB-EGF serves not only to mitogenically signal to neighboring 
cells in autocrine/paracrine fashion following wounding, its CTD also drives proliferation 
in the secreting cell (314).  Meanwhile prolonged juxtacrine signaling inhibits this CTD-
driven cell cycle progression (314). HB-EGF also protects the cell from anoikis, a 
specialized form of apoptosis that occurs when cells lose contact with their basement 
membrane, allowing the cells to instead undergo cornification (171, 288). In normal and 
psoriatic skin, HB-EGF is expressed diffusely in all layers, though co-localization with 
ErbB3 increases in the stratum granulosum and stratum corneum,  leading to an increased 
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activation of PI3K through EGFR-ErbB3 heterodimers, enhanced cell longevity, and 
epidermal thickening (145).  
Transforming Growth Factor-Alpha (TGF- α): TGF-α is a high affinity EGFR 
ligand that causes rapid EGFR recycling (287). In the epidermis, TGF-α is expressed in 
the basal, spinous, and granular layers (275).  The human TGFA gene is located on the 
minus arm of chromosome 2p13. The 106,914 base pair transcript is translated into a 160 
amino acid, 17kDa protein comprised of 6 exons with tissue-dependent splice variants 
(274). TGF-α is cleaved by tumor necrosis factor-alpha converting enzyme 
(TACE/ADAM17), MMP1and ADAM10 (315) to create a 5.2 kDa soluble TGF-α (133, 
315, 316). Alternately spliced products excluding exon 6, or part of exon 5 and 6 were 
elevated in conditioned medium from squamous cell carcinoma cells. These transcripts 
were cleaved as readily as wild type TGF-α, but led to enhanced proliferation in both 
cancerous and normal keratinocytes (274). TGF-α bound to EGFRs maintains epidermal 
signaling capacity by inducing rapid recycling to the cell surface (287). 
In mice, loss of TGF-α creates a distinctive phenotype of wavy hairs growing 
from irregular hair follicles (317). Knockout mice also display decreased ear wound 
healing, but this result was not replicated in other wounding assays (318). Targeted 
overexpression of TGF-α causes spontaneous papillomas and epidermal hyperplasia 
reminiscent of psoriasis (319). In mice overexpressing TGF-α under a K1 promoter, mice 
exhibited increased incidences of epidermal tumorigenesis as well as enhanced sensitivity 
to tumor promoting phorbol esthers (320). 
TGF-α was the first EGFR ligand whose secretion was reported to be enhanced in 
keratinocytes exposed to TCDD (7, 8).  Elevated TGF-α is observed in TCDD exposed 
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tissues in vivo, including murine palates where leads to cleft palates and urogenitary 
tracts (3, 102). Pathophysiologically it is elevated in epidermal hyperproliferative 
disorders such as psoriasis and atopic dermatitis in humans (161, 179, 180). 
Epiregulin (EREG): EREG is the last EGFR ligand found to be secreted by 
keratinocytes (196). Identified in 2000, EREG is located between EPGN and AREG on 
chromosome 4q13 (279). The 4.8 kb transcript is translated into a 19 kDa protein 
comprised of 169 amino acids (279, 287). EREG is cleaved by TACE and ADAM10 
(316), and, like TGF-α, EREG causes rapid receptor cycling following endocytosis (287). 
In mice, the loss of EREG led to a late-onset, chronic dermatitis (321). Histological 
examination of these plaques and unaffected skin showed epidermal thickening and 
increased infiltration of macrophages into the skin (321). Shirasawa et al. posit that 
EREG’s role in the skin is to mediate inflammatory response (321) as secreted and 
membrane-bound EREG regulate cytokine production by the keratinocyte and 
neighboring Langerhans cells (321). However, other work in keratinocytes supports a 
strongly mitogenic effect of EREG (322) and it is also upregulated in psoriatic plaques in 
humans, frequently accompanied by an increase in AREG and TGF-α (323).  In addition, 
EREG is upregulated by TCDD in mice (8, 9, 104) which occurs via  an XRE-dependent 
mechanism in murine keratinocytes.  However, this promoter motif is not present in 
human cells (9). 
Other EGFR Ligands: The remaining six EGFR ligands have limited to no 
known role in the epidermis. BTC is secreted from cells in the hair follicle (272, 281). 
While this can lead to induction of EGFR ligands in neighboring skin cells in vivo (281) 
and has been observed to be increase angiogenesis in wounded skin (272), it is not 
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observed in keratinocytes in vitro (272). EPGN similarly has no known role in the 
epidermis, but it has been shown to induce sebaceous hyperproliferation in utero (111). 
NRG 1-4 have not been observed in skin. 
The role of growth factors and exogenous chemicals in epidermal wound healing 
The epidermis has a high degree of plasticity, owing to the ability of skin to 
respond to damage. In the case of wounding, the epidermal barrier is disrupted, and 
importantly, keratinocyte desmosomes and TJs are lost, taking away desmosomally 
clustered juxtacrine signaling and leading to the enhanced secretion of growth factors that 
drive keratinocyte migration and healing (105, 324).  The immediate response of the skin 
to wounding is not epidermal barrier repair, but rather, formation of a blood clot. 
Polymorphonuclear (PMN) neutrophils are attracted to the clot site and serve an 
antibacterial function, releasing antibacterial respiratory burst and phagocytizing debris 
(325). After the PMN fulfill their task, dermal and epidermal macrophages phagocytize 
them and other damaged or dead cells (325, 326). Over time, macrophages and 
monocytes in the wound decrease, allowing for the keratinocyte-driven proliferative stage 
of wound healing to begin (327). 
As the inflammatory stage of wound healing ends, fibroblasts from the dermis 
migrate into the wound site, and re-establish the ECM. Macrophage-secreted cytokines 
recruit endothelial cells for angiogenesis (327). Once a solid layer of granulation tissue, 
comprised of new blood vessels, fibroblasts, inflammatory cells and the fresh ECM (328) 
has developed, the basal keratinocytes are directed by MMP-induced cleavage of growth 
factors to migrate across the injured epithelium (329). These EGFR ligands provide a 
strong proliferative pressure following the re-establishment of cell-cell contacts. 
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Differentiation and reformation of the epidermal barrier follow (329). However, it is the 
inherent plasticity of this system wherein EGFR ligands are capable of both maintaining 
differentiated state and driving dedifferentiation that is commonly exploited in 
hyperproliferative skin diseases.  
Epidermal homeostasis and disease 
While Ca drives differentiation in keratinocytes, EGFR signaling represents a 
powerful and complex proliferative stimulus which must be overcome in order to switch 
to a program of terminal differentiation. However, the assumption that Ca-induced 
differentiation progresses by silencing the proliferative signaling of the EGFR is too 
simplistic. Both EGFR and Ca activate PKC which drives differentiation and, in a 
negative feedback mechanism, silences the EGFR (253, 259).  Ca is also involved in the 
activation of MMPs which cleave pro-EGF like ligands and increase autocrine and 
paracrine signaling (133, 240). However, there is interplay between EGFR 
phosphorylation, signaling, and Ca mediated signaling that is not well understood. One 
proposed mechanism of Ca/EGFR signaling cross-talk involves a desmosomal cadherin 
protein, Dsg1 (128).  The desmoglein family of proteins Dsg2 and 3 are expressed in the 
stratum basale of the epidermis while Dsg1 is expressed suprabasally (330). Dsg1 is 
involved in normal cell adhesion, regulation of cell size, and morphological changes of 
differentiating keratinocytes (128) wherein they become broader, flatter, and more tightly 
associated with neighboring cells (107). Dsg1 also decreases ERK activity without 
affecting total protein content and induces markers of terminal differentiation (K10 and 
Lor) in a manner independent of its role in adhesion (128). These data suggest that Ca 
regulates keratinocyte differentiation through the inhibition of pro-proliferative ERK 
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signaling (173, 236). In addition, they are consistent with the ability of Ca to inhibit EGF-
mediated induction of ERK signaling in cultured keratinocytes (177) and the reversible 
growth arrest and the expression of early markers of differentiation observed in 
keratinocytes treated with EGFR inhibitors (236). 
In some ways, keratinocyte differentiation is the physiological opposite of 
proliferation.  However, the reality is more nuanced. Nowhere is this interplay between 
differentiation and proliferation more apparent than in epidermal disease. While it is 
difficult to parse the hyperinflammatory or autoimmune aspects of chronic skin disorders 
such as psoriasis, ichthyoses, or atopic dermatitis, these diseases also contain an 
epidermal component wherein the epidermal barrier is compromised, frequently in the 
presence of epidermal thickening (142). In these diseases, alteration of keratin expression 
or disruption of differentiation-associated lipid synthesis lead to poorly cornified cells 
(134, 319).  Autoimmune or genetic disruption of desmosomes, TJs, or other cell-cell 
contact mimics wounding in an otherwise intact epidermis (120, 153, 331).   
As discussed above, the loss of cell-cell contact-dependent juxtacrine connections of 
EGFR ligands such as AREG, HB-EGF, and EREG leads to MMP-dependent cleavage of 
these ligands (182, 332) and a potential change in how an EGFR ligand signals.  For 
instance, soluble HB-EGF contributes to wound healing and cellular migration while 
membrane-bound HB-EGF maintains a differentiated state and an intact barrier (332). 
However, increased amounts of EGFR ligands also drive epidermal proliferation which 
leads to epidermal thickening, a trait shared in many chronic epidermal diseases where 
EGFR or its ligands are frequently overexpressed in lesional skin (155). Further, 
keratinocytes in hyperproliferative skin disorders do not differentiate normally, and 
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accelerated migration from basal to suprabasal layers in the presence of mediators of 
inflammation leads to thicker plaques of poorly differentiated keratinocytes which further 
damage barrier function.  In addition, genes associated with keratinocyte differentiation, 
such as Lor and Flg, are frequently down-regulated in psoriatic patients (152, 158, 333) 
in the presence of upregulated or otherwise heightened presence of EGFR ligands (176) . 
Introduction to the Research Questions 
NHEK as an in vitro model of epidermal homeostasis 
 TCDD has historically been studied in cells of various epidermal lineages (Table 
6), systems far less complex than multihormone driven systems such as gonads, 
reproductive tracts or immune cells, and in vivo endpoints typically involving an  
epidermal component (4, 7).  In skin, TCDD causes clear and easily interpreted 
endpoints in epidermal homeostasis and provides a defined platform for insight into AhR 
signaling and epidermal homeostasis. Well-established methods for monolayer and 
organotypic cell culture of primary keratinocytes in chemically-defined medium exist in 
which to study epidermal proliferation and differentiation (334). These are based upon 
initial work by Rheinwald and Green who determined minimal requirements for the 
growth and maintenance of primary keratinocytes (334). Further modifications to this 
method  have led to a defined system wherein primary cell cultures of human 
keratinocytes derived from neonatal foreskins establish close intercellular contacts, 
stratify, cornify, and express markers of differentiation such as keratins 1 and 10, Ivl, 
Lor, Flg, and Tgm1 as in a normal epidermis (334, 335). 
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Table 6. Comparisons of keratinocyte cell lines 
Cell Line Source Transformed Passages Differentiation 
Competent? 
Known alterations References 
NHEK Neonatal foreskin  Primary 5 Yes Individual genomic 
differences 
(239, 334) 
N/TERT1 Neonatal foreskin Yes, TERT Immortal Yes Loss of p16INK 
TERT expression 
(339) 
HaCat Adult male, distal 
periphery of 
melanoma 




SCC-12F 60 yo male, Facial 
SCC 
Yes, spont. Immortal Yes From immunosuppressed 
transplant recipient 
(343, 344) 
A431 85 yo female, SCC Yes, spont. Immortal Incomplete P53 deletion 
Enhanced EGFR 
(345) 
Abbreviations: TERT –telomerase reverse transcriptase
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In vitro, extracellular Ca
 
mimics the gradient existing in vivo where Ca is low 
basally and higher in the granular/cornified layers (147, 336).  After 24 hours in high 
extracellular Ca (between 1.2 and 2.0 mM) more than 95% of keratinocytes are arrested 
in G1 phase (337). Differences in physiological and pathophysiological proliferation or 
differentiation are not just molecular; marked changes in cellular morphology can be seen 
in less than a day (Figure 8). After 20 hours, cells treated with 1.8 mM Ca appear to be 
cornifying. They flatten into a larger, more differentiated phenotype and the borders of 
cells become less distinct as the NHEKs form a sheet. This morphology has been 
correlated with a suprabasal keratinocyte phenotype (13, 338). Conversely cells grown in 
the absence of TCDD or Ca, or cells treated with 100 ng/mL recombinant human EGF 
maintain clear borders. As time progresses, EGF-treated cells begin to stratify, then take 
on a fibroblast-like shape to migrate and fill this new layer. TCDD-treated NHEKs--also 
stratify, and take on an irregular appearance marked with vesicles and irregular borders. 
However, despite their appearance, TCDD does not induce apoptosis in NHEKs (4) and 
later work performed on these cells will show them to be equal if not more responsive to 
EGFR ligands than their basal medium-treated cohort. Nevertheless, these cells are 
clearly not behaving in fashions comparable to physiological models of proliferation 
(EGF) or differentiation (Ca) (4). 
TCDD alters proliferation and differentiation 
Both TCDD- and Ca-induced differentiation are associated with decreased [
125
I]-
EGF binding indicative of EGFR loss from the cell surface (13, 14). However, studies 
assessing TCDD and Ca effects on [
125
I]-EGF binding have not examined the time-course 







Figure 8. Confluent NHEKs following treatment with basal medium, EGF, 
Ca, or TCDD. EGF and TCDD induce stratification while TCDD and Ca induce 
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mechanism by which it occurs. In spite of loss of EGFRs from the cell surface, TCDD 
induces the expression of several EGFR ligands including TGF-α and EREG in vivo and 
in vitro (3, 7, 9), and promotes a hyperproliferative state in vivo (13, 74, 346). In 
keratinocyte cell culture, TCDD increases the secretion and production of several ligands, 
including TGF-α in humans and mice and EREG directly through an XRE upstream of 
the EREG TSS in mice (7-9). It is not clear that these increases in EGFR ligand secretion 
are shown to be directly responsible for alterations in proliferation. Additional data on 
TCDD’s role in epidermal proliferation is equivocal and dependent upon growth and 
treatment protocols, endpoints, as well as cell lineage (Table 7). In mice, less responsive 
hairless (hr-/hr-) mice showed more hyperplasia than TCDD-sensitive mice which 
showed accelerated differentiation suggesting TCDD mimics Ca in driving differentiation 
and suppressing EGFR signaling  (51). However human patients with chloracne present 
with epidermal thickening, an effect caused by unchecked proliferation or slowed 
epidermal turnover (74).   
Although TCDD neither binds to nor directly modifies the EGFR (72), TCDD 
may alter cellular proliferation by mimicking some aspects of EGFR signaling (72). Mice 
exposed in utero to TCDD or EGF display similar phenotypes including premature eyelid 
opening, premature tooth eruption, decreases in body and thymic weight (348), and 
abnormal palatogenesis (102). However, TCDD decreases EGFR binding both in vitro 
and in vivo (14, 16, 348), a response that was less extensive in murine strains with lower 
sensitivity to the effects of TCDD (16). These data correlate TCDD responses with loss 
of binding and could result from alteration of EGFR synthesis, phosphorylation status, 
transactivation of the EGFR, or through production of an autocrine growth factor  
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Table 7. EGFR downregulation leads to differing endpoints depending on treatment condition 
 
 Osborne 1986 
(16) 
Hudson 1985 (14) Boonstra 1985 
(347) 
O’Keefe 1983 (15) O’Keefe et al. 1982 (295) 
Ca (mM) 
low/high 
0.05 / 1.1 0.06 / 1.8 0.06 / 1.6 <0.01 / 1.1 0.09 / 1.8 
EGF 8 ng/mL 8 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 
TCDD 10 nM 100 nM -- -- -- 
Cells NHEK SCC-12F SCC-12F NHEK NHEK 
Medium 75% DMEM/F12, 
penstrep, 
hydrocortisone, 
ctx, 5% FBS 




transferrin, 5 ng/mL insulin 
Pre-binding 
treatment 
24 h + Ca 
0-72 h TCDD 
24 h + Ca 
96 h + TCDD 
120 h + EGF 







C 30 min, 37
o
C 2 h, RT 4 h, 4
o




Results TCDD ↓ EGFR 
binding, 2-fold ↑ 
CE, 51% ↓ DNA 
synthesis, 54% ↓ in 
basal cell number 
Ca ↑ envelope 
competence, 
TCDD/Ca behaved 
like Ca rather than 
TCDD 
Ca dependent 
binding loss is 
dose-dependent 
5-fold increase in 
EGFR with no 
change in activity 
Differentiated cells do not 
bind EGF, EGF causes 60% 
↓ in [
125
I]-EGF binding at 2 
h. 
Abbreviations: DMEM Dulbecco’s minimal essential medium; F12 –Ham’s F12 medium, FBS-fetal bovine serum, ctx—cholera 
toxin, 75% DMEM/F12: 75% DMEM, 25% Ham’s F12 
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(8, 66). One suggested mechanism is that TCDD activates the EGFR in a non-canonical 
ligand-independent manner. TCDD increases PKC signaling and thus the activity of 
several non-RTKs, resulting in enhanced EGFR phosphorylation in the plasma membrane 
(349). For example, the non-RTK, c-src, is bound cytosolically in a complex with Hsp90 
and the AhR, and released upon AhR ligand binding (350). When released from the AhR 
protein complex by AhR-ligand binding, c-src is activate and could phosphorylate and 
activate the EGFR, leading to a ligand-independent TCDD-induced proliferation (211, 
351).  Alternatively, TCDD-induced production of EGFR ligands could drive TCDD’s 
proliferative response through a ligand-dependent receptor activation. 
In addition to its proliferative effect, TCDD also accelerates differentiation as 
evidenced by assays of barrier function or quantitation of protein or mRNA for markers 
of differentiation (1, 5, 18).  This occurs in the face of decreases in receptor number, 
suggesting that loss of receptor signaling is important, even though TCDD is increasing 
ligand production.   
Experimental design  
Both TCDD- and Ca-treated cells show a loss of [
125
I]-EGF binding suggesting a 
down-regulation or relocalization of EGFRs (15). In NHEKs, exposure to high 
extracellular Ca causes concentration-dependent decreases in high affinity [
125
I]-EGF 
binding (15). Likewise, TCDD treatment decreased EGF binding, EGF-induced DNA 
synthesis, and increased CE competence (13).  Hudson et al. (14) found that this TCDD-
induced repression of EGF signaling was enhanced in NHEKs grown in the presence of 
high (1.8 mM) extracellular Ca, while binding was less affected in low Ca which selects 
for basal, proliferating cells. However, down-regulation is not simply a means of 
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silencing receptor signaling; it can also alter signaling dynamics, serving as another layer 
of spatial and temporal control of complex networks of response to environmental cues 
(352). 
To address how alterations in EGFR signaling modulate the proliferative 
capacity of NHEKs,  we first explored to what degree EGFR down-regulation leads 
to a loss of signaling in Ca-induced keratinocyte differentiation and TCDD-induced 
hyperproliferation.  In the second chapter of this work we sought to identify which 
ligands were produced in NHEKs grown in high Ca (1.8 mM) to define their role in 
physiological EGFR down-regulation. We further determined if EGFR down-regulation 
affected EGFR competence in activating ERK-signaling, and modified proliferative 
capacity.  In the third chapter, we explored the impact of TCDD on EGFR down-
regulation and cellular responses.   To answer these questions we used ligand-specific 
enzyme-linked immunosorbent assays (ELISAs) to identify and quantify EGFR ligands 
secreted under conditions of high Ca or TCDD. We then interfered with ligand activity 
and measured the impact on Ca- or TCDD-induced proliferation, ERK activity, or EGFR 
down-regulation  
While this work addresses the question of how Ca and TCDD induce EGFR 
down-regulation, it also shows that even under differentiating conditions, the EGFR still 
plays an active role in regulating keratinocyte function. It has also lays the groundwork 
for future studies examining the combined role of TCDD and Ca on epidermal 





1. Sutter CH, Bodreddigari S, Campion C, Wible RS, Sutter TR 2011 2,3,7,8-
Tetrachlorodibenzo-p-dioxin increases the expression of genes in the human epidermal 
differentiation complex and accelerates epidermal barrier formation. Toxicol Sci 
124:128-137  
2. Hankinson O 2009 Repression of aryl hydrocarbon receptor transcriptional activity by 
epidermal growth factor. Mol Interv 9:116-118  
3. Abbott BD, Buckalew AR, DeVito MJ, Ross D, Bryant PL, Schmid JE 2003 EGF 
and TGF-alpha expression influence the developmental toxicity of TCDD: dose response 
and AhR phenotype in EGF, TGF-alpha, and EGF + TGF-alpha knockout mice. Toxicol 
Sci 71:84-95  
4. Loertscher JA, Sadek CS, Allen-Hoffmann BL 2001 Treatment of normal human 
keratinocytes with 2,3,7,8-tetrachlorodibenzo-p-dioxin causes a reduction in cell number, 
but no increase in apoptosis. Toxicol Appl Pharmacol 175:114-120  
5. Loertscher JA, Lin TM, Peterson RE, Allen-Hoffmann BL 2002 In utero exposure 
to 2,3,7,8-tetrachlorodibenzo-p-dioxin causes accelerated terminal differentiation in fetal 
mouse skin. Toxicol Sci 68:465-472  
6. Sutter CH, Yin H, Li Y, Mammen JS, Bodreddigari S, Stevens G, Cole JA, Sutter 
TR 2009 EGF receptor signaling blocks aryl hydrocarbon receptor-mediated 
transcription and cell differentiation in human epidermal keratinocytes. Proc Natl Acad 
Sci U S A 106:4266-4271  
7. Gaido KW, Maness SC, Leonard LS, Greenlee WF 1992 2,3,7,8-
Tetrachlorodibenzo-p-dioxin-dependent regulation of transforming growth factors-alpha 
and -beta 2 expression in a human keratinocyte cell line involves both transcriptional and 
post-transcriptional control. J Biol Chem 267:24591-24595  
8. Choi EJ, Toscano DG, Ryan JA, Riedel N, Toscano WA,Jr 1991 Dioxin induces 
transforming growth factor-alpha in human keratinocytes. J Biol Chem 266:9591-9597  
9. Patel RD, Kim DJ, Peters JM, Perdew GH 2006 The aryl hydrocarbon receptor 
directly regulates expression of the potent mitogen epiregulin. Toxicol Sci 89:75-82  
10. Xie Z, Bikle DD 2007 The recruitment of phosphatidylinositol 3-kinase to the E-
cadherin-catenin complex at the plasma membrane is required for calcium-induced 
phospholipase C-gamma1 activation and human keratinocyte differentiation. J Biol Chem 
282:8695-8703  
 66 
11. Xie Z, Singleton PA, Bourguignon LY, Bikle DD 2005 Calcium-induced human 
keratinocyte differentiation requires src- and fyn-mediated phosphatidylinositol 3-kinase-
dependent activation of phospholipase C-gamma1. Mol Biol Cell 16:3236-3246  
12. Calautti E, Missero C, Stein PL, Ezzell RM, Dotto GP 1995 Fyn Tyrosine Kinase 
is Involved in Keratinocyte Differentiation Control. Genes Dev 9:2279-2291  
13. Greenlee WF, Dold KM, Osborne R 1985 Actions of 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) on human epidermal keratinocytes in culture. In vitro Cell Dev Biol 
21:509-512  
14. Hudson LG, Toscano WA,Jr, Greenlee WF 1985 Regulation of epidermal growth 
factor binding in a human keratinocyte cell line by 2,3,7,8-tetrachlorodibenzo-p-dioxin. 
Toxicol Appl Pharmacol 77:251-259  
15. O'Keefe EJ, Payne RE,Jr 1983 Modulation of the epidermal growth factor receptor 
of human keratinocytes by calcium ion. J Invest Dermatol 81:231-235  
16. Osborne R, Greenlee WF 1985 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) 
enhances terminal differentiation of cultured human epidermal cells. Toxicol Appl 
Pharmacol 77:434-443  
17. Enan E, Matsumura F 1996 Identification of c-Src as the integral component of the 
cytosolic Ah receptor complex, transducing the signal of 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) through the protein phosphorylation pathway. Biochem Pharmacol 
52:1599-1612  
18. Kennedy LH, Sutter CH, Leon Carrion S, Tran QT, Bodreddigari S, Kensicki E, 
Mohney RP, Sutter TR 2013 2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated production 
of reactive oxygen species is an essential step in the mechanism of action to accelerate 
human keratinocyte differentiation. Toxicol Sci 132:235-249  
19. National Toxicology Program 2011 2,3,7,8-Tetrachlorodibenzo-p-dioxin. Rep 
Carcinog 12:396-398  
20. DeVito MJ, Schecter A 2002 Exposure assessment to dioxins from the use of 
tampons and diapers. Environ Health Perspect 110:23-28  
21. Dearfield KL, Edwards SR, O'Keefe MM, Abdelmajid NM, Blanchard AJ, 
Labarre DD, Bennett PA 2013 Dietary estimates of dioxins consumed in U.S. 
Department of Agriculture-regulated meat and poultry products. J Food Prot 76:1597-
1607  
22. Pirkle JL, Wolfe WH, Patterson DG, Needham LL, Michalek JE, Miner JC, 
Peterson MR, Phillips DL 1989 Estimates of the half-life of 2,3,7,8-tetrachlorodibenzo-
 67 
p-dioxin in Vietnam Veterans of Operation Ranch Hand. J Toxicol Environ Health 
27:165-171  
23. Sorg O, Zennegg M, Schmid P, Fedosyuk R, Valikhnovskyi R, Gaide O, 
Kniazevych V, Saurat JH 2009 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) poisoning 
in Victor Yushchenko: identification and measurement of TCDD metabolites. Lancet 
374:1179-1185  
24. Milbrath MO, Wenger Y, Chang CW, Emond C, Garabrant D, Gillespie BW, 
Jolliet O 2009 Apparent half-lives of dioxins, furans, and polychlorinated biphenyls as a 
function of age, body fat, smoking status, and breast-feeding. Environ Health Perspect 
117:417-425  
25. Michalek JE, Tripathi RC, Caudill SP, Pirkle JL 1992 Investigation of TCDD 
half-life heterogeneity in veterans of Operation Ranch Hand. J Toxicol Environ Health 
35:29-38  
26. Pohjanvirta R, Tuomisto J 1994 Short-term toxicity of 2,3,7,8-tetrachlorodibenzo-
p-dioxin in laboratory animals: effects, mechanisms, and animal models. Pharmacol Rev 
46:483-549  
27. Pohjanvirta R, Vartiainen T, Uusi-Rauva A, Monkkonen J, Tuomisto J 1990 
Tissue distribution, metabolism, and excretion of 14C-TCDD in a TCDD-susceptible and 
a TCDD-resistant rat strain. Pharmacol Toxicol 66:93-100  
28. Sutter CH, Bodreddigari S, Sutter TR, Carlson EA, Silkworth JB 2010 Analysis 
of the CYP1A1 mRNA dose-response in human keratinocytes indicates that relative 
potencies of dioxins, furans, and PCBs are species and congener specific. Toxicol Sci 
118:704-715  
29. Sterling JB, Hanke CW 2005 Dioxin toxicity and chloracne in the Ukraine. J Drugs 
Dermatol 4:148-150  
30. Soong DK, Ling YC 1997 Reassessment of PCDD/DFs and Co-PCBs toxicity in 
contaminated rice-bran oil responsible for the disease "Yu-Cheng". Chemosphere 
34:1579-1586  
31. Mitoma C, Uchi H, Tsukimori K, Yamada H, Akahane M, Imamura T, Utani A, 
Furue M 2015 Yusho and its latest findings-A review in studies conducted by the Yusho 
Group. Environ Int 82:41-48  
32. Aoki Y 2001 Polychlorinated biphenyls, polychlorinated dibenzo-p-dioxins, and 
polychlorinated dibenzofurans as endocrine disrupters--what we have learned from 
Yusho disease. Environ Res 86:2-11  
 68 
33. Wang SL, Tsai PC, Yang CY, Guo YL 2008 Increased risk of diabetes and 
polychlorinated biphenyls and dioxins: a 24-year follow-up study of the Yucheng cohort. 
Diabetes Care 31:1574-1579  
34. Tlustos C, Anderson W, Flynn A, Pratt I 2014 Additional exposure of the Irish 
adult population to dioxins and PCBs from the diet as a consequence of the 2008 Irish 
dioxin food contamination incident. Food Addit Contam Part A Chem Anal Control Expo 
Risk Assess 31:889-904  
35. Pratt IS, Anderson WA, Crowley D, Daly SF, Evans RI, Fernandes AR, 
Fitzgerald M, Geary MP, Keane DP, Malisch R, McBride J, Morrison JJ, Reilly A, 
Tlustos C 2012 Polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated 
dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs) in breast milk of first-time 
Irish mothers: impact of the 2008 dioxin incident in Ireland. Chemosphere 88:865-872  
36. Homberger E, Reggiani G, Sambeth J, Wipf HK 1979 The Seveso accident: its 
nature, extent and consequences. Ann Occup Hyg 22:327-367  
37. Warner M, Mocarelli P, Samuels S, Needham L, Brambilla P, Eskenazi B 2011 
Dioxin exposure and cancer risk in the Seveso Women's Health Study. Environ Health 
Perspect 119:1700-1705  
38. Engelhaupt E 2008 Happy birthday, Love Canal. Environ Sci Technol 42:8179-8186  
39. Brown P, Clapp R 2002 Looking back on Love Canal. Public Health Rep 117:95-98  
40. Druschel C, Sharpe-Stimac M, Cross P 2001 Process of and problems in changing 
a birth defects registry reporting system. Teratology 64 Suppl 1:S30-6  
41. Austin AA, Fitzgerald EF, Pantea CI, Gensburg LJ, Kim NK, Stark AD, Hwang 
SA 2011 Reproductive outcomes among former Love Canal residents, Niagara Falls, 
New York. Environ Res 111:693-701  
42. Kielb CL, Pantea CI, Gensburg LJ, Jansing RL, Hwang SA, Stark AD, 
Fitzgerald EF 2010 Concentrations of selected organochlorines and chlorobenzenes in 
the serum of former Love Canal residents, Niagara Falls, New York. Environ Res 
110:220-225  
43. Gensburg LJ, Pantea C, Kielb C, Fitzgerald E, Stark A, Kim N 2009 Cancer 
incidence among former Love Canal residents. Environ Health Perspect 117:1265-1271  
44. Gensburg LJ, Pantea C, Fitzgerald E, Stark A, Hwang SA, Kim N 2009 Mortality 
among former Love Canal residents. Environ Health Perspect 117:209-216  
45. Sun M 1983 Missouri's costly dioxin lesson. Science 219:367-369  
 69 
46. Umbreit TH, Hesse EJ, Gallo MA 1988 Bioavailability and cytochrome P-450 
induction from 2,3,7,8-tetrachlorodibenzo-P-dioxin contaminated soils from Times 
Beach, Missouri, and Newark, New Jersey. Drug Chem Toxicol 11:405-418  
47. Adam J Lieberman, Simona Kwon 2004 Facts versus fears: a review of the greatest 
unfounded health scares of recent times. New York, NY: American Council on Science 
and Health; 64  
48. Gough M 1991 Human exposures from dioxin in soil--a meeting report. J Toxicol 
Environ Health 32:205-235  
49. Brown J 2012 Route 66 State Park in Eureka Cleared by EPA Officials. Eureka-
Wildwood Patch  
50. Hankinson O 2005 Role of coactivators in transcriptional activation by the aryl 
hydrocarbon receptor. Arch Biochem Biophys 433:379-386  
51. Knutson JC, Poland A 1982 Response of murine epidermis to 2,3,7,8-
tetrachlorodibenzo-p-dioxin: interaction of the ah and hr loci. Cell 30:225-234  
52. Kawajiri K, Fujii-Kuriyama Y 2007 Cytochrome P450 gene regulation and 
physiological functions mediated by the aryl hydrocarbon receptor. Arch Biochem 
Biophys 464:207-212  
53. Swanson HI 2002 DNA binding and protein interactions of the AHR/ARNT 
heterodimer that facilitate gene activation. Chem Biol Interact 141:63-76  
54. Dere E, Forgacs AL, Zacharewski TR, Burgoon LD 2011 Genome-wide 
computational analysis of dioxin response element location and distribution in the human, 
mouse, and rat genomes. Chem Res Toxicol 24:494-504  
55. Zhang L, Savas U, Alexander DL, Jefcoate CR 1998 Characterization of the mouse 
Cyp1B1 gene. Identification of an enhancer region that directs aryl hydrocarbon receptor-
mediated constitutive and induced expression. J Biol Chem 273:5174-5183  
56. Lusska A, Shen E, Whitlock JP,Jr 1993 Protein-DNA interactions at a dioxin-
responsive enhancer. Analysis of six bona fide DNA-binding sites for the liganded Ah 
receptor. J Biol Chem 268:6575-6580  
57. Sutter TR, Tang YM, Hayes CL, Wo YY, Jabs EW, Li X, Yin H, Cody CW, 
Greenlee WF 1994 Complete cDNA sequence of a human dioxin-inducible mRNA 
identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol 
Chem 269:13092-13099  
 70 
58. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR 1996 17 beta-
estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U 
S A 93:9776-9781  
59. Emi Y, Ikushiro S, Iyanagi T 1996 Xenobiotic responsive element-mediated 
transcriptional activation in the UDP-glucuronosyltransferase family 1 gene complex. J 
Biol Chem 271:3952-3958  
60. Cho JS, Chang MS, Rho HM 2001 Transcriptional activation of the human Cu/Zn 
superoxide dismutase gene by 2,3,7,8-tetrachlorodibenzo-p-dioxin through the 
xenobiotic-responsive element. Mol Genet Genomics 266:133-141  
61. Yoo HY, Chang MS, Rho HM 1999 Xenobiotic-responsive element for the 
transcriptional activation of the rat Cu/Zn superoxide dismutase gene. Biochem Biophys 
Res Commun 256:133-137  
62. Swedenborg E, Ruegg J, Makela S, Pongratz I 2009 Endocrine disruptive 
chemicals: mechanisms of action and involvement in metabolic disorders. J Mol 
Endocrinol 43:1-10  
63. Gregoraszczuk EL 2002 Dioxin exposure and porcine reproductive hormonal 
activity. Cad Saude Publica 18:453-462  
64. Aluru N, Renaud R, Leatherland JF, Vijayan MM 2005 Ah Receptor-mediated 
impairment of interrenal steroidogenesis involves StAR protein and P450scc gene 
attenuation in rainbow trout. Toxicol Sci 84:260-269  
65. Liu S, Abdelrahim M, Khan S, Ariazi E, Jordan VC, Safe S 2006 Aryl 
hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast 
cancer cells. Biol Chem 387:1209-1213  
66. Safe S, Wormke M, Samudio I 2000 Mechanisms of inhibitory aryl hydrocarbon 
receptor-estrogen receptor crosstalk in human breast cancer cells. J Mammary Gland Biol 
Neoplasia 5:295-306  
67. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, 
Watowich SS, Jetten AM, Tian Q, Dong C 2009 Critical regulation of early Th17 cell 
differentiation by interleukin-1 signaling. Immunity 30:576-587  
68. Mohinta S, Kannan AK, Gowda K, Amin SG, Perdew GH, August A 2015 
Differential regulation of th17 and T regulatory cell differentiation by aryl hydrocarbon 
receptor dependent xenobiotic response element dependent and independent pathways. 
Toxicol Sci 145:233-243  
69. Ovrevik J, Lag M, Lecureur V, Gilot D, Lagadic-Gossmann D, Refsnes M, 
Schwarze PE, Skuland T, Becher R, Holme JA 2014 AhR and Arnt differentially 
 71 
regulate NF-kappaB signaling and chemokine responses in human bronchial epithelial 
cells. Cell Commun Signal 12:48-014-0048-8  
70. Vogel CF, Khan EM, Leung PS, Gershwin ME, Chang WL, Wu D, Haarmann-
Stemmann T, Hoffmann A, Denison MS 2014 Cross-talk between aryl hydrocarbon 
receptor and the inflammatory response: a role for nuclear factor-kappaB. J Biol Chem 
289:1866-1875  
71. Lee YH, Lin CH, Hsu PC, Sun YY, Huang YJ, Zhuo JH, Wang CY, Gan YL, 
Hung CC, Kuan CY, Shie FS 2015 Aryl hydrocarbon receptor mediates both 
proinflammatory and anti-inflammatory effects in lipopolysaccharide-activated 
microglia. Glia 63:1138-1154  
72. Haarmann-Stemmann T, Bothe H, Abel J 2009 Growth factors, cytokines and their 
receptors as downstream targets of arylhydrocarbon receptor (AhR) signaling pathways. 
Biochem Pharmacol 77:508-520  
73. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H, Takahashi S, 
Kouzmenko A, Nohara K, Chiba T, Fujii-Kuriyama Y, Kato S 2007 Dioxin receptor 
is a ligand-dependent E3 ubiquitin ligase. Nature 446:562-566  
74. Panteleyev AA, Bickers DR 2006 Dioxin-induced chloracne--reconstructing the 
cellular and molecular mechanisms of a classic environmental disease. Exp Dermatol 
15:705-730  
75. Williams JA, Zhang J, Jeon H, Nitta T, Ohigashi I, Klug D, Kruhlak MJ, 
Choudhury B, Sharrow SO, Granger L, Adams A, Eckhaus MA, Jenkinson SR, 
Richie ER, Gress RE, Takahama Y, Hodes RJ 2014 Thymic medullary epithelium and 
thymocyte self-tolerance require cooperation between CD28-CD80/86 and CD40-CD40L 
costimulatory pathways. J Immunol 192:630-640  
76. Ahrenhoerster LS, Leuthner TC, Tate ER, Lakatos PA, Laiosa MD 2015 
Developmental exposure to 2,3,7,8 tetrachlorodibenzo-p-dioxin attenuates later-life 
Notch1-mediated T cell development and leukemogenesis. Toxicol Appl Pharmacol 
283:99-108  
77. Kerkvliet NI, Brauner JA 1987 Mechanisms of 1,2,3,4,6,7,8-heptachlorodibenzo-p-
dioxin (HpCDD)-induced humoral immune suppression: evidence of primary defect in T-
cell regulation. Toxicol Appl Pharmacol 87:18-31  
78. Vos O 1978 Effect of bacterial lipopolysaccharide on proliferation of CFU-S. Exp 
Hematol 6:688-693  
79. White KL,Jr, Lysy HH, McCay JA, Anderson AC 1986 Modulation of serum 
complement levels following exposure to polychlorinated dibenzo-p-dioxins. Toxicol 
Appl Pharmacol 84:209-219  
 72 
80. Clark DA, Sweeney G, Safe S, Hancock E, Kilburn DG, Gauldie J 1983 Cellular 
and genetic basis for suppression of cytotoxic T cell generation by haloaromatic 
hydrocarbons. Immunopharmacology 6:143-153  
81. House RV, Lauer LD, Murray MJ, Thomas PT, Ehrlich JP, Burleson GR, Dean 
JH 1990 Examination of immune parameters and host resistance mechanisms in B6C3F1 
mice following adult exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Toxicol Environ 
Health 31:203-215  
82. Tucker AN, Vore SJ, Luster MI 1986 Suppression of B cell differentiation by 
2,3,7,8-tetrachlorodibenzo-p-dioxin. Mol Pharmacol 29:372-377  
83. Luebke RW, Copeland CB, Diliberto JJ, Akubue PI, Andrews DL, Riddle MM, 
Williams WC, Birnbaum LS 1994 Assessment of host resistance to Trichinella spiralis 
in mice following preinfection exposure to 2,3,7,8-TCDD. Toxicol Appl Pharmacol 
125:7-16  
84. Luster MI, Boorman GA, Dean JH, Luebke RW, Lawson LD 1980 The effect of 
adult exposure to diethylstilbestrol in the mouse: alterations in immunological functions. 
J Reticuloendothel Soc 28:561-569  
85. Pesatori AC, Consonni D, Rubagotti M, Grillo P, Bertazzi PA 2009 Cancer 
incidence in the population exposed to dioxin after the "Seveso accident": twenty years of 
follow-up. Environ Health 8:39-069X-8-39  
86. Baan R, Grosse Y, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-
Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, WHO International Agency 
for Research on Cancer Monograph Working Group 2009 A review of human 
carcinogens--Part F: chemical agents and related occupations. Lancet Oncol 10:1143-
1144  
87. Boffetta P, Mundt KA, Adami HO, Cole P, Mandel JS 2011 TCDD and cancer: a 
critical review of epidemiologic studies. Crit Rev Toxicol 41:622-636  
88. Huff J, Lucier G, Tritscher A 1994 Carcinogenicity of TCDD: experimental, 
mechanistic, and epidemiologic evidence. Annu Rev Pharmacol Toxicol 34:343-372  
89. Maronpot RR, Foley JF, Takahashi K, Goldsworthy T, Clark G, Tritscher A, 
Portier C, Lucier G 1993 Dose response for TCDD promotion of hepatocarcinogenesis 
in rats initiated with DEN: histologic, biochemical, and cell proliferation endpoints. 
Environ Health Perspect 101:634-642  
90. Ray S, Swanson HI 2009 Activation of the aryl hydrocarbon receptor by TCDD 
inhibits senescence: a tumor promoting event? Biochem Pharmacol 77:681-688  
 73 
91. White SS, Birnbaum LS 2009 An overview of the effects of dioxins and dioxin-like 
compounds on vertebrates, as documented in human and ecological epidemiology. J 
Environ Sci Health C Environ Carcinog Ecotoxicol Rev 27:197-211  
92. Sutter CH, Rahman M, Sutter TR 2006 Uncertainties related to the assignment of a 
toxic equivalency factor for 1,2,3,4,6,7,8,9-octachlorodibenzo-p-dioxin. Regul Toxicol 
Pharmacol 44:219-225  
93. Grufferman S, Lupo PJ, Vogel RI, Danysh HE, Erhardt EB, Ognjanovic S 2014 
Parental military service, agent orange exposure, and the risk of rhabdomyosarcoma in 
offspring. J Pediatr 165:1216-1221  
94. Yang M, Park MS, Lee HS 2006 Endocrine disrupting chemicals: human exposure 
and health risks. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 24:183-224  
95. Foster WG, Maharaj-Briceno S, Cyr DG 2010 Dioxin-induced changes in 
epididymal sperm count and spermatogenesis. Environ Health Perspect 118:458-464  
96. Gray LE,Jr, Kelce WR, Monosson E, Ostby JS, Birnbaum LS 1995 Exposure to 
TCDD during development permanently alters reproductive function in male Long Evans 
rats and hamsters: reduced ejaculated and epididymal sperm numbers and sex accessory 
gland weights in offspring with normal androgenic status. Toxicol Appl Pharmacol 
131:108-118  
97. Bonde JP, Toft G, Rylander L, Rignell-Hydbom A, Giwercman A, Spano M, 
Manicardi GC, Bizzaro D, Ludwicki JK, Zvyezday V, Bonefeld-Jorgensen EC, 
Pedersen HS, Jonsson BA, Thulstrup AM, INUENDO 2008 Fertility and markers of 
male reproductive function in Inuit and European populations spanning large contrasts in 
blood levels of persistent organochlorines. Environ Health Perspect 116:269-277  
98. Toft G 2014 Persistent organochlorine pollutants and human reproductive health. 
Dan Med J 61:B4967  
99. Sofo V, Gotte M, Lagana AS, Salmeri FM, Triolo O, Sturlese E, Retto G, Alfa 
M, Granese R, Abrao MS 2015 Correlation between dioxin and endometriosis: an 
epigenetic route to unravel the pathogenesis of the disease. Arch Gynecol Obstet  
100. Rehder H, Sanchioni L, Cefis F, Gropp A 1978 Pathological and embryological 
studies on abortion cases related to the Seveso accident. Schweiz Med Wochenschr 
108:1617-1625  
101. Silkworth JB, Cutler DS, Antrim L, Houston D, Tumasonis C, Kaminsky LS 
1989 Teratology of 2,3,7,8-tetrachlorodibenzo-p-dioxin in a complex environmental 
mixture from the love canal. Fundam Appl Toxicol 13:1-15  
 74 
102. Abbott BD, Birnbaum LS 1990 TCDD-induced altered expression of growth 
factors may have a role in producing cleft palate and enhancing the incidence of clefts 
after coadministration of retinoic acid and TCDD. Toxicol Appl Pharmacol 106:418-432  
103. Muenyi CS, Carrion SL, Jones LA, Kennedy LH, Slominski AT, Sutter CH, 
Sutter TR 2014 Effects of in utero exposure of C57BL/6J mice to 2,3,7,8-
tetrachlorodibenzo-p-dioxin on epidermal permeability barrier development and function. 
Environ Health Perspect 122:1052-1058  
104. Choi SS, Miller MA, Harper PA 2006 In utero exposure to 2,3,7,8-
tetrachlorodibenzo-p-dioxin induces amphiregulin gene expression in the developing 
mouse ureter. Toxicol Sci 94:163-174  
105. Proksch E, Brandner JM, Jensen JM 2008 The skin: an indispensable barrier. 
Exp Dermatol 17:1063-1072  
106. Braun KM, Prowse DM 2006 Distinct epidermal stem cell compartments are 
maintained by independent niche microenvironments. Stem Cell Rev 2:221-231  
107. Candi E, Schmidt R, Melino G 2005 The cornified envelope: a model of cell death 
in the skin. Nat Rev Mol Cell Biol 6:328-340  
108. Holick MF 2014 Sunlight, ultraviolet radiation, vitamin D and skin cancer: how 
much sunlight do we need? Adv Exp Med Biol 810:1-16  
109. Goding CR 2007 Melanocytes: the new Black. Int J Biochem Cell Biol 39:275-279  
110. Taylor SC 2002 Skin of color: biology, structure, function, and implications for 
dermatologic disease. J Am Acad Dermatol 46:S41-62  
111. Dahlhoff M, Frances D, Kloepper JE, Paus R, Schafer M, Niemann C, 
Schneider MR 2014 Overexpression of epigen during embryonic development induces 
reversible, epidermal growth factor receptor-dependent sebaceous gland hyperplasia. Mol 
Cell Biol 34:3086-3095  
112. Lampe MA, Burlingame AL, Whitney J, Williams ML, Brown BE, Roitman E, 
Elias PM 1983 Human stratum corneum lipids: characterization and regional variations. 
J Lipid Res 24:120-130  
113. Zlotogorski A 1987 Distribution of skin surface pH on the forehead and cheek of 
adults. Arch Dermatol Res 279:398-401  
114. Sato K, Kang WH, Saga K, Sato KT 1989 Biology of sweat glands and their 
disorders. I. Normal sweat gland function. J Am Acad Dermatol 20:537-563  
 75 
115. Fuchs E 1998 Beauty is skin deep: the fascinating biology of the epidermis and its 
appendages. Harvey Lect 94:47-77  
116. Mainiero F, Pepe A, Yeon M, Ren Y, Giancotti FG 1996 The intracellular 
functions of alpha6beta4 integrin are regulated by EGF. J Cell Biol 134:241-253  
117. Mackenzie IC 1997 Retroviral transduction of murine epidermal stem cells 
demonstrates clonal units of epidermal structure. J Invest Dermatol 109:377-383  
118. Potten CS 1974 The epidermal proliferative unit: the possible role of the central 
basal cell. Cell Tissue Kinet 7:77-88  
119. Houben E, De Paepe K, Rogiers V 2007 A keratinocyte's course of life. Skin 
Pharmacol Physiol 20:122-132  
120. Ohnemus U, Kohrmeyer K, Houdek P, Rohde H, Wladykowski E, Vidal S, 
Horstkotte MA, Aepfelbacher M, Kirschner N, Behne MJ, Moll I, Brandner JM 
2008 Regulation of epidermal tight-junctions (TJ) during infection with exfoliative toxin-
negative Staphylococcus strains. J Invest Dermatol 128:906-916  
121. Brandner JM, Kief S, Grund C, Rendl M, Houdek P, Kuhn C, Tschachler E, 
Franke WW, Moll I 2002 Organization and formation of the tight junction system in 
human epidermis and cultured keratinocytes. Eur J Cell Biol 81:253-263  
122. Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, 
Ponzin D, McKeon F, De Luca M 2001 P63 Identifies Keratinocyte Stem Cells. Proc 
Natl Acad Sci U S A 98:3156-3161  
123. Ng DC, Su MJ, Kim R, Bikle DD 1996 Regulation of involucrin gene expression 
by calcium in normal human keratinocytes. Front Biosci 1:a16-24  
124. Adhikary G, Crish JF, Gopalakrishnan R, Bone F, Eckert RL 2005 Involucrin 
expression in the corneal epithelium: an essential role for Sp1 transcription factors. Invest 
Ophthalmol Vis Sci 46:3109-3120  
125. Eckert RL, Crish JF, Robinson NA 1997 The epidermal keratinocyte as a model 
for the study of gene regulation and cell differentiation. Physiol Rev 77:397-424  
126. Kirfel G, Herzog V 2004 Migration of epidermal keratinocytes: mechanisms, 
regulation, and biological significance. Protoplasma 223:67-78  
127. Duden R, Franke WW 1988 Organization of desmosomal plaque proteins in cells 
growing at low calcium concentrations. J Cell Biol 107:1049-1063  
 76 
128. Getsios S, Simpson CL, Kojima S, Harmon R, Sheu LJ, Dusek RL, Cornwell 
M, Green KJ 2009 Desmoglein 1-dependent suppression of EGFR signaling promotes 
epidermal differentiation and morphogenesis. J Cell Biol 185:1243-1258  
129. Su MJ, Bikle DD, Mancianti ML, Pillai S 1994 1,25-Dihydroxyvitamin D3 
potentiates the keratinocyte response to calcium. J Biol Chem 269:14723-14729  
130. Denning MF, Dlugosz AA, Williams EK, Szallasi Z, Blumberg PM, Yuspa SH 
1995 Specific protein kinase C isozymes mediate the induction of keratinocyte 
differentiation markers by calcium. Cell Growth Differ 6:149-157  
131. Thacher SM, Rice RH 1985 Keratinocyte-specific transglutaminase of cultured 
human epidermal cells: relation to cross-linked envelope formation and terminal 
differentiation. Cell 40:685-695  
132. LaCelle PT, Lambert A, Ekambaram MC, Robinson NA, Eckert RL 1998 In 
vitro cross-linking of recombinant human involucrin. Skin Pharmacol Appl Skin Physiol 
11:214-226  
133. Tallant C, Marrero A, Gomis-Ruth FX 2010 Matrix metalloproteinases: fold and 
function of their catalytic domains. Biochim Biophys Acta 1803:20-28  
134. Henderson J, Northstone K, Lee SP, Liao H, Zhao Y, Pembrey M, 
Mukhopadhyay S, Smith GD, Palmer CN, McLean WH, Irvine AD 2008 The burden 
of disease associated with filaggrin mutations: a population-based, longitudinal birth 
cohort study. J Allergy Clin Immunol 121:872-7.e9  
135. Elias PM, Ahn SK, Denda M, Brown BE, Crumrine D, Kimutai LK, Komuves 
L, Lee SH, Feingold KR 2002 Modulations in epidermal calcium regulate the expression 
of differentiation-specific markers. J Invest Dermatol 119:1128-1136  
136. Lippens S, Hoste E, Vandenabeele P, Agostinis P, Declercq W 2009 Cell death in 
the skin. Apoptosis 14:549-569  
137. Melino G, Knight RA, Nicotera P 2005 How many ways to die? How many 
different models of cell death? Cell Death Differ 12 Suppl 2:1457-1462  
138. Rickelt S, Moll I, Franke WW 2011 Intercellular adhering junctions with an 
asymmetric molecular composition: desmosomes connecting Merkel cells and 
keratinocytes. Cell Tissue Res 346:65-77  
139. Elias P, Ahn S, Brown B, Crumrine D, Feingold KR 2002 Origin of the 
epidermal calcium gradient: regulation by barrier status and role of active vs passive 
mechanisms. J Invest Dermatol 119:1269-1274  
 77 
140. Watt FM 1988 Proliferation and terminal differentiation of human epidermal 
keratinocytes in culture. Biochem Soc Trans 16:666-668  
141. Potten CS, Saffhill R, Maibach HI 1987 Measurement of the transit time for cells 
through the epidermis and stratum corneum of the mouse and guinea-pig. Cell Tissue 
Kinet 20:461-472  
142. Gelfant S 1976 The cell cycle in psoriasis: a reappraisal. Br J Dermatol 95:577-590  
143. Morris R, Argyris TS 1983 Epidermal Cell Cycle and Transit Times during 
Hyperplastic Growth Induced by Abrasion or Treatment with 12-O-
Tetradecanoylphorbol-13-acetate. Cancer Research 43:4935-4942  
144. Ristow HJ 1987 A major factor contributing to epidermal proliferation in 
inflammatory skin diseases appears to be interleukin 1 or a related protein. Proc Natl 
Acad Sci U S A 84:1940-1944  
145. Piepkorn M, Predd H, Underwood R, Cook P 2003 Proliferation-differentiation 
relationships in the expression of heparin-binding epidermal growth factor-related factors 
and erbB receptors by normal and psoriatic human keratinocytes. Arch Dermatol Res 
295:93-101  
146. Elias PM, Nau P, Hanley K, Cullander C, Crumrine D, Bench G, Sideras-
Haddad E, Mauro T, Williams ML, Feingold KR 1998 Formation of the epidermal 
calcium gradient coincides with key milestones of barrier ontogenesis in the rodent. J 
Invest Dermatol 110:399-404  
147. Menon GK, Elias PM, Lee SH, Feingold KR 1992 Localization of calcium in 
murine epidermis following disruption and repair of the permeability barrier. Cell Tissue 
Res 270:503-512  
148. Eckert RL, Crish JF, Efimova T, Dashti SR, Deucher A, Bone F, Adhikary G, 
Huang G, Gopalakrishnan R, Balasubramanian S 2004 Regulation of involucrin gene 
expression. J Invest Dermatol 123:13-22  
149. Rice RH, Green H 1979 Presence in human epidermal cells of a soluble protein 
precursor of the cross-linked envelope: activation of the cross-linking by calcium ions. 
Cell 18:681-694  
150. Pillai S, Bikle DD, Mancianti ML, Cline P, Hincenbergs M 1990 Calcium 
regulation of growth and differentiation of normal human keratinocytes: modulation of 
differentiation competence by stages of growth and extracellular calcium. J Cell Physiol 
143:294-302  
151. Thomsen SF 2014 Atopic dermatitis: natural history, diagnosis, and treatment. 
ISRN Allergy 2014:354250  
 78 
152. Segre JA 2006 Epidermal barrier formation and recovery in skin disorders. J Clin 
Invest 116:1150-1158  
153. Kitajima Y 2014 150(th) anniversary series: Desmosomes and autoimmune disease, 
perspective of dynamic desmosome remodeling and its impairments in pemphigus. Cell 
Commun Adhes 21:269-280  
154. Akiyama M 2011 The roles of ABCA12 in keratinocyte differentiation and lipid 
barrier formation in the epidermis. Dermatoendocrinol 3:107-112  
155. Nanney LB, King LE,Jr, Dale BA 1990 Epidermal growth factor receptors in 
genetically induced hyperproliferative skin disorders. Pediatr Dermatol 7:256-265  
156. Taieb A, Labreze C 2002 Collodion baby: what's new. J Eur Acad Dermatol 
Venereol 16:436-437  
157. Rice RH, Bradshaw KM, Durbin-Johnson BP, Rocke DM, Eigenheer RA, 
Phinney BS, Schmuth M, Gruber R 2013 Distinguishing ichthyoses by protein 
profiling. PLoS One 8:e75355  
158. Tschachler E 2007 Psoriasis: the epidermal component. Clin Dermatol 25:589-595  
159. Denda M, Fuziwara S, Inoue K 2003 Influx of calcium and chloride ions into 
epidermal keratinocytes regulates exocytosis of epidermal lamellar bodies and skin 
permeability barrier homeostasis. J Invest Dermatol 121:362-367  
160. Jensen JM, Proksch E 2009 The skin's barrier. G Ital Dermatol Venereol 144:689-
700  
161. Franzke CW, Cobzaru C, Triantafyllopoulou A, Loffek S, Horiuchi K, 
Threadgill DW, Kurz T, van Rooijen N, Bruckner-Tuderman L, Blobel CP 2012 
Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent 
terminal keratinocyte differentiation. J Exp Med 209:1105-1119  
162. Zhao Y, Sudol M, Hanafusa H, Krueger J 1992 Increased tyrosine kinase activity 
of c-Src during calcium-induced keratinocyte differentiation. Proc Natl Acad Sci U S A 
89:8298-8302  
163. Hennings H, Kruszewski FH, Yuspa SH, Tucker RW 1989 Intracellular calcium 
alterations in response to increased external calcium in normal and neoplastic 
keratinocytes. Carcinogenesis 10:777-780  
164. Yuspa SH, Elgjo K, Morse MA, Wiebel FJ 1977 Retinyl acetate modulation of 
cell growth kinetics and carcinogen--cellular interaction in mouse epidermal cell cultures. 
Chem Biol Interact 16:251-264  
 79 
165. Bleasdale JE, Bundy GL, Bunting S, Fitzpatrick FA, Huff RM, Sun FF, Pike JE 
1989 Inhibition of phospholipase C dependent processes by U-73, 122. Adv 
Prostaglandin Thromboxane Leukot Res 19:590-593  
166. Jaken S, Yuspa SH 1988 Early signals for keratinocyte differentiation: role of 
Ca2+-mediated inositol lipid metabolism in normal and neoplastic epidermal cells. 
Carcinogenesis 9:1033-1038  
167. Menon GK, Elias PM, Feingold KR 1994 Integrity of the permeability barrier is 
crucial for maintenance of the epidermal calcium gradient. Br J Dermatol 130:139-147  
168. Choi EH, Ahn SK, Lee SH 1997 The changes of stratum corneum interstices and 
calcium distribution of follicular epithelium of experimentally induced comedones (EIC) 
by oleic acid. Exp Dermatol 6:29-35  
169. Mauro TM, Pappone PA, Isseroff RR 1990 Extracellular calcium affects the 
membrane currents of cultured human keratinocytes. J Cell Physiol 143:13-20  
170. Celli A, Sanchez S, Behne M, Hazlett T, Gratton E, Mauro T 2010 The 
epidermal Ca(2+) gradient: Measurement using the phasor representation of fluorescent 
lifetime imaging. Biophys J 98:911-921  
171. Singh AB, Harris RC 2005 Autocrine, paracrine and juxtacrine signaling by EGFR 
ligands. Cell Signal 17:1183-1193  
172. Tran QT, Kennedy LH, Leon Carrion S, Bodreddigari S, Goodwin SB, Sutter 
CH, Sutter TR 2012 EGFR regulation of epidermal barrier function. Physiol Genomics 
44:455-469  
173. Medema JP, Sark MW, Backendorf C, Bos JL 1994 Calcium inhibits epidermal 
growth factor-induced activation of p21ras in human primary keratinocytes. Mol Cell 
Biol 14:7078-7085  
174. Green MR, Couchman JR 1985 Differences in human skin between the epidermal 
growth factor receptor distribution detected by EGF binding and monoclonal antibody 
recognition. J Invest Dermatol 85:239-245  
175. Jost M, Kari C, Rodeck U 2000 The EGF receptor - an essential regulator of 
multiple epidermal functions. Eur J Dermatol 10:505-510  
176. Schneider MR, Werner S, Paus R, Wolf E 2008 Beyond wavy hairs: the 
epidermal growth factor receptor and its ligands in skin biology and pathology. Am J 
Pathol 173:14-24  
177. Lee E, Jeon SH, Yi JY, Jin YJ, Son YS 2001 Calcipotriol inhibits autocrine 
phosphorylation of EGF receptor in a calcium-dependent manner, a possible mechanism 
 80 
for its inhibition of cell proliferation and stimulation of cell differentiation. Biochem 
Biophys Res Commun 284:419-425  
178. Watt FM 1988 Keratinocyte cultures: an experimental model for studying how 
proliferation and terminal differentiation are co-ordinated in the epidermis. J Cell Sci 90 ( 
Pt 4):525-529  
179. Gottlieb AB, Chang CK, Posnett DN, Fanelli B, Tam JP 1988 Detection of 
transforming growth factor alpha in normal, malignant, and hyperproliferative human 
keratinocytes. J Exp Med 167:670-675  
180. Elder JT, Fisher GJ, Lindquist PB, Bennett GL, Pittelkow MR, Coffey RJ,Jr, 
Ellingsworth L, Derynck R, Voorhees JJ 1989 Overexpression of transforming growth 
factor alpha in psoriatic epidermis. Science 243:811-814  
181. Cook PW, Brown JR, Cornell KA, Pittelkow MR 2004 Suprabasal expression of 
human amphiregulin in the epidermis of transgenic mice induces a severe, early-onset, 
psoriasis-like skin pathology: expression of amphiregulin in the basal epidermis is also 
associated with synovitis. Exp Dermatol 13:347-356  
182. Stoll SW, Johnson JL, Bhasin A, Johnston A, Gudjonsson JE, Rittie L, Elder 
JT 2010 Metalloproteinase-mediated, context-dependent function of amphiregulin and 
HB-EGF in human keratinocytes and skin. J Invest Dermatol 130:295-304  
183. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A 2001 The epidermal growth 
factor receptor family as a central element for cellular signal transduction and 
diversification. Endocr Relat Cancer 8:11-31  
184. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW 2003 
Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 
284:31-53  
185. Stoll SW, Kansra S, Peshick S, Fry DW, Leopold WR, Wiesen JF, Sibilia M, 
Zhang T, Werb Z, Derynck R, Wagner EF, Elder JT 2001 Differential utilization and 
localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant 
keratinocytes. Neoplasia 3:339-350  
186. Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C, Gullick WJ 
1992 Expression of the c-erbB-3 protein in normal human adult and fetal tissues. 
Oncogene 7:1273-1278  
187. Xian W, Rosenberg MP, DiGiovanni J 1997 Activation of erbB2 and c-src in 
phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion. 
Oncogene 14:1435-1444  
 81 
188. Buac K, Xu M, Cronin J, Weeraratna AT, Hewitt SM, Pavan WJ 2009 NRG1 / 
ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation 
and promotion of proliferation. Pigment Cell Melanoma Res 22:773-784  
189. De Potter IY, Poumay Y, Squillace KA, Pittelkow MR 2001 Human EGF 
receptor (HER) family and heregulin members are differentially expressed in epidermal 
keratinocytes and modulate differentiation. Exp Cell Res 271:315-328  
190. Fan YX, Wong L, Johnson GR 2005 EGFR kinase possesses a broad specificity 
for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without 
affecting substrate binding affinity. Biochem J 392:417-423  
191. Schulze WX, Deng L, Mann M 2005 Phosphotyrosine interactome of the ErbB-
receptor kinase family. Mol Syst Biol 1:2005.0008  
192. Marcotte R, Zhou L, Kim H, Roskelly CD, Muller WJ 2009 c-Src associates with 
ErbB2 through an interaction between catalytic domains and confers enhanced 
transforming potential. Mol Cell Biol 29:5858-5871  
193. Kiguchi K, Bol D, Carbajal S, Beltran L, Moats S, Chan K, Jorcano J, 
DiGiovanni J 2000 Constitutive expression of erbB2 in epidermis of transgenic mice 
results in epidermal hyperproliferation and spontaneous skin tumor development. 
Oncogene 19:4243-4254  
194. Kim HH, Sierke SL, Koland JG 1994 Epidermal growth factor-dependent 
association of phosphatidylinositol 3-kinase with the erbB3 gene product. J Biol Chem 
269:24747-24755  
195. Lemmon MA, Bu Z, Ladbury JE, Zhou M, Pinchasi D, Lax I, Engelman DM, 
Schlessinger J 1997 Two EGF molecules contribute additively to stabilization of the 
EGFR dimer. EMBO J 16:281-294  
196. Macdonald-Obermann JL, Adak S, Landgraf R, Piwnica-Worms D, Pike LJ 
2013 Dynamic Analysis of the EGF Receptor-ErbB2-ErbB3 Network by Luciferase 
Fragment Complementation Imaging. J Biol Chem 288:30773-30784  
197. Tao RH, Maruyama IN 2008 All EGF(ErbB) receptors have preformed homo- and 
heterodimeric structures in living cells. J Cell Sci 121:3207-3217  
198. Agelaki S, Spiliotaki M, Markomanolaki H, Kallergi G, Mavroudis D, 
Georgoulias V, Stournaras C 2009 Caveolin-1 regulates EGFR signaling in MCF-7 
breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther 
8:1470-1477  
199. Mineo C, Gill GN, Anderson RG 1999 Regulated migration of epidermal growth 
factor receptor from caveolae. J Biol Chem 274:30636-30643  
 82 
200. Jost M, Huggett TM, Kari C, Rodeck U 2001 Matrix-independent survival of 
human keratinocytes through an EGF receptor/MAPK-kinase-dependent pathway. Mol 
Biol Cell 12:1519-1527  
201. Graus-Porta D, Beerli RR, Daly JM, Hynes NE 1997 ErbB-2, the preferred 
heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. 
EMBO J 16:1647-1655  
202. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper 
LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y 1998 Differential 
endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling 
superiority to receptor heterodimers. EMBO J 17:3385-3397  
203. Wang Q, Villeneuve G, Wang Z 2005 Control of epidermal growth factor receptor 
endocytosis by receptor dimerization, rather than receptor kinase activation. EMBO Rep 
6:942-948  
204. Hackel PO, Zwick E, Prenzel N, Ullrich A 1999 Epidermal growth factor 
receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11:184-
189  
205. Carpenter G, Cohen S 1976 125I-labeled human epidermal growth factor. Binding, 
internalization, and degradation in human fibroblasts. J Cell Biol 71:159-171  
206. Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, Dikic I 2003 
Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. 
Nat Cell Biol 5:461-466  
207. Kornilova E, Sorkina T, Beguinot L, Sorkin A 1996 Lysosomal targeting of 
epidermal growth factor receptors via a kinase-dependent pathway is mediated by the 
receptor carboxyl-terminal residues 1022-1123. J Biol Chem 271:30340-30346  
208. Ettenberg SA, Rubinstein YR, Banerjee P, Nau MM, Keane MM, Lipkowitz S 
1999 cbl-b inhibits EGF-receptor-induced apoptosis by enhancing ubiquitination and 
degradation of activated receptors. Mol Cell Biol Res Commun 2:111-118  
209. Sun Q, Jackson RA, Ng C, Guy GR, Sivaraman J 2010 Additional 
serine/threonine phosphorylation reduces binding affinity but preserves interface 
topography of substrate proteins to the c-Cbl TKB domain. PLoS One 5:e12819  
210. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP 2008 
Clathrin-mediated internalization is essential for sustained EGFR signaling but 
dispensable for degradation. Dev Cell 15:209-219  
 83 
211. Wu W, Graves LM, Gill GN, Parsons SJ, Samet JM 2002 Src-dependent 
phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for 
zinc-induced Ras activation. J Biol Chem 277:24252-24257  
212. Xia L, Wang L, Chung AS, Ivanov SS, Ling MY, Dragoi AM, Platt A, Gilmer 
TM, Fu XY, Chin YE 2002 Identification of both positive and negative domains within 
the epidermal growth factor receptor COOH-terminal region for signal transducer and 
activator of transcription (STAT) activation. J Biol Chem 277:30716-30723  
213. Mueller KL, Powell K, Madden JM, Eblen ST, Boerner JL 2012 EGFR Tyrosine 
845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells 
Require Activation of p38 MAPK. Transl Oncol 5:327-334  
214. Nogami M, Yamazaki M, Watanabe H, Okabayashi Y, Kido Y, Kasuga M, 
Sasaki T, Maehama T, Kanaho Y 2003 Requirement of autophosphorylated tyrosine 
992 of EGF receptor and its docking protein phospholipase C gamma 1 for membrane 
ruffle formation. FEBS Lett 536:71-76  
215. Okabayashi Y, Kido Y, Okutani T, Sugimoto Y, Sakaguchi K, Kasuga M 1994 
Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are 
binding sites of Shc in intact cells. J Biol Chem 269:18674-18678  
216. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, 
Kumar R 2003 Suppression of epidermal growth factor receptor, mitogen-activated 
protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous 
cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2:345-351  
217. Bishayee A, Beguinot L, Bishayee S 1999 Phosphorylation of tyrosine 992, 1068, 
and 1086 is required for conformational change of the human epidermal growth factor 
receptor c-terminal tail. Mol Biol Cell 10:525-536  
218. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, 
Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y 1999 Ubiquitin ligase 
activity and tyrosine phosphorylation underlie suppression of growth factor signaling by 
c-Cbl/Sli-1. Mol Cell 4:1029-1040  
219. Stern KA, Visser Smit GD, Place TL, Winistorfer S, Piper RC, Lill NL 2007 
Epidermal growth factor receptor fate is controlled by Hrs tyrosine phosphorylation sites 
that regulate Hrs degradation. Mol Cell Biol 27:888-898  
220. Cichocki M, Szamalek M, Dalek M, Baer-Dubowska W 2012 Correlation 
between EGFR Y1068 tyrosine phosphorylation and AP-1 activation by tumor promoter 
12-O-tetradecanoylphorbol-13-acetate in mouse skin. Environ Toxicol Pharmacol 33:92-
97  
 84 
221. Skolnik EY, Batzer A, Li N, Lee CH, Lowenstein E, Mohammadi M, Margolis 
B, Schlessinger J 1993 The function of GRB2 in linking the insulin receptor to Ras 
signaling pathways. Science 260:1953-1955  
222. Zwick E, Hackel PO, Prenzel N, Ullrich A 1999 The EGF receptor as central 
transducer of heterologous signalling systems. Trends Pharmacol Sci 20:408-412  
223. Olayioye MA 2001 Update on HER-2 as a target for cancer therapy: intracellular 
signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 3:385-389  
224. Batzer AG, Blaikie P, Nelson K, Schlessinger J, Margolis B 1995 The 
phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal 
growth factor receptor. Mol Cell Biol 15:4403-4409  
225. Feinmesser RL, Wicks SJ, Taverner CJ, Chantry A 1999 Ca2+/calmodulin-
dependent kinase II phosphorylates the epidermal growth factor receptor on multiple sites 
in the cytoplasmic tail and serine 744 within the kinase domain to regulate signal 
generation. J Biol Chem 274:16168-16173  
226. Rojas M, Yao S, Lin YZ 1996 Controlling epidermal growth factor (EGF)-
stimulated Ras activation in intact cells by a cell-permeable peptide mimicking 
phosphorylated EGF receptor. J Biol Chem 271:27456-27461  
227. Yamauchi T, Adachi S, Yasuda I, Nakashima M, Kawaguchi J, Nishii Y, 
Yoshioka T, Okano Y, Hirose Y, Kozawa O, Moriwaki H 2011 UVC radiation 
induces downregulation of EGF receptor via phosphorylation at serine 1046/1047 in 
human pancreatic cancer cells. Radiat Res 176:565-574  
228. Klapper LN, Waterman H, Sela M, Yarden Y 2000 Tumor-inhibitory antibodies 
to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. 
Cancer Res 60:3384-3388  
229. Shen F, Lin Q, Childress C, Yang W 2008 Identification of the domain in ErbB2 
that restricts ligand-induced degradation. Cell Signal 20:779-786  
230. Kwon YK, Bhattacharyya A, Alberta JA, Giannobile WV, Cheon K, Stiles CD, 
Pomeroy SL 1997 Activation of ErbB2 during wallerian degeneration of sciatic nerve. J 
Neurosci 17:8293-8299  
231. Muthuswamy SK, Gilman M, Brugge JS 1999 Controlled dimerization of ErbB 
receptors provides evidence for differential signaling by homo- and heterodimers. Mol 
Cell Biol 19:6845-6857  
232. Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE 2009 
Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of 
 85 
poor survival for breast cancer patients with hormone receptor-positive tumors. Breast 
Cancer Res 11:R11  
233. Ouyang X, Gulliford T, Epstein RJ 1998 The duration of phorbol-inducible ErbB2 
tyrosine dephosphorylation parallels that of receptor endocytosis rather than threonine-
686 phosphorylation: implications for the physiological role of protein kinase C in 
growth factor receptor signalling. Carcinogenesis 19:2013-2019  
234. Ouyang X, Gulliford T, Zhang H, Smith G, Huang G, Epstein RJ 2001 
Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-
expression and poor prognosis in human breast cancer. Mol Cell Biochem 218:47-54  
235. Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G, 
Kerber G, Citri A, Lavi S, Eilam R, Chalifa-Caspi V, Eshhar Z, Pikarsky E, Pinkas-
Kramarski R, Bacus SS, Yarden Y 2005 Epigen, the last ligand of ErbB receptors, 
reveals intricate relationships between affinity and mitogenicity. J Biol Chem 280:8503-
8512  
236. Peus D, Hamacher L, Pittelkow MR 1997 EGF-receptor tyrosine kinase inhibition 
induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 
109:751-756  
237. Sorkin A 2001 Internalization of the epidermal growth factor receptor: role in 
signalling. Biochem Soc Trans 29:480-484  
238. Khavari TA, Rinn J 2007 Ras/Erk MAPK signaling in epidermal homeostasis and 
neoplasia. Cell Cycle 6:2928-2931  
239. Park GT, Kim HY, Kim EK, Yang JM 2007 Autocrine extracellular signal-
regulated kinase activation in normal human keratinocytes is not interrupted by calcium 
triggering and is involved in the control of cell cycle at the early stage of calcium-
induced differentiation. J Korean Med Sci 22:290-297  
240. Kansra S, Stoll SW, Johnson JL, Elder JT 2004 Autocrine extracellular signal-
regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-
mediated release of amphiregulin triggers signaling from ErbB1 to ERK. Mol Biol Cell 
15:4299-4309  
241. Nanney LB, Gates RE, Todderud G, King LE,Jr, Carpenter G 1992 Altered 
distribution of phospholipase C-gamma 1 in benign hyperproliferative epidermal 
diseases. Cell Growth Differ 3:233-239  
242. Calautti E, Li J, Saoncella S, Brissette JL, Goetinck PF 2005 Phosphoinositide 3-
kinase signaling to Akt promotes keratinocyte differentiation versus death. J Biol Chem 
280:32856-32865  
 86 
243. Roux PP, Blenis J 2004 ERK and p38 MAPK-activated protein kinases: a family of 
protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68:320-344  
244. Cobb MH 1999 MAP kinase pathways. Prog Biophys Mol Biol 71:479-500  
245. Galabova-Kovacs G, Kolbus A, Matzen D, Meissl K, Piazzolla D, Rubiolo C, 
Steinitz K, Baccarini M 2006 ERK and beyond: insights from B-Raf and Raf-1 
conditional knockouts. Cell Cycle 5:1514-1518  
246. Zeigler ME, Chi Y, Schmidt T, Varani J 1999 Role of ERK and JNK pathways in 
regulating cell motility and matrix metalloproteinase 9 production in growth factor-
stimulated human epidermal keratinocytes. J Cell Physiol 180:271-284  
247. Leof EB 2000 Growth factor receptor signalling: location, location, location. Trends 
Cell Biol 10:343-348  
248. Glading A, Uberall F, Keyse SM, Lauffenburger DA, Wells A 2001 Membrane 
proximal ERK signaling is required for M-calpain activation downstream of epidermal 
growth factor receptor signaling. J Biol Chem 276:23341-23348  
249. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, Wright A, 
Vanderbilt C, Cobb MH 2001 MAP kinases. Chem Rev 101:2449-2476  
250. Dajee M, Tarutani M, Deng H, Cai T, Khavari PA 2002 Epidermal Ras blockade 
demonstrates spatially localized Ras promotion of proliferation and inhibition of 
differentiation. Oncogene 21:1527-1538  
251. Rhee SG, Suh PG, Ryu SH, Lee SY 1989 Studies of inositol phospholipid-specific 
phospholipase C. Science 244:546-550  
252. Newton AC 1995 Protein kinase C: structure, function, and regulation. J Biol Chem 
270:28495-28498  
253. Denning MF, Dlugosz AA, Cheng C, Dempsey PJ, Coffey RJ,Jr, Threadgill 
DW, Magnuson T, Yuspa SH 2000 Cross-talk between epidermal growth factor 
receptor and protein kinase C during calcium-induced differentiation of keratinocytes. 
Exp Dermatol 9:192-199  
254. Koese M, Rentero C, Kota BP, Hoque M, Cairns R, Wood P, Vila de Muga S, 
Reverter M, Alvarez-Guaita A, Monastyrskaya K, Hughes WE, Swarbrick A, Tebar 
F, Daly RJ, Enrich C, Grewal T 2013 Annexin A6 is a scaffold for PKCalpha to 
promote EGFR inactivation. Oncogene 32:2858-2872  
255. Garrod D, Chidgey M 2008 Desmosome structure, composition and function. 
Biochim Biophys Acta 1778:572-587  
 87 
256. Godsel LM, Hsieh SN, Amargo EV, Bass AE, Pascoe-McGillicuddy LT, Huen 
AC, Thorne ME, Gaudry CA, Park JK, Myung K, Goldman RD, Chew TL, Green 
KJ 2005 Desmoplakin assembly dynamics in four dimensions: multiple phases 
differentially regulated by intermediate filaments and actin. J Cell Biol 171:1045-1059  
257. Wallis S, Lloyd S, Wise I, Ireland G, Fleming TP, Garrod D 2000 The alpha 
isoform of protein kinase C is involved in signaling the response of desmosomes to 
wounding in cultured epithelial cells. Mol Biol Cell 11:1077-1092  
258. Dlugosz AA, Cheng C, Denning MF, Dempsey PJ, Coffey RJ,Jr, Yuspa SH 
1994 Keratinocyte growth factor receptor ligands induce transforming growth factor 
alpha expression and activate the epidermal growth factor receptor signaling pathway in 
cultured epidermal keratinocytes. Cell Growth Differ 5:1283-1292  
259. Yang LC, Ng DC, Bikle DD 2003 Role of protein kinase C alpha in calcium 
induced keratinocyte differentiation: defective regulation in squamous cell carcinoma. J 
Cell Physiol 195:249-259  
260. Hirsch E, Costa C, Ciraolo E 2007 Phosphoinositide 3-kinases as a common 
platform for multi-hormone signaling. J Endocrinol 194:243-256  
261. Hirsch E, Lembo G, Montrucchio G, Rommel C, Costa C, Barberis L 2006 
Signaling through PI3Kgamma: a common platform for leukocyte, platelet and 
cardiovascular stress sensing. Thromb Haemost 95:29-35  
262. Maffucci T, Falasca M 2007 Phosphoinositide 3-kinase-dependent regulation of 
phospholipase Cgamma. Biochem Soc Trans 35:229-230  
263. Pankow S, Bamberger C, Klippel A, Werner S 2006 Regulation of epidermal 
homeostasis and repair by phosphoinositide 3-kinase. J Cell Sci 119:4033-4046  
264. Suzuki A, Itami S, Ohishi M, Hamada K, Inoue T, Komazawa N, Senoo H, 
Sasaki T, Takeda J, Manabe M, Mak TW, Nakano T 2003 Keratinocyte-specific Pten 
deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and 
tumor formation. Cancer Res 63:674-681  
265. Vermi W, Giurisato E, Lonardi S, Balzarini P, Rossi E, Medicina D, Bosisio D, 
Sozzani S, Pellegrini W, Doglioni C, Marchetti A, Rossi G, Pileri S, Facchetti F 2013 
Ligand-Dependent Activation of EGFR in Follicular Dendritic Cells Sarcoma is 
Sustained by Local Production of Cognate Ligands. Clin Cancer Res 19:5027-5038  
266. Lin Q, Yang W, Cerione RA 2006 Measurement of epidermal growth factor 
receptor turnover and effects of Cdc42. Methods Enzymol 406:614-625  
267. Harris RC, Chung E, Coffey RJ 2003 EGF receptor ligands. Exp Cell Res 284:2-
13  
 88 
268. Falls DL 2003 Neuregulins and the neuromuscular system: 10 years of answers and 
questions. J Neurocytol 32:619-647  
269. Schneider MR, Wolf E 2009 The epidermal growth factor receptor ligands at a 
glance. J Cell Physiol 218:460-466  
270. Brown PM, Debanne MT, Grothe S, Bergsma D, Caron M, Kay C, O'Connor-
McCourt MD 1994 The extracellular domain of the epidermal growth factor receptor. 
Studies on the affinity and stoichiometry of binding, receptor dimerization and a binding-
domain mutant. Eur J Biochem 225:223-233  
271. Schneider MR, Yarden Y 2014 Structure and function of epigen, the last EGFR 
ligand. Semin Cell Dev Biol 28:57-61  
272. Schneider MR, Antsiferova M, Feldmeyer L, Dahlhoff M, Bugnon P, Hasse S, 
Paus R, Wolf E, Werner S 2008 Betacellulin regulates hair follicle development and 
hair cycle induction and enhances angiogenesis in wounded skin. J Invest Dermatol 
128:1256-1265  
273. Poumay Y, de Rouvroit CL 2012 HB-EGF, the growth factor that accelerates 
keratinocyte migration, but slows proliferation. J Invest Dermatol 132:2129-2130  
274. Xu X, Liao J, Creek KE, Pirisi L 1999 Human keratinocytes and tumor-derived 
cell lines express alternatively spliced forms of transforming growth factor-alpha mRNA, 
encoding precursors lacking carboxyl-terminal valine residues. Oncogene 18:5554-5562  
275. Luetteke NC, Qiu TH, Peiffer RL, Oliver P, Smithies O, Lee DC 1993 TGF 
alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 
mice. Cell 73:263-278  
276. Cheng Y, Prusoff WH 1973 Relationship between the inhibition constant (K1) and 
the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic 
reaction. Biochem Pharmacol 22:3099-3108  
277. Jones JT, Akita RW, Sliwkowski MX 1999 Binding specificities and affinities of 
egf domains for ErbB receptors. FEBS Lett 447:227-231  
278. Shoyab M, Plowman GD, McDonald VL, Bradley JG, Todaro GJ 1989 
Structure and function of human amphiregulin: a member of the epidermal growth factor 
family. Science 243:1074-1076  
279. Shirakata Y, Komurasaki T, Toyoda H, Hanakawa Y, Yamasaki K, Tokumaru 
S, Sayama K, Hashimoto K 2000 Epiregulin, a novel member of the epidermal growth 
factor family, is an autocrine growth factor in normal human keratinocytes. J Biol Chem 
275:5748-5753  
 89 
280. Shirakata Y 2010 Regulation of epidermal keratinocytes by growth factors. J 
Dermatol Sci 59:73-80  
281. Shirakata Y, Tokumaru S, Sayama K, Hashimoto K 2010 Auto- and cross-
induction by betacellulin in epidermal keratinocytes. J Dermatol Sci 58:162-164  
282. Coffey RJ,Jr, Graves-Deal R, Dempsey PJ, Whitehead RH, Pittelkow MR 1992 
Differential regulation of transforming growth factor alpha autoinduction in a 
nontransformed and transformed epithelial cell. Cell Growth Differ 3:347-354  
283. Barnard JA, Graves-Deal R, Pittelkow MR, DuBois R, Cook P, Ramsey GW, 
Bishop PR, Damstrup L, Coffey RJ 1994 Auto- and cross-induction within the 
mammalian epidermal growth factor-related peptide family. J Biol Chem 269:22817-
22822  
284. Beerli RR, Hynes NE 1996 Epidermal growth factor-related peptides activate 
distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem 
271:6071-6076  
285. Piepkorn M, Lo C, Plowman G 1994 Amphiregulin-dependent proliferation of 
cultured human keratinocytes: autocrine growth, the effects of exogenous recombinant 
cytokine, and apparent requirement for heparin-like glycosaminoglycans. J Cell Physiol 
159:114-120  
286. Zaczek A, Brandt B, Bielawski KP 2005 The diverse signaling network of EGFR, 
HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic 
approaches. Histol Histopathol 20:1005-1015  
287. Roepstorff K, Grandal MV, Henriksen L, Knudsen SL, Lerdrup M, Grovdal L, 
Willumsen BM, van Deurs B 2009 Differential effects of EGFR ligands on endocytic 
sorting of the receptor. Traffic 10:1115-1127  
288. Singh AB, Sugimoto K, Harris RC 2007 Juxtacrine activation of epidermal growth 
factor (EGF) receptor by membrane-anchored heparin-binding EGF-like growth factor 
protects epithelial cells from anoikis while maintaining an epithelial phenotype. J Biol 
Chem 282:32890-32901  
289. Iwamoto R, Mekada E 2000 Heparin-binding EGF-like growth factor: a juxtacrine 
growth factor. Cytokine Growth Factor Rev 11:335-344  
290. Willmarth NE, Ethier SP 2006 Autocrine and juxtacrine effects of amphiregulin 
on the proliferative, invasive, and migratory properties of normal and neoplastic human 
mammary epithelial cells. J Biol Chem 281:37728-37737  
291. Ceresa BP 2012 Spatial regulation of epidermal growth factor receptor signaling by 
endocytosis. Int J Mol Sci 14:72-87  
 90 
292. Cohen S 1965 The stimulation of epidermal proliferation by a specific protein 
(EGF). Dev Biol 12:394-407  
293. Edwin F, Wiepz GJ, Singh R, Peet CR, Chaturvedi D, Bertics PJ, Patel TB 
2006 A historical perspective of the EGF receptor and related systems. Methods Mol Biol 
327:1-24  
294. Moriki T, Maruyama H, Maruyama IN 2001 Activation of preformed EGF 
receptor dimers by ligand-induced rotation of the transmembrane domain. J Mol Biol 
311:1011-1026  
295. O'Keefe E, Battin T, Payne R,Jr 1982 Epidermal growth factor receptor in human 
epidermal cells: direct demonstration in cultured cells. J Invest Dermatol 78:482-487  
296. Berasain C, Avila MA 2014 Amphiregulin. Semin Cell Dev Biol  
297. Seykora JT 2010 Grabbing amphiregulin by the tail to better understand 
keratinocyte growth. J Invest Dermatol 130:1966-1968  
298. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massague J, Kang 
Y 2009 ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic 
signaling cascade for bone metastasis. Genes Dev 23:1882-1894  
299. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, Werb Z 2005 
Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via 
ADAM17-dependent shedding of epithelial amphiregulin. Development 132:3923-3933  
300. Ryu B, Moriarty WF, Stine MJ, DeLuca A, Kim DS, Meeker AK, Grills LD, 
Switzer RA, Eller MS, Alani RM 2011 Global analysis of BRAFV600E target genes in 
human melanocytes identifies matrix metalloproteinase-1 as a critical mediator of 
melanoma growth. J Invest Dermatol 131:1579-1583  
301. Weber S, Saftig P 2012 Ectodomain shedding and ADAMs in development. 
Development 139:3693-3709  
302. Du B, Altorki NK, Kopelovich L, Subbaramaiah K, Dannenberg AJ 2005 
Tobacco smoke stimulates the transcription of amphiregulin in human oral epithelial 
cells: evidence of a cyclic AMP-responsive element binding protein-dependent 
mechanism. Cancer Res 65:5982-5988  
303. Cook PW, Pittelkow MR, Piepkorn M 1999 Overexpression of amphiregulin in 
the epidermis of transgenic mice induces a psoriasis-like cutaneous phenotype. J Invest 
Dermatol 113:860  
304. Ritchlin CT 2005 Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 17:406-
412  
 91 
305. Stoll SW, Johnson JL, Li Y, Rittie L, Elder JT 2010 Amphiregulin carboxy-
terminal domain is required for autocrine keratinocyte growth. J Invest Dermatol 
130:2031-2040  
306. Rittie L, Kansra S, Stoll SW, Li Y, Gudjonsson JE, Shao Y, Michael LE, Fisher 
GJ, Johnson TM, Elder JT 2007 Differential ErbB1 signaling in squamous cell versus 
basal cell carcinoma of the skin. Am J Pathol 170:2089-2099  
307. Besner G, Higashiyama S, Klagsbrun M 1990 Isolation and characterization of a 
macrophage-derived heparin-binding growth factor. Cell Regul 1:811-819  
308. Iwamoto R, Higashiyama S, Mitamura T, Taniguchi N, Klagsbrun M, Mekada 
E 1994 Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin 
receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates 
functional receptors and diphtheria toxin sensitivity. EMBO J 13:2322-2330  
309. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M 1997 Matrix 
metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage 
at a specific juxtamembrane site. J Biol Chem 272:31730-31737  
310. Yu WH, Woessner JF,Jr, McNeish JD, Stamenkovic I 2002 CD44 anchors the 
assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor 
and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16:307-323  
311. Davis-Fleischer KM, Besner GE 1998 Structure and function of heparin-binding 
EGF-like growth factor (HB-EGF). Front Biosci 3:d288-99  
312. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G 1996 All ErbB 
receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol 
Chem 271:5251-5257  
313. Stoll SW, Rittie L, Johnson JL, Elder JT 2012 Heparin-binding EGF-like growth 
factor promotes epithelial-mesenchymal transition in human keratinocytes. J Invest 
Dermatol 132:2148-2157  
314. Toki F, Nanba D, Matsuura N, Higashiyama S 2005 Ectodomain shedding of 
membrane-anchored heparin-binding EGF like growth factor and subcellular localization 
of the C-terminal fragment in the cell cycle. J Cell Physiol 202:839-848  
315. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell 
WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, 
Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA 1998 An 
essential role for ectodomain shedding in mammalian development. Science 282:1281-
1284  
 92 
316. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, 
Hartmann D, Saftig P, Blobel CP 2004 Distinct roles for ADAM10 and ADAM17 in 
ectodomain shedding of six EGFR ligands. J Cell Biol 164:769-779  
317. Jhappan C, Takayama H, Dickson RB, Merlino G 1994 Transgenic mice provide 
genetic evidence that transforming growth factor alpha promotes skin tumorigenesis via 
H-ras-dependent and H-ras-independent pathways. Cell Growth Differ 5:385-394  
318. Kim I, Mogford JE, Chao JD, Mustoe TA 2001 Wound epithelialization deficits 
in the transforming growth factor-alpha knockout mouse. Wound Repair Regen 9:386-
390  
319. Dominey AM, Wang XJ, King LE,Jr, Nanney LB, Gagne TA, Sellheyer K, 
Bundman DS, Longley MA, Rothnagel JA, Greenhalgh DA 1993 Targeted 
overexpression of transforming growth factor alpha in the epidermis of transgenic mice 
elicits hyperplasia, hyperkeratosis, and spontaneous, squamous papillomas. Cell Growth 
Differ 4:1071-1082  
320. Wang XJ, Greenhalgh DA, Roop DR 2000 Transgenic coexpression of v-Ha-ras 
and transforming growth factor alpha increases epidermal hyperproliferation and 
tumorigenesis and predisposes to malignant conversion via endogenous c-Ha-ras 
activation. Mol Carcinog 27:200-209  
321. Shirasawa S, Sugiyama S, Baba I, Inokuchi J, Sekine S, Ogino K, Kawamura 
Y, Dohi T, Fujimoto M, Sasazuki T 2004 Dermatitis due to epiregulin deficiency and a 
critical role of epiregulin in immune-related responses of keratinocyte and macrophage. 
Proc Natl Acad Sci U S A 101:13921-13926  
322. Pittelkow MR, Cook PW, Shipley GD, Derynck R, Coffey RJ,Jr 1993 
Autonomous growth of human keratinocytes requires epidermal growth factor receptor 
occupancy. Cell Growth Differ 4:513-521  
323. Shirakata Y, Kishimoto J, Tokumaru S, Yamasaki K, Hanakawa Y, Tohyama 
M, Sayama K, Hashimoto K 2007 Epiregulin, a member of the EGF family, is over-
expressed in psoriatic epidermis. J Dermatol Sci 45:69-72  
324. Sahin U, Blobel CP 2007 Ectodomain shedding of the EGF-receptor ligand epigen 
is mediated by ADAM17. FEBS Lett 581:41-44  
325. Greenhalgh DG 1998 The role of apoptosis in wound healing. Int J Biochem Cell 
Biol 30:1019-1030  
326. Santoro MM, Gaudino G 2005 Cellular and molecular facets of keratinocyte 
reepithelization during wound healing. Exp Cell Res 304:274-286  
 93 
327. Newton PM, Watson JA, Wolowacz RG, Wood EJ 2004 Macrophages restrain 
contraction of an in vitro wound healing model. Inflammation 28:207-214  
328. Amini-Nik S, Cambridge E, Yu W, Guo A, Whetstone H, Nadesan P, Poon R, 
Hinz B, Alman BA 2014 beta-Catenin-regulated myeloid cell adhesion and migration 
determine wound healing. J Clin Invest 124:2599-2610  
329. Iwamoto R, Handa K, Mekada E 1999 Contact-dependent growth inhibition and 
apoptosis of epidermal growth factor (EGF) receptor-expressing cells by the membrane-
anchored form of heparin-binding EGF-like growth factor. J Biol Chem 274:25906-
25912  
330. Chidgey M, Brakebusch C, Gustafsson E, Cruchley A, Hail C, Kirk S, Merritt 
A, North A, Tselepis C, Hewitt J, Byrne C, Fassler R, Garrod D 2001 Mice lacking 
desmocollin 1 show epidermal fragility accompanied by barrier defects and abnormal 
differentiation. J Cell Biol 155:821-832  
331. Waschke J 2008 The desmosome and pemphigus. Histochem Cell Biol 130:21-54  
332. Shirakata Y, Kimura R, Nanba D, Iwamoto R, Tokumaru S, Morimoto C, 
Yokota K, Nakamura M, Sayama K, Mekada E, Higashiyama S, Hashimoto K 2005 
Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin 
wound healing. J Cell Sci 118:2363-2370  
333. Kim BE, Howell MD, Guttman-Yassky E, Gilleaudeau PM, Cardinale IR, 
Boguniewicz M, Krueger JG, Leung DY 2011 TNF-alpha downregulates filaggrin and 
loricrin through c-Jun N-terminal kinase: role for TNF-alpha antagonists to improve skin 
barrier. J Invest Dermatol 131:1272-1279  
334. Rheinwald JG, Green H 1977 Epidermal growth factor and the multiplication of 
cultured human epidermal keratinocytes. Nature 265:421-424  
335. Rasmussen C, Thomas-Virnig C, Allen-Hoffmann BL 2013 Classical human 
epidermal keratinocyte cell culture. Methods Mol Biol 945:161-175  
336. Forslind B, Lindberg M, Roomans GM, Pallon J, Werner-Linde Y 1997 Aspects 
on the physiology of human skin: studies using particle probe analysis. Microsc Res Tech 
38:373-386  
337. Missero C, Di Cunto F, Kiyokawa H, Koff A, Dotto GP 1996 The absence of 
p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor 
progression. Genes Dev 10:3065-3075  
338. Loertscher JA, Sattler CA, Allen-Hoffmann BL 2001 2,3,7,8-
Tetrachlorodibenzo-p-dioxin alters the differentiation pattern of human keratinocytes in 
organotypic culture. Toxicol Appl Pharmacol 175:121-129  
 94 
339. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, 
Li FP, Rheinwald JG 2000 Human keratinocytes that express hTERT and also bypass a 
p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal 
growth and differentiation characteristics. Mol Cell Biol 20:1436-1447  
340. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig 
NE 1988 Normal keratinization in a spontaneously immortalized aneuploid human 
keratinocyte cell line. J Cell Biol 106:761-771  
341. Fusenig NE, Breitkreutz D, Dzarlieva RT, Boukamp P, Bohnert A, Tilgen W 
1983 Growth and differentiation characteristics of transformed keratinocytes from mouse 
and human skin in vitro and in vivo. J Invest Dermatol 81:168s-75s  
342. Deyrieux AF, Wilson VG 2007 In vitro culture conditions to study keratinocyte 
differentiation using the HaCaT cell line. Cytotechnology 54:77-83  
343. Rheinwald JG, Beckett MA 1980 Defective terminal differentiation in culture as a 
consistent and selectable character of malignant human keratinocytes. Cell 22:629-632  
344. Whitlow MB, Klein LM 1997 Response of SCC-12F, a human squamous cell 
carcinoma cell line, to complement attack. J Invest Dermatol 109:39-45  
345. Rosdy M, Bernard BA, Schmidt R, Darmon M 1986 Incomplete epidermal 
differentiation of A431 epidermoid carcinoma cells. In vitro Cell Dev Biol 22:295-300  
346. Ge NL, Elferink CJ 1998 A direct interaction between the aryl hydrocarbon 
receptor and retinoblastoma protein. Linking dioxin signaling to the cell cycle. J Biol 
Chem 273:22708-22713  
347. Boonstra J, De Laat SW, Ponec M 1985 Epidermal growth factor receptor 
expression related to differentiation capacity in normal and transformed keratinocytes. 
Exp Cell Res 161:421-433  
348. Madhukar BV, Brewster DW, Matsumura F 1984 Effects of in vivo-administered 
2,3,7,8-tetrachlorodibenzo-p-dioxin on receptor binding of epidermal growth factor in the 
hepatic plasma membrane of rat, guinea pig, mouse, and hamster. Proc Natl Acad Sci U S 
A 81:7407-7411  
349. Bombick DW, Madhukar BV, Brewster DW, Matsumura F 1985 TCDD 
(2,3,7,8-tetrachlorodibenzo-p-dioxin) causes increases in protein kinases particularly 
protein kinase C in the hepatic plasma membrane of the rat and the guinea pig. Biochem 
Biophys Res Commun 127:296-302  
350. Xie G, Peng Z, Raufman JP 2012 Src-mediated aryl hydrocarbon and epidermal 
growth factor receptor cross talk stimulates colon cancer cell proliferation. Am J Physiol 
Gastrointest Liver Physiol 302:G1006-15  
 95 
351. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ 1999 c-Src-
mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and 
Tyr1101 is associated with modulation of receptor function. J Biol Chem 274:8335-8343  
352. Joslin EJ, Opresko LK, Wells A, Wiley HS, Lauffenburger DA 2007 EGF-
receptor-mediated mammary epithelial cell migration is driven by sustained ERK 





 CHAPTER TWO 
 
Calcium causes ligand-independent EGFR down-regulation.  
 
Summary Statement 
Ca-induced EGFR down-regulation is EGFR ligand- independent. While TGF-α 
and AREG maintain a population of EGFRs which preserve a proliferative capacity in 
confluent NHEKs, loss of EGFR ligands is insufficient to reverse EGFR binding loss or 
alter signaling through ERK. 
Abstract 
Extracellular calcium (Ca) induces epidermal differentiation, regulating 
desmosome formation and inducing markers of keratinocyte differentiation. Previous 
work shows that Ca reduces EGFR by ~50%, suggesting that loss of pro-proliferative 
EGFR signals precede differentiation. In this study, we examined the effect of high (1.8 
mM) extracellular Ca on [
125
I]-EGF binding, EGFR ligand secretion, ERK activity, and 
proliferation in normal human epidermal keratinocytes. Ca caused a rapid and sustained 
decrease in [
125
I]-EGF binding relative to basal cells. Secretion of the EGFR ligand 
amphiregulin (AREG) increased with time in culture, while transforming growth factor-α 
(TGF-α) secretion was time- and Ca-dependent. Inhibiting EGFR ligand secretion with 
the metalloproteinase inhibitor batimastat reversed EGFR down-regulation in Ca-treated 
cells, while neutralizing AREG, TGF-α or both did not. Ca reduced ERK activity in 
NHEKs, a response intensified by TGF-α neutralization. However, AREG neutralization 
had no effect on this decreased ERK activity.  Ca-treated NHEKs had 15% fewer cells 
yet EdU labelling showed no significant difference in proliferative capacity.  
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Interestingly, the proliferative capacity did depend upon the presence EGFRs.  Our data 
suggest that Ca-induced EGFR down-regulation is ligand-independent but that 
differentiated keratinocytes down-regulate EGFRs but require the continued presence of 
EGFRs to maintain a population of proliferating cells.     
1. Introduction 
Keratinocytes in the stratum basale of the epidermis are cuboidal, undifferentiated 
epithelial cells that asymmetrically divide and migrate superficially through the layers of 
the epidermis. As they progress upwards, cells undergo cytoskeletal changes that lead to 
adopting a squamous phenotype (Arnemann et al., 1993; Franke et al., 1987) and an 
increase in tight junctions and desmosomal contacts (Jensen and Proksch, 2009; O'Keefe 
et al., 1987).  Differentiating keratinocytes undergo changes to their protein expression 
profile and the composition of their cellular membrane (Ng et al., 1996; Pillai et al., 
1990), and extrude lamellar granules containing specialized lipids and fatty acids which 
contribute to epidermal barrier strength. This process, known as cornification, is integral 
in forming the epidermal barrier, which prevents transdermal water loss and infection 
(Candi et al., 2005).  
Extracellular calcium (Ca) plays an important role in nearly all facets of 
epidermal differentiation. Within the epidermis, elevation of extracellular Ca increases 
the expression of differentiation markers (Rice and Green, 1979) and causes 
redistribution of the desmosomal protein desmoplakin and  the formation of desmosomes 
(Godsel et al., 2005;O'Keefe et al., 1987).   Ca also causes a rapid and sustained down-
regulation of the epidermal growth factor receptor (EGFR) in a variety of cell lines 
(O'Keefe et al., 1982;O 'Keefe and Payne, 1983), suggesting that keratinocyte 
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differentiation requires the suppression of the pro-proliferative signaling associated with 
EGFR activation. In fact, Getsios et al. (Getsios et al., 2009) showed that the desmosomal 
protein desmoglein 1 (Dsg1) suppresses ERK signaling as an important step in promoting 
terminal differentiation of confluent keratinocytes.   Finally, Ca activates matrix 
metalloproteinases (MMPs) which cleave membrane-bound ligands that aid in cell 
migration through the epidermis (Edwards et al., 2008; Franzke et al., 2012; Tallant et al., 
2010) as well as transglutaminase 1,  which crosslinks proteins in the cellular membrane 
to form the stratum corneum (Candi et al., 2005; Thacher and Rice, 1985).  
The EGFR is a member of the ErbB family of receptor tyrosine kinases, which 
includes the EGFR, ErbB2, ErbB3, and ErbB4 (Prenzel et al., 2001) with EGFR, ErbB2, 
and ErbB3 being found in the epidermis (Stoll et al., 2001). The EGFR and its preferred 
dimerization partner, ErbB2 (Macdonald-Obermann et al., 2013; Schneider et al., 
2008a;Xian et al., 1997), are found at the highest density in the stratum basale where 
keratinocytes are actively proliferating (Jost et al., 2001;Nanney et al., 1990). 
Keratinocytes express ErbB3 in suprabasal layers (Kiguchi et al., 2000; Piepkorn et al., 
1994), suggesting that EGFR-ErbB3 dimers are involved in location-dependent 
differentiation (De Potter et al., 2001; Macdonald-Obermann et al., 2013; Piepkorn et al., 
2003).  Suppression of EGFR signaling is clearly important in promoting differentiation 
as, in vitro, treatment of confluent keratinocyte cultures with EGF promotes 
transepithelial water loss (TEWL) and down-regulate clusters of genes involved in 
ceramide biosynthesis, tight junction formation, and epidermal differentiation (Tran et al., 
2012).  In addition, the increased expression of the EGFR and its ligands, which is often 
observed in hyperproliferative diseases, is accompanied by impaired barrier function, 
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(Schneider et al., 2008b; Segre, 2006). Finally, microarray studies in our lab showed that 
EGF treatment upregulates genes involved in epidermal disease (Tran et al., 2012). 
Together these data show that EGFR activity plays an important role in determining 
keratinocyte differentiation status.   
In spite of the importance of the EGFR in cellular proliferation, silencing the 
receptor can impede differentiation. EGFR signaling has been linked to activation of 
protein kinase C-alpha (PKCα) signaling in differentiating keratinocytes (Koese et al., 
2013;Wallis et al., 2000) and studies in EGFR -/- mice showed hypophosphorylated PKC 
impedes post-natal barrier function and causes chronic dermatitis (Denning et al., 
2000;Yang et al., 2003). In fact, murine genetic knockout of TGF-α causes decreased 
wound healing (Kim et al., 2001) and abnormal differentiation of hair follicles (Kim et 
al., 2001). Further, mice deficient in ADAM17 (an MMP that cleaves pro-EGFR ligands) 
do not develop competent epidermal barriers, similar to EGFR -/- mice (Kitajima, 2014).  
These data suggest that the EGFR is necessary for complete epidermal differentiation. 
Although elevations in extracellular Ca down-regulate EGFRs in keratinocytes, 
the mechanism(s) involved is unclear. Typically, receptor down-regulation is ligand-
mediated and assessed by measuring changes in [
125
I]-EGF binding.  However EGF is not 
secreted in the epidermis or its accessory structures. In fact, keratinocytes secrete a 
number of EGFR ligands including amphiregulin (AREG), epiregulin (EREG), heparin 
binding EGF-like growth factor (HB-EGF), and transforming growth factor-alpha (TGF-
α)  (Macdonald-Obermann et al., 2013;Schneider et al., 2008b).  MMP-dependent 
autocrine secretion of AREG and TGF-α is important in regulating normal proliferation 
and epidermal thickening (Schneider et al., 2008a;Stoll et al., 2010), while HB-EGF 
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regulates wound healing and keratinocyte migration (Iwamoto and Mekada, 2000). In 
addition, each ligand has a distinct effect on EGFR activation as well as differing abilities 
to induce receptor degradation or recycling.  
The impact of Ca on EGFR down-regulation, receptor signaling, ligand production, 
and proliferation/differentiation have been extensively studied, but using a variety of cell 
types, culture conditions and Ca concentrations. (Borowiec et al., 2013).  These 
differences in culture conditions make it difficult to draw conclusions as to the effects of 
Ca on EGFR signaling and responsiveness.  Because of the complexity of interpreting 
historical data across a wide range of cell lineages and experimental designs, we used a 
defined set of culture and experimental conditions to identify the mechanisms of Ca-
induced differentiation and its impact on EGFR signaling in NHEKs.  We show that 
elevated extracellular Ca (1.8 mM) rapidly decreases EGFR number and increases the 
production of TGF-α. However, despite increases in both AREG and TGF-α down-
regulation of EGFRs is ligand-independent.  In addition, EGFR down-regulation is 
associated with decreases in ERK activity and keratinocyte cell number that are not 
altered by interfering with AREG or TGF-α availability.   
2. Results 
EGFR down-regulation by Ca 
 
Previous studies have shown that treating confluent NHEKs with high 
extracellular Ca causes the loss of cell-surface EGFRs (Choi et al., 1991;O'Keefe et al., 
1982;Osborne and Greenlee, 1985). In order to determine how rapidly this response 
occurs and to compare it to ligand-induced down-regulation by EGF, we performed 
radioligand binding assays in NHEKs.  EGF (100 ng/ml) rapidly reduced 
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Figure 1: Calcium treatment down-regulates EGF receptors. NHEKs were grown 
as described in Materials and Methods and treated for the times indicated with EGF 
(100 ng/ml) or Ca (1.8 mM) then [
125
I]-EGF binding was determined as described in 
the Materials and Methods. Data have been normalized to protein content and are 
expressed as the % time-matched control and reported as the means + s.e.m. of three 
experiments assayed in triplicate.  The dashed line indicates 100%. * indicates p<0.05 





I]-EGF binding to ~10% of control values by 4 h, maintaining this significant 
(p<0.05) level of inhibition for the duration of the experiment.  Reductions in [
125
I]-EGF 
binding took longer to reach maximal inhibition in Ca-treated cells, with significant 
effect on [
125
I]-EGF binding from 4 hours onward (p<0.05) (Fig. 1).  At 8 h, binding was 
reduced to 51% of control values and remained between 40-60% through 72 h.   
Effect of Ca on EGFR ligand secretion 
 
Keratinocytes secrete several EGFR ligands including AREG, EREG, HB-EGF, 
and TGF-α (Macdonald-Obermann et al., 2013; Schneider et al., 2008a). Our observation 
that Ca treatment mimics decreased [
125
I]-EGF binding (Fig. 1) suggested that Ca 
induced the secretion of an EGFR ligand(s) that drives EGFR down- regulation. To 
assess the impact of Ca on EGFR ligand secretion, we assayed conditioned medium for 
the presence of the EGFR ligands TGF-α, AREG, and HB-EGF.  These ligands were 
chosen based upon literature ties to epidermal disease, wounding, and homeostasis 
(Kennedy et al., 2013; Tran et al., 2012). TGF-α secretion was significantly enhanced by 
Ca treatment at 72 hours (p<0.05; Fig. 2A) going from 115 pg/ml in basal cells at 72 h to 
425 pg/ml.  Although AREG secretion increased with time in culture (Fig. 2B), Ca had 
no effect on its secretion.  HB-EGF concentrations were below the detection limits of our 
ELISAs (Appendix A) consistent with the low levels of HB-EGF produced by NHEKs in 
culture (Piepkorn et al., 2003). 
Role of EGFR ligands in EGFR down-regulation 
 
The data presented in Figure 2 show that NHEKs secrete significantly elevated 
levels of AREG at 72 h (p < 0.05) and that TGF-α is elevated in Ca-treated cells (p < 
0.05). This suggests that one or both ligands causes the loss of [
125
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Figure 2. Calcium increases TGF-α but not AREG secretion.  NHEKs 
were treated for increasing times with Ca (1.8 mM) and culture medium was 
collected.  (A) AREG and (B) TGF-α content were determined by ELISA 
assay as described in Materials and Methods.  Data are means + s.e.m. of 
three experiments assayed in triplicate. (a) indicates p < 0.05 from Time 0. * 
indicates p < 0.05 for Ca-treated cells compared to time matched controls 
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assess the role of these ligands in mediating Ca-dependent EGFR down-regulation, 
NHEKs were treated with Ca in the presence or absence of batimastat, a broad spectrum 
metalloproteinase inhibitor (Rasmussen and McCann, 1997). Consistent with observed 
decreases in [
125
I]-EGF binding (Fig. 1), treating NHEKs with Ca significantly reduced 
biotinylated EGF binding at 72 h (p<0.05; Fig. 3).  Batimastat relieved receptor down-
regulation in Ca-treated cells such that biotin-EGF binding was not significantly different 
from basal cells (Fig. 3A), indicating that that the shedding of a MMP-cleaved protein(s) 
relieves EGFR down-regulation. Batimastat was not able to reverse EGF-induced down-
regulation (Fig. 3A), consistent with EGF addition to the medium rather than being 
released by the cells.  To identify the ligand involved in EGFR down-regulation, NHEKs 
were treated with neutralizing antibodies for AREG or TGF-α alone or in combination.  
Surprisingly, neutralizing ligands alone or in combination had no significant effect on 
receptor down-regulation suggesting that Ca-induced decreases in biotin-EGF binding 
were ligand-independent. (Fig. 3B).   
The Effect of Ca on ERK activity 
The continued presence of EGFRs and the production of TGF-α and AREG in Ca-
treated cells suggests that cells retain responsiveness to locally produced EGFR ligands.  
To determine if this is the case, cells were treated for 72 hours with Ca in the absence or 
presence of neutralizing antibodies for AREG (15 µg/ml) or TGF-α (5 µg/ml) alone or in 
combination.  ERK activity was 55% lower in Ca-treated cells (p<0.05), consistent with 
the decrease in EGF binding observed in Figures 1 and 2.  However, neutralizing AREG, 



























































































c o n t
a n ti-A R E G
a n ti-T G F -


































Figure 3.  Effect of altering ligand availability on EGFR down-regulation.  (A) 
NHEKs were treated with Ca (1.8 mM) for 72 h in the absence or presence of batimastat 
(bat; 3 µM) or (B) neutralizing antibodies for TGF-α (5 µg/ml) or AREG (15 µg/ml) 
alone or in combination.  Biotin-EGF binding was then determined as described in 
Materials and Methods.  Basal refers to K-SFM without Ca; control refers to treatments 
in the absence of batimastat or neutralizing antibodies. Data are means + s.e.m. of six 
experiments assayed in triplicate, normalized to crystal violet staining, and reported as 
the % biotin-EGF bound in basal cells.  (a) indicates significantly different from the 
basal control (p <0.05), The dashed line indicates basal control normalized to 100%. 
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Ca-treated cells (Fig. 4), indicating that the local production of TGF-α and AREG was 
not maintaining ERK activity in these cells. 
Role of EGFR ligands in regulating cell number 
 
The continued presence of EGFRs and the production of both TGF- and AREG could 
indicate that these ligands play a role in cell proliferation. To assess the effect of 
individual EGFR ligands on cell number, we utilized fluorescence-based double stranded 
DNA analysis.  Treatment with Ca led to a significant 15.2% decrease in cell number 
relative to basal cells (Fig. 5A). Neutralizing AREG or TGF-α independently had no 
significant effect on cell number in basal or Ca-treated cells.  Neutralizing both AREG 
and TGF-α significantly reduced cell number in basal cells (p<0.05) but had no greater 
effect than Ca alone on cell number in Ca-treated cells (Fig. 5A). To address this EGFR-
dependence,  we measured the impact of interfering with EGFR activity on DNA 
synthesis using EdU labeling of actively proliferating cells treated for 72 h with Ca in the 
presence or absence of the EGFR inhibitor, PD153035 (300 nM).  We first counted the 
total number of cells per field and found that it was not significantly different between 
basal and Ca- treated cells. PD153035 significantly reduced the number of EdU-labeled 
nuclei in basal and Ca-treated cells (Fig. 5B, C) indicating that DNA synthesis is 
dependent upon the continued presence of signaling-competent EGFRs.   
3. Discussion 
The epidermis is a continually renewing stratified epithelium that forms a 
protective barrier to the external environment.  Proliferating cells in the basal layer 
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Figure 4.  Effect of altering ligand availability on ERK activity. To assess the 
effect of secreted ligands on ERK activity, NHEKs were grown to confluence and 
treated for 72 h with 1.8 mM Ca in the presence or absence of batimastat (bat; 3 M) 
or neutralizing antibodies for TGF-α (5 µg/ml) or AREG (15 µg/ml) alone or in 
combination. ERK activity was measured via PACE assay as described in Materials 
and Methods.  Basal refers to K-SFM without Ca, control refers to treatments in the 
absence of inhibitors. Data are means + s.e.m. of three experiments assayed in 
triplicate.  The dashed line indicates the basal control normalized to 100%. (a) 







Figure 5. Effect of reducing EGFR ligand availability on cell number. In (A) 
NHEKs were grown in the presence or absence of neutralizing antibodies for TGF-
α (5 μg/ml), AREG (15 μg/ml) or both. After treatment, cells were frozen and 
dsDNA labeled as described in Materials and Methods. Basal refers to K-SFM 
without Ca; vehicle refers to treatments in the absence of neutralizing antibodies. 
Data are means + s.e.m. of three separate experiments assayed in tripicate and 
reported as percentage of basal vehicle. (a) indicates significantly different from 
basal control (p < 0.05).  In (B) and (C), NHEKs were grown to confluence in glass 
chamber slides and then treated for 72 h with Ca (1.8 mM) in the presence or 
absence of PD153035 (300 nM), an EGFR inhibitor. During the last 16 h they were 
incubated with 10 mM EdU and labeled as described in the Materials and Methods. 
(B) Representative confocal images of total (DAPI; 405 nm, blue) and EdU-
staining nuclei (647 nm, pink) at 20x magnification.  (C) Proliferative index of Edu 
positive nuclei per field (EdU labeled/DAPI labeled).  Data are means + s.e.m. from 
quantifications of five fields from three separate experiments. ** indicates 





desquamation.  Ca is an important modulator of this differentiation process (Eckert et al., 
2004) with high extracellular Ca rapidly increasing the expression of differentiation 
markers such as involucrin, loricrin, and transglutaminase-1 (Rice and Green, 1979) and 
more slowly inducing cornification (Pillai et al., 1990). High extracellular Ca also down-
regulates the EGFR (O'Keefe and Payne, 1983), a response that has been interpreted to 
show that differentiation requires suppression of epidermal EGFR signaling (Getsios et 
al., 2009; Jensen and Proksch, 2009; O'Keefe et al., 1982; O'Keefe and Payne, 1983). 
However, EGFR ligand production (Fig. 2) is maintained in the face of receptor down-
regulation (Fig. 1) and differentiation (Campion et al., 2016; Rice and Green, 1978) 
leading us to wonder what role the ligands play in receptor down-regulation and the 
cellular consequences of receptor loss.  In this study, we show that the Ca-induced down-
regulation of EGFRs in NHEK is ligand-independent even though it is associated with 
constitutive production of AREG and increased TGF-α secretion. Further, it is associated 
with a reduction in ERK activity and cell number but the maintenance of a small pool of 
proliferating cells that require the continued presence of the EGFR .   
Treatment of NHEKs with high (1.8 mM) extracellular Ca reduced [
125
I]-EGF 
binding by 50% within 8 hours (Fig. 1), a response comparable to that observed by 
Osborne and by others (Hudson et al., 1985;Osborne and Greenlee, 1985).  ERK activity 
decreased to a level comparable to EGFR down-regulation (Fig. 4) and led to a reduction 
of total cell number in Ca-treated cells at 72 h (Fig. 5). This would suggest that Ca-
induced differentiation effectively “turns off” EGFR signaling in order to progress with 
epidermal differentiation.  
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However, this decrease in receptor number was accompanied by an increase in 
TGF-α secretion in Ca-treated cells (Fig. 2B) on a background of elevated AREG at 72 h 
(Fig. 2A).   Denning et al. (Denning et al., 2000) showed similar effects of Ca on TGF-α 
mRNA, indicating that Ca regulates both the expression and production of this EGFR 
ligand. In addition, AREG secretion increased with time in culture in both basal and Ca-
treated cells, presenting NHEKs with two EGFR ligands potentially capable of down-
regulating the EGFR. Additionally, while there were fewer cells in vitro, we found that 
EGFR-dependent proliferation in Ca-treated cells was the same as in basal treated cells 
(Fig. 5C). These data, conversely, suggest that EGFRs in differentiating keratinocytes are 
providing a sufficient proliferative signal in at least a small population of cells, and 
provides a mechanism through the release of ligand as to how this may be occurring.  
 In fact, when basal or Ca-treated cells were treated with the metalloproteinase 
inhibitor batimastat, the EGFR down-regulation in Ca-treated cells was reversed (Fig. 4) 
and biotin-EGF binding in basal cells was enhanced (Fig. 3A).  These data argue that 
there is an effect of a locally released ligand(s) on EGFR binding in both basal and Ca-
treated cells. However, when we removed AREG from the culture medium with a 
neutralizing antibody, there was no change in biotin-EGF binding in basal or Ca-treated 
cells.  While interfering with TGF-α appears to intensity EGFR down-regulation in Ca-
treated cells, this change is not significantly different and neutralizing both ligands was 
similarly ineffective.    
The ability of batimastat to reverse down-regulation while neutralizing antibodies 
could not would seem to argue that another EGFR ligand is involved EGFR down-
regulation.  HB-EGF, which down-regulates EGFRs (Stoll et al., 2001), could play this 
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role.  However, HB-EGF is typically associated with wound healing and keratinocyte 
migration (Poumay and de Rouvroit, 2012) responses not activated in our cultures. More 
importantly, we could not detect HB-EGF in the medium of basal or Ca-treated cells by 
ELISA (Appendix A).  Recent studies show that EREG is present in skin and drives 
keratinocyte proliferation (Macdonald-Obermann et al., 2013).  However, when we 
neutralized EREG alone, or in combination with TGF-α and AREG, we could still not 
relieve EGFR downregulation (Appendix A). It is possible that a cryptic EGFR ligand 
down-regulates EGFRs in the skin, and there is evidence in literature that betacellulin 
plays a role in hair follicle development (Schneider et al., 2008b;Shirakata et al., 2010) 
and epigen has been shown to play a role in sebaceous gland development and pathology 
within the epidermis (Schafer et al., 2014). However, while in vivo, it is possible these 
ligands play a role, given their localized expression and secretion, it is less likely that 
they are affecting our system which models the interfollicular epidermis. 
 This leaves two possibilities: First, that batimastat has effects on EGFR levels 
independent of EGFR ligand secretion.  However, batimastat mimics the MMP cleavage 
site in substrate (Brown, 1995) blocking actions of MMPs -1, -2, -3,  -7, and 9 (Wang et 
al., 2005),  and we could find no evidence in the literature for off-target effects on any 
signaling molecule that leads to differentiation.  This leaves us with the possibility that 
EGFR down-regulation is ligand-independent.  In fact, Ca activates phospholipase C 
independent of a receptor-ligand signaling event (Punnonen et al., 1993).  This, in turn, 
would result in an increase in protein kinase C (PKC) activity.  Since EGFR signaling 
activity is inhibited by PKC-dependent phosphorylation of T
654
 (van Baal et al., 2012) 
and PKC activation by phorbol esters reduced EGFR binding by 40-50% in in SV40 
 112 
transformed keratinocytes (Xue et al., 1996), PLC-mediated and PKC-dependent signals 
might mediate EGFR down-regulation in Ca-treated keratinocytes. Further studies are 
required to identify the ligand-independent mechanisms that might result in EGFR down-
regulation.   
Receptor down-regulation is typically thought of as a means of reducing cellular 
responses to the continued presence of agonist (Mizuno et al, 2005). If TGF-α and AREG 
are not involved in receptor down-regulation, what other role might they play?  Recent 
studies have shown that receptor down-regulation is an important mechanism for shaping 
ERK signaling dynamics and encoding specific cellular responses.  In mammary 
epithelial cells, autocrine delivery of an EGFR ligand produced a persistent reduction in 
EGFR number that promoted cell migration in response to prolonged ERK signaling 
(Joslin et al., 2007).  In contrast, acute elevations in ERK activity produced by exogenous 
EGF were not effective in promoting cell migration. In Ca-treated NHEKs, the reduction 
in EGFR binding was accompanied by a marked decrease in ERK activity, a response 
comparable to that reported by (Getsios et al., 2009;O'Keefe et al., 1982) and indicating 
that having fewer receptors at the cell surface lowered signaling competence.    However, 
AREG and TGF-α were not maintaining ERK signaling in basal or Ca-treated cells,  as 
neutralizing AREG and TGF-α, alone or in combination had no effect on ERK activity. 
These data argue that the local production of AREG and TGF-α is not involved in 
proliferation, a response typically associated with ERK activity, and we see that this is, in 
fact, true for Ca-treated cultures where cell number was significantly lower than that 
observed in basal cells and was not affected by neutralizing AREG and TGF-α either 
alone or in combination (Fig 5A).  In fact, based on the decrease in ERK activity, the 
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15% reduction of total cell number in Ca-treated cells at 72 h (Fig. 5) was not unexpected 
and suggest that Ca-induced differentiation effectively “turns off” EGFR/ERK signaling 
in order to progress with epidermal differentiation.  Interestingly, AREG and TGF-α do 
appear to be important in maintaining cell number in basal cells, as  neutralizing both 
ligands  significantly lowers cell number.  This may not be surprising as the basal cell 
medium contains 0.09 mM Ca, a concentration which results in more rapid growth and 
greater NHEK saturation densities than that supported by 1.2 mM Ca (Micallef et al., 
2009).  Furthermore, EdU labeling of basal and Ca-treated cells indicated that both 
populations required a functional EGFR to maintain a pool of proliferating cells (Fig. 
5B,C) that was comparable in both cell populations. Removal of EGFR ligands is likely 
not affecting cell number in Ca-treated cells as the majority of cells are growth-arrested 
and differentiated.  In this case, the presence of the small population of proliferating cells 
and the maintenance of a reduced number of EGFR at the cell surface might be a 
mechanism for preserving EGFR ligand responsiveness in face of damage to the 
epithelium.  The EGFR-dependent proliferation observed in Fig 5C could be due to trans-
activation of the EGFR by a Ca-activated non-receptor tyrosine kinase such as pyk2 or 
src and there is evidence in literature which shows these proteins are activated during 
keratinocyte differentiation  (Calautti et al., 2005; Gschwind et al., 2001; Xie et al., 
2005). 
Although we did not address this in our study, the last possible role of the ligands in 
post-confluent Ca-treated cells is that they play a role in keratinocyte differentiation.  
ADAM17-/-  mice which do not produce soluble TGF-α show reduced barrier 
permeability and delayed differentiation, a phenotype shared by EGFR -/- mice (Franzke 
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et al., 2012).   This finding is supported by the ability of exogenous TGF-α to rescue 
barrier formation (Franzke et al., 2012), and observations that TGF-α mRNA (Denning et 
al., 2000) and protein (Fig 2) increase in differentiating cells in vitro. Removal of EGFR 
ligands is likely not affecting cell number in Ca-treated cells as the majority of cells are 
growth-arrested and differentiated.   
Taken together, these data suggest that TGF-α secretion is differentiation-associated 
rather than proliferative. In our work, we found neutralizing TGF-α caused noticeable 
though non-significant reduction in both biotin-EGF binding (Fig 3B) and ERK 
activation (Fig 4). This observation was similar to that in 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD)-treated NHEKs grown in low (0.09 mM) Ca under identical experimental 
conditions (Campion et al., 2016), a condition which causes a differentiation-like 
phenotype in proliferative cells.  This suggests that TGF-α, rather than driving EGFR 
down-regulation and silencing it, is maintaining a basal level of surface-associated 
EGFRs capable of responding to EGFR ligand in order to repair and maintain the 
epidermis.   
In summary, our data show that Ca-induced EGFR down-regulation occurs through 
what appears to be a ligand-independent method. Ca induced EGFR down-regulation 
while ERK signaling and proliferation require ligands in basal cells. MMP-dependent 
secretion of both AREG and TGF-α drives ERK activation and maintains proliferation in 
basal keratinocytes. Ca induces TGF-α secretion while AREG production is associated 
with increasing time in culture and confluence regardless of treatment. However, while 
we show that Ca maintains a small population of EGFR dependent, proliferating cells, the 
predominant phenotype induced by Ca is differentiation. It is likely, however, that this 
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sub-population of proliferative cells provide a sufficient proliferative capacity to maintain 
and repair the epidermis. Further work should be undertaken to examine the extent of this 
role of as well as that of secreted EGFR ligands on keratinocyte differentiation.  
4. Materials and Methods 
Cell Culture  
 
In all experiments, fifth passage NHEKs from neonatal foreskins (Lonza, 
Mapleton, IL) were plated at 5,000 cells/cm
2
 in Costar 24- or 96-well cell culture dishes 
(Corning, Corning, NY). Cells were maintained in keratinocyte serum-free medium (K-
SFM; Gibco Invitrogen, Carlsbad, CA) containing 0.09 mM Ca, 5 ng/ml recombinant 
human EGF, and 50 µg/ml bovine pituitary extract (BPE). The medium was changed 
every 48 h until confluence.   At confluence, cells were changed to K-SFM without 
supplements (basal medium) for 48 h then transferred to basal medium containing high 
Ca (1.8 mM) as described in each figure legend. In some experiments, EGF (Bachem, 
Torrance, CA) was added to basal medium to serve as a positive control for ligand-
induced EGFR down-regulation. For immunofluorescence, NHEKs were plated in glass 
chamber slides (BD Biosciences, San Jose, CA) that had been coated with fetal bovine 
serum. The medium was changed every 72 h until confluence. At confluence, cells were 
treated as described above and then subjected to experimental protocols for 72 h.   
Binding of labeled EGF to intact cells 
 
Time-dependent loss of cell-surface associated EGFRs was determined in NHEKs 
grown to confluence in 24-well dishes (Corning, Corning, NY) and treated for 8-72 h in 
Ca-containing medium. Following treatment, cells were washed with HEPES-buffered K-
SFM.   [
125
I]-EGF/ml (specific activity 1128 Ci/mmol; Perkin Elmer, Waltham, MA) was 
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diluted in HEPES-buffered K-SFM with 0.1 % bovine serum albumin (BSA) and binding 
reactions were initiated by the addition of 200 µl of [
125
I]-EGF (250,000 cpm/ml) to each 
well in the presence or absence of 1 µg excess unlabeled EGF.  Binding reactions were 
carried out for 60 min at 37
o
C and terminated by rapid washing with ice-cold phosphate-
buffered saline (PBS). Monolayers were solubilized in 0.2N NaOH and aliquots were 
assayed for protein content using a Bio-Rad Protein Assay (Bio-Rad Laboratories, 
Hercules, CA), and radioactivity by a Packard Cobra II Gamma counter (Perkin Elmer, 
San Jose, CA).  Non-specific binding was subtracted from total counts and specific 
binding was normalized to protein content.  Data are reported as the percentage of 
binding observed in time-matched controls and are the means + s.e.m. of three separate 
binding experiments assayed in triplicate.   
Measurement of AREG, HB-EGF, and TGF-α secretion by NHEKs 
 
NHEK-conditioned medium was collected from basal or Ca-treated cells 4-72 h 
after treatment and stored frozen in aliquots at -80
o
C until analyzed for AREG, HB-EGF, 
or TGF-α content using ELISA kits from Abcam (Cambridge, MA).  Undiluted samples 
were added to the assay and AREG, HB-EGF, and TGF-α content were determined from 
standard curves.  Data are reported in pg/ml and are the means + s.e.m. of three 
experiments assayed in duplicate. HB-EGF was not detected in culture medium from 
either basal or Ca-treated NHEKs and was not assessed in the neutralization experiments.  
Alteration of ligand activity 
 
To investigate the role of each secreted ligand in the loss of EGF binding, cells 
were grown in 96-well cell culture dishes as described above in the presence or absence 
of 3 μM batimastat (Tocris Bioscience, Minneapolis, MN) or neutralizing antibodies for 
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AREG or TGF-α. To neutralize secreted ligands, antibodies to AREG (15 µg/ml), TGF-α 
(5 µg/ml) or both, were added to the medium.  Medium was spiked with batimastat or 
neutralizing antibody after 36 h of treatment. The effect of interfering with EGFR ligand 
availability on cell-surface EGFRs was determined using biotinylated-EGF (Invitrogen, 
Carlsbad CA) in a modified protocol from DeWit et al. (, 2000). This assay was adopted 
to increase assay throughput and conserve antibody.  After treating with Ca + batimastat 
or neutralizing antibodies, plates were washed in ice-cold PBS and incubated for 1 h on 
ice with 10 ng/ml biotinylated EGF in the presence or absence of 1 µg/ml unlabeled EGF. 
Cells were fixed for 30 min at 37
o
C in 4% formaldehyde, washed once with PBS 
followed by two five-minute washes in PBS containing 50 mM glycine. Cells were 
blocked in 2% gelatin in PBS with 0.1% Triton X-100 (PBS-T) for 1 h at 37
o
C, then 
incubated for 1 h at 37
o
C in PBS-T containing 0.2% gelatin and streptavidin-HRP (1:500; 
Cell Signaling Technology, Danvers, MA). Plates were subjected to three five-min 
washes with PBS-T, and two five-min washes with PBS before developing with 1-Step 
Ultra TMB-ELISA Substrate (Thermo Fisher, Waltham, MA). Data were measured 
colorimetrically at 450 nm and normalized to crystal violet absorbance at 595 nm (as a 
measure of cell number) using a BioTek Synergy H1 microplate reader (Biotek 
Instruments, Inc, Winooski VT). Binding was reported as a percentage of that in cells 
grown in basal medium without inhibitors or antibodies.  
Phosphoantibody Cell Based ELISA (PACE) and crystal violet staining 
 
To test the effects of EGFR down-regulation on basal ERK activity, NHEKs 
grown in 96-well plates were treated for 72 h in the absence and presence of batimastat or 
EGFR ligand neutralizing antibodies as described above.  At 72 h, basal ERK activity 
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was measured by PACE assay as described in Kramer et al. (, 2008). Briefly, treatments 
were terminated by rapid washing with ice cold PBS and cells were fixed in 4% 
formaldehyde in PBS, blocked, and incubated overnight with an activation-specific rabbit 
monoclonal antibody [phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204); #4370, Cell 
Signaling Technology, Danvers, MA]. The assays were developed by incubating with a 
HRP-conjugated goat anti-rabbit IgG and 1-Step Ultra TMB-ELISA Substrate and read at 
450 nm. To normalize to cell number, fixed cells were washed and stained with 0.04% 
crystal violet (Sigma Aldrich, St. Louis, MO) (w/v) in 4% ethanol. Cells were lysed 
overnight in 10% SDS and lysates read at 595 nm following the protocol described by 
Kueng et al. (, 1989). Absorbance was read on a BioTek Synergy H1 microplate reader 
and data were expressed as a ratio of ERK (450 nm)/cell number (595 nm). 
EdU Labeling of NHEKs 
 
Cells grown in glass chamber slides were treated at confluence for 72 h with 1.8 
mM Ca in the presence or absence of PD153035, an efficacious and selective EGFR 
inhibitor, as described above. Sixteen hours before the end of the experiment, cells were 
incubated with 10 μM 5-ethynyl-2´-deoxyuridine (EdU), fixed with 4% formaldehyde in 
PBS then permeabilized with 0.5% Triton-X 100 in PBS prior to incubation with the 
Click-It reaction cocktail containing copper sulfate (CuSO4) and an AlexaFlour-
conjugated azide that was crosslinked to cellular EdU as per manufacturer’s protocols 
(ClickIt EdU Imaging kit; Invitrogen, Carlsbad, CA).  Slides were then coverslipped 
using DAPI-containing mounting medium to stain nuclei.  Cells were imaged at 20x 
magnification on Nikon A1 confocal microscope (Nikon, Inc, Melville, NY) at 647 nm 
for EdU-positive nuclei and 405 nm for total nuclei.  Identical image capture parameters 
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were used for all images.  EdU positive nuclei as well as total (DAPI-labeled) nuclei were 
counted using CellProfiler version 2.1.0 (Broad Institute, Cambridge, MA). Images were 
converted to gray scale then counted via “count objects” selecting for circularity and 
filtering using a Mixture of Gaussian (MoG) Global correction with standard threshold 
correction factors, and upper and lower bounds (1.0, 0.0, 1.0, respectively) (Carpenter et 
al., 2006).  Five random fields on each of 3 slides were counted for all treatments and 
conditions.  
Double-stranded DNA analysis 
 
To support crystal violet data as an indicator of cell number, double stranded 
DNA was labelled using the FluoReporter blue fluorometric dsDNA Quantitation kit 
(Molecular Probes, Inc, Eugene, OR) following manufacturer’s protocol (362). Briefly, 
cells were grown to confluence in black-walled and clear bottom plates and treated with 
1.8 mM Ca + 300 nM batimastat or neutralizing antibodies as described above. At 72 
hours, medium was removed and plates were frozen at -80
o
C to lyse cells. Plates were 
then thawed and rehydrated with Hoechst 33258 in Tris-NaCl-EDTA buffer and 
fluorescence was measured on a BioTek Synergy H1 microplate reader with excitation 
and emissions filters at 360 nm and 460 nm, respectively. Cell number in each treatment 
group was determined from a standard curve plated at the start of the experiment.   
Data analyses 
 
EGFR binding data and PACE assays were performed in three experiments 
utilizing triplicate wells. Data were analyzed via two-way ANOVA and significance (p < 
0.05) was determined using a Bonferroni post-hoc test as performed in Prism GraphPad 
software version 5.0 (La Jolla, CA). TGF-α and AREG ELISAs were performed with 
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conditioned medium from three experiments and assayed in duplicate. EGFR ligand 
concentration was determined from standard curves and analyzed via one- or two-way 
ANOVA with a Bonferroni post-hoc test as appropriate.  
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Role of EGF Receptor ligands in TCDD-induced EGFR down-regulation and 
cellular proliferation 
 
Abstract   
In cultures of normal human epidermal keratinocytes (NHEKs), 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) induces the expression of the epidermal growth 
factor receptor ligands transforming growth factor-α (TGF-α) and epiregulin (EREG).  
TCDD also down-regulates EGF receptors (EGFR), suggesting that decreases in 
signaling contribute to the effects of TCDD. In this study, we treated post-confluent 
NHEKs with 10 nM TCDD and assessed its effects on EGFR binding, EGFR ligand 
secretion, basal ERK activity, and proliferation. TCDD caused time-dependent deceases 
in [
125
I]-EGF binding to levels 78% of basal cell values at 72 h.  Amphiregulin (AREG) 
levels increased with time in culture in basal and TCDD-treated cells, while TGF-α and 
epiregulin (EREG) secretion were stimulated by TCDD. Inhibiting EGFR ligand release 
with the metalloproteinase inhibitor batimastat prevented EGFR down-regulation.  
Neutralizing antibodies for AREG and EREG relieved receptor down-regulation while 
neutralizing TGF-α intensified EGFR down-regulation. Treating NHEKs with AREG or 
TGF-α caused rapid internalization of receptors with TGF-α promoting recycling within 
90 min.  EREG had limited effects on rapid internalization or recycling.  TCDD treatment 
increased ERK activity, a response reduced by batimastat and the neutralization of all 
three ligands indicating that the EGFR and its ligands maintain ERK activity.  All three 
EGFR ligands were required for the maintenance of total cell number in basal and 
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TCDD-treated cultures. The EGFR inhibitor PD153035 blocked basal and TCDD-
induced increases in the number of cells labeled by 5-ethynyl-2´-deoxyuridine EdU), 
identifying an EGFR-dependent pool of proliferating cells that is larger in TCDD-treated 
cultures.  Overall, these data indicate that TCDD-induced EGFR down-regulation in 
NHEKs is caused by AREG, TGF-α and EREG, while TGF-α enhances receptor 
recycling to maintain a pool of EGFR at the cell surface. These receptors are required for 
ERK activity, maintenance of total cell number, and stimulate stimulating the 
proliferation of a small subset cells.   
1. Introduction  
The epidermis is a stratified squamous epithelium that provides a barrier against 
the entrance of pathogens and foreign substances and protects the body from dehydration. 
Keratinocytes within the stratum basale are cuboidal, undifferentiated epithelial cells that 
divide and migrate superficially through the layers of the epidermis. Cells in the stratum 
basale maintain the proliferative capacity of the epidermis while the epidermal barrier is 
established as cells migrate outwardly and cornify [1]. As they progress upwards and 
differentiate, keratinocytes become more squamous-like [2,3], alter their membrane 
lipids, cross-link proteins and lose organelles such as mitochondria and nuclei [4-6].  The 
differentiation process is accompanied by decreases in epidermal growth factor receptor 
(EGFR) number at the cell surface (down-regulation), a reduction in EGFR signaling, and 
the attenuation of epidermal proliferative capacity [1,7-9], demonstrating the central role 
EGFRs play in the balance between proliferation in the basal layers and differentiation in 
the upper layers [10]. 
Keratinocytes express three members of the ErbB family of receptor tyrosine 
kinases, the EGFR (ErbB1), ErbB2, and ErbB3 (reviewed in [11]) with the EGFR 
 133 
appearing to be the most important member mediating ligand effects in these cells [12]. 
The fourth family member, ErbB4, is not expressed in skin [12].  Each ErbB receptor 
possesses differing ligand affinities, as well as overlapping, but distinct downstream 
signaling cascades and distribution within the epidermis [13]. EGFR activation leads to  
receptor dimerization and phosphorylation of tyrosine residues in the receptor’s C 
terminus which provides docking sites for scaffolding and signaling molecules.  All ErbB 
receptors can form homo- or heterodimers but EGFR homodimers engage cellular 
endocytic machinery leading to EGFR internalization and degradation, while ErbB 
heterodimers recycle to the cell membrane [14,15].  The EGFR is expressed in all 
epidermal layers [12], but its density is greatest in the stratum basale where it drives 
proliferation in cells that have lost contact with the matrix [16,17].   
  Cells expressing EGFRs typically produce EGFR ligands that maintain cells in 
the absence of exogenous growth factors [18-21]. Normal keratinocytes produce 
amphiregulin (AREG), epiregulin (EREG), transforming growth factor-alpha (TGF-α) 
and heparin binding EGF-like growth factor (HB-EGF) [11]. Amphiregulin is produced 
in the largest quantities, consistent with its ability to induce the strongest autocrine 
stimulation to cell growth [22].  In contrast, TGF-α, HB-EGF, and epiregulin are 
expressed at very low levels [23].  Keratinocyte production of TGF-α [24,25] and EREG 
[26] can also be increased by treating cells with 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD), a response consistent with the ability of TCDD to stimulate proliferation.  
However, TCDD-mediated increases in TGF-α and EREG are also accompanied by 
accelerated differentiation [27-30] and down-regulation of keratinocyte EGFRs [30-32], 
and studies in our lab have shown that inhibiting EGFR activation promotes the 
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differentiating effects of TCDD [28].   These data suggest that the loss of EGFR signaling 
mediates the accelerated differentiation of TCDD-treated keratinocytes.        
Cellular responses to a ligand are determined by the number of receptors 
activated, and receptor down-regulation is a mechanism for modifying signaling 
dynamics to limit cellular responses [33,34]. The down-regulation of EGFRs observed as 
keratinocytes differentiate or in cells treated with TCDD may be an adaptive mechanism 
to maintain but redirect responsiveness in the face of continued agonist presence [35].   In 
mammary epithelial cells, Joslin et al.  [36] showed that local production of EGFR 
ligands reduced EGFR number, but elevated basal ERK activity and enhanced cell 
migration to levels greater than that produced by exogenous EGF.  Thus, rather than 
prevent EGFR signaling by receptor down-regulation, the local production of EGFR 
ligands by keratinocytes could fine tune EGFR signaling as receptor down-regulation is 
inversely proportional to receptor activity [37].  In this study, we used normal human 
epidermal keratinocytes (NHEKs) to study the mechanism involved in TCDD-induced 
EGFR down-regulation and the impact of down-regulation on EGFR signaling and 
cellular proliferation in post-confluent cultures.  We show that TCDD increases the 
production of TGF-α and EREG, and that down-regulation of EGFRs is mediated by 
AREG, EREG, and TGF-α. In addition, we show that TGF-α promotes receptor 
recycling. These changes in receptor availability are associated with ligand-dependent 
elevations in ERK activity as well as an increase in a small pool of proliferating cells.    
2. Materials and methods 
2.1. Cell Culture 
 
 In all experiments, fifth passage NHEKs from neonatal foreskins (Lonza, 
Mapleton, IL) were plated at 5,000 cells/cm
2
 in Costar 24- or 96-well cell culture dishes 
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(Corning, Corning, NY). Cells were maintained in keratinocyte serum-free medium (K-
SFM; Gibco Invitrogen, Carlsbad, CA) containing 0.09 mM Ca, 5 ng/ml recombinant 
human EGF (EGF) and 50 µg/ml bovine pituitary extract. The medium was changed 
every 48 h until confluence.  At confluence, cells were changed to K-SFM without 
supplements (basal medium) for 48 h then transferred to basal medium containing TCDD 
(10 nM) as described in each figure legend. In some experiments, recombinant human 
EGF (EGF; Bachem, Torrance, CA) was added to basal medium to serve as a positive 
control for ligand-induced EGFR down-regulation. For immunofluorescence, NHEKs 
were plated in glass chamber slides (BD Biosciences, San Jose, CA) that had been coated 
with fetal bovine serum. The medium was changed every 72 h until confluence, at which 
time cells were treated for 72 h as described above and then subjected to experimental 
protocols as described below. 
2.2    EGFR ligand ELISAs  
 
Culture medium was collected from basal and TCDD-treated cells 4-72 h after 
treatment and stored frozen in aliquots at -80
o
C until analyzed for AREG, HB-EGF, or 
TGF-α content using ELISA kits from Abcam (Cambridge, MA) and EREG content 
using a kit from Antibodies-Online Inc. (Atlanta, GA).  Undiluted samples were added to 
the assay and ligand content was interpolated from standard curves.  Data are reported in 
pg/ml and are the means + SEM of three experiments assayed in duplicate.  
2.3   Phosphoantibody Cell Based ELISA (PACE) and crystal violet staining   
 
To test the effects of EGFR down-regulation on ERK activity, NHEKs grown in 
96-well plates were treated for 72 h in the absence and presence of batimastat or EGFR 
ligand neutralizing antibodies as described below.  At 72 h, ERK activity was measured 
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by PACE assay as described by [38]. Briefly, treatments were terminated by rapid 
washing with ice-cold PBS and cells were fixed in 4% formaldehyde in PBS, blocked, 
and incubated overnight with an activation-specific rabbit monoclonal ERK antibody 
[phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204); Cell Signaling Technology, 
Danvers, MA]. The assays were developed by incubating with an HRP-conjugated goat 
anti-rabbit IgG and 1-Step Ultra TMB-ELISA substrate and read at 450 nm using a 
BioTek Synergy H1 microplate reader. To normalize to cell number, fixed cells were 
washed and stained with 0.04% crystal violet (Sigma Aldrich, St. Louis, MO) (w/v) in 
4% ethanol following the protocol described in [39]. Cells were lysed overnight in 10% 
SDS and absorbance was measured at 595 nm. Data are expressed as a ratio of ERK (450 
nm)/cell number (595 nm). 
2.4. Interfering with ligand action 
 
  To investigate the role of each secreted ligand in EGFR down-regulation, ERK 
activation, and TCDD-induced proliferation, cells were grown in 96-well cell culture 
dishes in the presence or absence of 3 μM batimastat (Tocris Bioscience, Minneapolis, 
MN), a broad spectrum metalloproteinase (MMP) inhibitor [40], or neutralizing 
antibodies for TGF-α (5 μg/ml; R&D Systems, Minneapolis, MN), AREG (15 μg/ml; 
R&D Systems), or EREG (5 μg/ml; R&D Systems). The neutralizing capability of each 
antibody was verified by spiking basal medium with 0-30 ng/ml exogenous TGF-α,  
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AREG, or EREG and preincubating with or without the appropriate amount of 
neutralizing antibody. Plates were then stopped after five minutes, and ERK activation 
was measured using a PACE assay. Anti-TGF-α, anti-AREG, and anti-EREG all 
effectively neutralized high doses of their respective ligands (Fig. 1).  Neutralizing 
antibodies were then added to binding assays, PACE assays and proliferation assays as 
described. 




Time-dependent loss of cell-surface EGFRs was determined in NHEKs grown to 
confluence in 24-well dishes (Corning, Corning, NY) and treated for 4-72 h in TCDD-
containing medium. Following treatment, cells were washed three times with HEPES-
buffered K-SFM.   [
125
I]-EGF/ml (specific activity 1128 Ci/mmol; Perkin Elmer, 
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Fig. 1  Validating the effects of each neutralizing antibody. NHEKs were grown 
to confluence as described in the Materials and Methods section then challenged for 
five minutes with medium containing the indicated concentrations of exogenous (A) 
AREG, (B) EREG, or (C) TGF-α that had been pre-absorbed for 2 h at 37
o
C with 
neutralizing antibody for AREG (15 μg/ml), EREG  (5 μg/ml), or TGF-α (5 µg/ml).  
ERK activation was then measured as described in the Methods. Data represent 





Waltham, MA) was diluted in HEPES-buffered K-SFM with 0.1 % bovine serum 
albumin (BSA) and binding reactions were initiated by the addition of 200 µL of [
125
I]-
EGF (250,000 cpm/ml) to each well in the presence or absence of excess (1 µg/ml) 
unlabeled EGF.  Binding reactions were carried out for 60 min at 37
o
C and terminated by 
rapid washing with ice-cold phosphate-buffered saline (PBS). Monolayers were 
solubilized in 0.2N NaOH and aliquots were assayed for protein content using a Bio-Rad 
Protein Assay (Bio-Rad Laboratories, Hercules, CA), and radioactivity by a Packard 
Cobra II Gamma counter (Perkin Elmer, San Jose, CA).  Specific binding was determined 
by subtracting non-specific binding from total counts bound and normalized to protein 
content.  Data are reported as the percentage of binding observed in time-matched 
controls and are means + SEM of three separate binding experiments assayed in 
triplicate.   
In order to conserve antibody and increase assay throughput while assessing the 
role of EGFR ligands in receptor down-regulation, cells were grown in 96-well dishes 
treated with EGF or TCDD for 72 h in the presence of batimastat or neutralizing 
antibodies as described above. Medium was spiked with batimastat or neutralizing 
antibody after 36 h of treatment. The effect of interfering with EGFR ligand availability 
on cell-surface EGFRs was determined using biotin-EGF (Invitrogen, Carlsbad CA) in a 
modified protocol from de Wit et al. [41]. Plates were washed in ice-cold PBS and 
incubated for 1 h on ice with 10 ng/ml biotin-EGF in the presence or absence of 1 µg/ml 
unlabeled EGF. Cells were fixed for 30 min at 37
o
C in 4% formaldehyde, washed once 
with PBS, followed by two five-min washes in PBS containing 50 mM glycine. Cells 




incubated with streptavidin-HRP at a 1:500 dilution (Cell Signaling Technology, 
Danvers, MA) in 0.2% gelatin in PBS-T for 1 h at 37
o
C. Plates were subjected to three 
five-min washes with PBS-T and two five-min washes with PBS before developing with 
1-Step Ultra TMB-ELISA Substrate (Thermo Fisher, Waltham, MA). Absorbance at 450 
nm was read on a BioTek Synergy H1 microplate reader and normalized to crystal violet 
absorbance at 595 nm.  Data are reported as the percentage of binding in basal cells. To 
assess the ability of each ligand to down-regulate EGFRs, post-confluent NHEKs were 
exposed to EGF, TGF-α, amphiregulin, or epiregulin for 5-120 min using concentrations 
equal to the maximum amount of that ligand in the cultures at 3 days.  Cells were then 
placed on ice and cell surface receptors were analyzed by measuring biotin-EGF binding 
as described above.   
2.6    Double-stranded DNA analysis  
 
As our previous study shows that TCDD treatment compromises mitochondrial 
function [42], analysis of changes in cell number was measured by double stranded DNA 
labeling using the FluoReporter blue fluorometric dsDNA Quantitation kit (Molecular 
Probes, Inc, Eugene, OR), following the manufacturer’s instructions. Briefly, cells were 
grown to confluence in clear bottom black well plates (Corning Costar, Corning NY) and 
treated with 10 nM TCDD in the absence or presence of 3µM batimastat or neutralizing 
antibodies. At 72 hours, medium was removed from the cells, and the plates were frozen 
at -80
o
C to lyse cells and release DNA. Plates were then thawed and rehydrated with 
Hoechst 33258 in Tris-NaCl-EDTA buffer and fluorescence was measured on a BioTek 
Synergy H1 microplate reader with excitation and emissions at 360 and 460 nm,  
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respectively. Cell number in each treatment group was determined from a standard curve 
plated at the start of the experiment.     
2.7   EdU Labeling  
 
At confluence, cells grown in glass chamber slides were treated for 72 h with 10 
nM TCDD in the presence or absence 300 nM PD153035 (EMD Millipore, Billerica, 
MA), a highly selective EGFR inhibitor. Sixteen hours before the end of the experiment, 
cells were incubated with 10 µM 5-ethynyl-2´-deoxyuridine (EdU), fixed with 4% 
formaldehyde in PBS then permeabilized with 0.5% Triton-X 100 in PBS.  Slides were 
incubated with the Click-It reaction cocktail containing copper sulfate and an AlexaFluor 
647-conjugated azide that was crosslinked to cellular EdU according to the 
manufacturer’s instructions (Invitrogen, Carlsbad, CA). Slides were coverslipped using 
DAPI-containing mounting medium to stain nuclei.  Cells were imaged at 20x 
magnification on a Nikon A1 confocal microscope (Nikon, Inc, Melville, NY) at 647 nm 
for EdU-positive nuclei and 405 nm for total nuclei.  Identical capture parameters were 
used for all images. EdU positive nuclei as well as total (DAPI-labeled) nuclei were 
counted using CellProfiler version 2.1.0 (Broad Institute, Cambridge, MA). Images were 
converted to gray scale then counted via “count objects” selecting for circularity and 
filtering using a Mixture of Gaussian (MoG) Global correction with standard threshold 
correction factors, and upper and lower bounds (1.0, 0.0, 1.0, respectively) [43].  The 
experiment was performed three times, with three slides per experiment.  Five random 




2.8. Data analyses 
 
   EGFR binding data and PACE assays were performed in three experiments 
utilizing triplicate wells. Data were analyzed via two-way ANOVA and significance (p < 
0.05) was determined using a Bonferroni post-hoc test as performed in Prism GraphPad 
software version 5.0 (La Jolla, CA). TGF-α, HB-EGF, AREG and EREG ELISAs were 
performed with culture medium collected from three experiments and assayed in 
duplicate. EGFR ligand concentrations were determined from standard curves and 





Fig. 2.TCDD decreases [
125
I]-EGF binding. NHEKs were grown as 
described in the Material and methods section and (A) treated for the times 
indicated with EGF (100 ng/ml) or TCDD (10 nM), then [
125
I]-EGF binding 
was determined. Data are reported as the means + SEM of three experiments 
assayed in triplicate. * indicates p<0.05 for treatment effect compared to time-
matched control  (B) NHEKs were treated for the times indicated with 
increasing concentrations of EGF (0.1-100 ng/ml), then [
125
I]-EGF binding 
was determined.  Data means + SD of one experiment assayed in triplicate. 





3. Results  
3.1. EGFR down-regulation in TCDD-treated cells 
 
  Previous studies have shown that treating NHEKs for 1-4 days with TCDD causes 
the loss of cell-surface EGFRs (
30-32
).  To determine how rapidly this response occurs and 
to compare it to ligand-induced down-regulation by EGF, we performed radioligand 
binding assays in NHEKs.  EGF (100 ng/ml) rapidly reduced [
125
I]-EGF binding to 
roughly 10% of control values by 4 h, maintaining this significant (p<0.05) level of 
inhibition for the duration of the experiment (Fig. 2A).  In contrast, TCDD treatment had 
a limited effect on [
125
I]-EGF binding during the first 24 h but by 48 h, binding had 
decreased to 64% of control.  At 72 h, binding rebounded to 78% of control values, but 
was still significantly lower than that in time-matched cells.  In no case was the reduction 
in binding in TCDD-treated cells as rapid or as complete as that observed with EGF 
treatment.  The decrease in [
125
I]-EGF binding observed in EGF- or TCDD-treated cells 
was not the result of time-dependent decreases in basal cell receptor number, as binding 
did not change significantly with time in culture (Fig. 3).    
To determine if lower doses of EGF could mimic the levels of down-regulation 
observed in TCDD-treated cells, NHEKs were treated with EGF (0.1-100 ng/ml) 
followed by the measurement of [
125
I]-EGF binding.  In cells treated with 0.1 ng/ml EGF, 
[
125
I]-EGF binding was reduced to 90% of control within 24 h while 1 ng/ml EGF 
reduced binding to 60% of control within 12 h.  By 72 h, [
125
I]-EGF binding had returned 
to control levels in cells treated with either EGF concentration.  Increasing the EGF dose 
to 10 or 100 ng/ml produced a more rapid, extensive, and persistent reduction in  [
125
I]-
EGF binding, reaching ~40% of control levels by  72 h for 10 ng/ml and 12% of control 
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values for 100 ng/ml (Fig. 2B).  These data show that the degree of receptor loss is dose-
dependent and low concentrations of EGF remove fewer receptors from the cell surface.     
3.2. Effect of TCDD on EGFR ligand secretion  
 
Keratinocytes secrete several EGFR ligands including AREG, EREG, HB-EGF, 
and TGF-α (see Pastore et al. [11]) with TCDD reported to increase the expression and 
production of TGF-α [24,25], and AREG  [44].  Our observation that TCDD treatment 
 
 


































Fig 3. Changes in [
125
I]-EGF binding with time in culture.  Basal NHEKs 
were grown as described in the Materials and Methods section and total 
[
125
I]-EGF binding was determined at each time point. Data are normalized 
to and reported as a % of total binding at T0 and reflect the means + SEM of 







I]-EGF binding (Fig. 1) suggested that the local production of an EGFR 
ligand(s) may drive receptor down-regulation.  To assess the impact of TCDD on EGFR 
ligand secretion, we measured AREG, EREG, TGF-α, and HB-EGF in culture medium 
over the course of 72 hours.  These ligands were chosen based upon literature, ties to 
epidermal disease and homeostasis, and evidence of TCDD-induced changes in mRNA 
expression by RT-PCR or microarray [42]. AREG secretion increased with time in 
culture. was comparable in both basal and TCDD-treated cells, and was inhibited by the 
broad-spectrum MMP inhibitor batimastat  (Fig. 4A,D).  EREG secretion was minimal 
(26 pg/ml) in basal cells, but at 72 h was present at a concentration of 718 pg/ml in 
culture medium from TCDD-treated cells (Fig. 4B). Like AREG, EREG production was 
inhibited by batimastat (Fig. 4E).  Batimastat-sensitive TGF-α secretion by basal cells 
increased by 65 % at 72 hours and TCDD significantly enhanced TGF-α production over 
basal cells at 72 hours treatment (Fig. 4C, F), a response comparable to that reported by 
Choi et al. [24].  At 72 h, the concentration of TGF-α in the medium from basal cells was 
119 pg/ml, versus 428 pg/ml in TCDD-treated cells.  This value is comparable on a molar 
level to ~ 0.5 ng/ml EGF, a value between the low doses of EGF (0.1 and 1 ng/ml) that 
produce modest decreases in [
125
I]-EGF binding in Fig. 1B.  HB-EGF concentrations 
were below the detection limits of our ELISA (data not shown), consistent with the low 
levels of HB-EGF produced by NHEKs in culture [45] and its primary role in wound 
healing and keratinocyte migration [46]. Together, the data in Fig. 4 indicate TCDD 





Fig. 4.  Effect of TCDD on MMP-dependent EGFR ligand secretion. NHEKs 
were treated for 2-72 h with TCDD (10 nM) and the culture medium was collected 
for the measurement of EGFR ligands. (A) AREG, (B) EREG or (C) TGF-α content 
were determined by  ELISA as described in Materials and methods section. Data are 
means + SEM of three experiments assayed in duplicate. * indicates significantly 
different from time-matched control (TMC), p< 0.05.  In D-F, cells were treated for 
72 h with vehicle or TCDD + 3 µM batimastat (bat). The culture medium was 
collected at 72 h for the measurement of (D) AREG, (E) EREG, or (F) TGF-α.  ND 
indicates not detectable.   
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3.3 Role of EGFR ligands in EGFR down-regulation 
 
   The data presented in Fig. 4 show that NHEKs secrete AREG, EREG, and TGF-
α, with TCDD enhancing the production of EREG and TGF-α.  These data suggest that  
an EGFR ligand(s) causes the loss of [
125
I]-EGF binding observed in TCDD-treated cells. 
To examine the role of these ligands in mediating TCDD-dependent EGFR down-
regulation, NHEKs were treated with TCDD or EGF in the presence or absence of 
batimastat (3 µM) or neutralizing antibodies for AREG, EREG, or TGF-α, alone or in 
combination. Consistent with [
125
I]-EGF binding (Fig. 2A), 10 nM TCDD and 10 ng/ml 
EGF significantly reduced biotin-EGF binding at 72 h with TCDD decreasing binding to 
44+11% and EGF to 38+19% of basal cells (Fig. 5A).  Batimastat relieved receptor 
down-regulation in TCDD-treated cells, indicating that the release of soluble EGFR 
ligands was driving receptor loss from the cell surface. As expected, batimastat had no 
effect on receptor down-regulation produced by the addition of exogenous EGF.   
  To examine the individual roles of the EGFR ligands in receptor down-regulation, 
NHEKs were treated with neutralizing antibodies for AREG, EREG, or TGF-α.  TCDD 
treatment reduced biotin-EGF binding to 43 + 7% of basal control values (Fig. 5B), and 
neutralizing AREG or EREG returned binding to levels that were not significantly 
different from basal control cells (67 + 13% and 61 + 10% of basal control levels, 
respectively).  These data indicate that both AREG and EREG contribute to EGFR down-
regulation in TCDD-treated cells.  In contrast, neutralizing TGF-α in TCDD-treated cells 
significantly enhanced EGFR down-regulation (11 + 1% of basal control levels), 
suggesting that TGF-α promotes receptor recycling rather than down-regulation.  When 




Fig. 5. Reducing EGFR ligand availability modifies EGFR down-
regulation in response to TCDD. (A) NHEKs were treated with or without 
TCDD (10 nM) or EGF (10 ng/ml) for 72 h in the absence or presence of 
batimastat (bat; 3 µM) or (B) neutralizing antibodies for AREG (15 µg/ml), 
EREG (5 µg/ml), TGF-α (5 µg/ml), or all three growth factors (anti-all-GF) 
for 72 h. The measurement of biotin-EGF binding was then determined as 
described in the Material and methods section. Basal refers to medium (K-
SFM) without TCDD; control refers to treatments in the absence of 
batimastat or neutralizing antibodies. Data are means + SEM of six 
experiments assayed in triplicate, normalized to crystal violet staining, and 
reported as the % biotin-EGF bound in basal control cells.  (a)  indicates 
significantly different from the basal control at p < 0.05. * indicates 
significantly different from the within treatment control (p <0.05).  
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binding remained at levels about 30 % of basal, indicating that the effect of neutralizing 
TGF-α predominates at 72 hours post-confluence. 
The enhanced down-regulation of EGFRs when TGF-α was neutralized suggested 
that TGF-α may alter EGFR trafficking in TCDD-treated cells.  Since the fate of an  
internalized receptor has a substantial impact on the duration of a receptor signal [36,47], 
we examined the effect of pretreating NHEKs with EGF, AREG, EREG or TGF-α on 
biotin-EGF binding.  NHEKs were treated for 5-120 min with concentrations of 
exogenous EGFR ligands comparable to the levels found in conditioned medium at 72 h, 
then the amount of biotin-EGF binding was assessed.  As observed in Fig. 2, treatment 
with EGF caused a rapid reduction in biotin-EGF binding to 11 + 4% of T0 values, a 
response that was sustained throughout the experiment (Fig. 6).  TGF-α reduced binding 
to 87% of T0 values within 10 min, while AREG reduced binding to 63% of T0 values by 
15 min. EREG did not affect biotin-EGF binding at any time point.  These data are 
consistent with all three ligands producing effects on EGFR trafficking distinct from 
those of EGF, and suggest that one or all maintain a population of EGFRs at the cell 
surface.   
3.4. Effect of EGFR ligands on ERK activity   
 
  Human keratinocytes maintain high steady-state levels of ERK activity due to the 
autocrine production of EGFR ligands [48] and the continued presence of EGFRs (Fig 
5B) could be important in maintaining ERK activity.  In fact, ERK activity was elevated 
in TCDD-treated cells as early as 24 h after the start of the treatment even in the face of a 
reduction in the number of EGFRs, and was significantly greater than time-matched 
controls at 72 h (Fig. 7A).  To determine which EGFR ligand(s) enhanced ERK activity,  
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we treated cells for 72 h with TCDD in the absence or presence of batimastat (3 µM) or 
neutralizing antibodies for AREG, EREG, or TGF-α alone, or in combination.  
Batimastat reduced ERK activity to 52% and 55% of control levels in both basal and 
TCDD-treated cells, respectively (Fig. 7B).  These data indicate that the residual EGFRs 
present on the cell surface are sufficient to maintain EGFR-dependent ERK activity in 
response to locally secreted EGFR ligands in both basal and TCDD- treated cells.  When 
we examined the roles of each EGFR ligand in maintaining ERK activity, neutralizing an 
individual ligand had no impact on the elevated ERK activity observed in TCDD-treated 
cells.  However, when NHEKs were incubated with all three neutralizing antibodies,  
 
Fig. 6. EGFR ligands differentially alter EGFR recycling. NHEKs were 
treated for 0-120 min with 60 ng/ml EGF and concentrations of ligands 
present in culture medium at 72 h (3000 ng/ml AREG, 412 ng/ml TGF-α or 
627 ng/ml EREG) then biotin-EGF binding was measured on ice to prevent 
internalization. The amount of biotin-EGF bound was then determined as 
described in the Materials and methods section.  Data are means + SEM of 
triplicate experiments. (a) indicates significantly different from T0 (p < 0.05). 







Fig. 7. TCDD-mediated increases in ERK activity are EGFR ligand-dependent. To 
assess the effect of TCDD on basal ERK activity over 72 h, NHEKs were grown for 0-72 
h with or without 10 nM TCDD and (A) basal ERK activity was measured at the indicated 
times as described in the Materials and methods section.  Data are reported as % time 
matched control and are means + SEM of three experiments assayed in triplicate. * 
indicates significant difference from the time-matched control  (p < 0.05) (B) To assess 
the role of secreted ligands on ERK activity, NHEKs were treated for 72 h with TCDD in 
the presence or absence of batimastat (bat; 3 M) or (C) neutralizing antibodies for 
AREG (15 µg/ml), EREG (5 µg/ml), TGF-α (5 µg/ml), or all three growth factors (anti-
all-GF). Basal refers to medium (K-SFM) without TCDD; control refers to treatments in 
the absence of inhibitors. Data are means + SEM of three experiments assayed in 
triplicate. In B, C, * indicates significantly different from TCDD alone (p < 0.05) and (a) 
indicates significantly different from basal control (p < 0.05). The dashed line indicates 





ERK activity was reduced to levels that were not significantly different from untreated  
basal cells (Fig. 7C).   These data indicate that all three ligands are required to produce 
the increase in ERK activity observed in TCDD-treated cells.   
3.5. Role of EGFR ligands in regulating cell number   
 
The presence of AREG, EREG, and TGF-α  in NHEK culture medium and the 
observation that all three ligands have an effect on EGFR down-regulation as well as 
maintenance of ERK activity led us to examine the role of each ligand plays in the 
proliferative response reported in TCDD-treated cells [25,26,49]. Cell numbers at 72 
hours were not different in basal and TCDD-treated cells (95713 + 2251 vs 94,360 + 
3175, respectively; Fig. 8A). These results are not surprising as these are post-confluent 
cultures. Neutralizing each individual ligand produced modest reductions in cell number, 
with greatest effect occurring in basal and TCDD-treated cells treated with the AREG 
antibody (a 6 % drop from 95,714 + 2251 to 90,314 + 650 cells in basal cultures and a 7 
% drop from 94,380 + 3175 to 88027 + 1412 cells in TCDD-treated cultures). While the 
loss of individual ligands was not statistically significant, neutralizing all three ligands 
reduced cell number significantly in both basal (10.3%) and TCDD-treated (11.3%) cells. 
These data indicate that all three EGFR ligands play a role in maintaining cell number in 
post-confluent monolayers of basal and TCDD-treated cells.  
Since TCDD produced no significant increase in cell number compared to basal 
cells, we wondered whether there might be a small population of cells proliferating in 
response to TCDD. To address this question, we measured DNA synthesis using EdU 
labeling in cells treated for 72 h with TCDD in the presence or absence of the EGFR 




Fig. 8. Reducing ligand availability affects cell number and 
proliferation. (A) NHEKs were grown in the presence or absence of 
neutralizing antibodies for AREG (15 µg/ml), EREG (5 µg/ml), TGF-α (5 
µg/ml) or all three growth factors (anti-all-GF) antibodies.  After treatment 
cell number was measured as described in the Materials and methods 
section. Basal refers to medium (K-SFM) without TCDD; control refers to 
treatments in the absence of neutralizing antibodies. Data are means + SEM 
of three separate experiments assayed in triplicate. * indicates significantly 
different from within treatment control.  (B) and (C), NHEKs were grown to 
confluence in glass chamber slides and then treated for 72 h with TCDD (10 
nM) in the presence or absence of PD153035 (300 nM), an EGFR inhibitor. 
During the last 16 h cells were incubated with 10 µM EdU to label 
proliferating cells. (B) Representative confocal images of total (DAPI; blue) 
and EdU-staining nuclei (pink) at 20x magnification.  Basal refers to 
medium (K-SFM) without TCDD; control refers to treatments in the absence 
of PD153035. (C) Proliferative index is determined as the percentage of the 
total cell population labeled by EdU [(EdU labeled/DAPI labeled) x100].  
Data are means + SEM from counting five fields from three separate 
experiments. * indicates significantly different from the within treatment 




increased the percentage of the cell population that was proliferating (Fig. 8B,C).   
Inhibiting EGFR activity with PD153035 significantly reduced this percentage in both 
basal and TCDD-treated cells.  The increased percentage of EdU positive nuclei in 
TCDD-treated cells in the face of a total cell population comparable to that of basal 
cultures, suggests that TCDD-treated cultures have a larger proliferative capacity than 
basal cells even in these post-confluent cultures.      
4. Discussion 
 The epidermis regenerates constantly, requiring the concurrent expression of 
proliferative programming in the basal layer and differentiation programming in the 
suprabasal layers [16,17].  The EGFR and its ligands play critical roles in regulating the 
balance between proliferation and differentiation.  EGFR number is greatest in the basal 
layer of the epidermis where its activation promotes proliferation and declines as 
keratinocytes migrate suprabasally and undergo terminal differentiation [16,17].  The 
EGFR and its ligands establish an autocrine loop in the skin with receptor activation 
stimulating cell proliferation in the basal layer, and with decreases in EGFR levels as the 
cells migrate suprabasally and differentiate [11,16,17].  The environmental toxin TCDD 
alters this autocrine loop by promoting EGFR down-regulation [30-32] and enhancing the 
production of receptor ligands [24-26].  These apparently opposing responses have been 
used to explain the proliferative effects of TCDD (increased EGFR ligand production) 
and its ability to accelerate keratinocyte differentiation (EGFR down-regulation and loss 
of signaling).  However, in vitro studies have shown that the increase in ligand 
production occurs in the face of reduced receptor number, an effect that should alter the 
cells’ ability to respond to the ligands.  Since cellular responses to an agonist reflect the 
number of receptors activated [37], we were interested in understanding how a decrease 
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in receptor number accompanied by increased ligand production might mediate the 
effects of TCDD in NHEKs.  Using post-confluent NHEKs, we show that TCDD 
increases the production of TGF-α and EREG, and that down-regulation of EGFRs is 
mediated by AREG, EREG and TGF-α. In addition, we show that TGF-α promotes 
receptor recycling. These changes in receptor availability are associated with an increase 
in steady-state ERK activity that is ligand-dependent, as well as an increase in a small 
pool of proliferating cells which maintains total cell number.   
 Basal NHEKs increase their AREG production while producing only small 
amounts TGF-α and virtually no EREG.  Since basal cells are grown in the absence of 
added growth factors, these data indicate that AREG is the EGFR ligand maintaining 
these cells in the absence of exogenous growth factors [18-21].  These data are consistent 
with the observations of Piepkorn et al. [22] who showed that AREG is the most 
abundant and efficacious regulator of keratinocyte growth.  TCDD-treated keratinocytes 
produced comparable amounts of AREG but had elevated production of both TGF-α and 
EREG, responses also observed by Choi et al. [24] and Patel et al. [26].  These changes 
in all three ligands occur at the same time that receptor numbers are declining, arguing 
that one or more of these ligands mediates EGFR down-regulation in TCDD-treated cells.  
When we inhibited EGFR ligand release with the MMP inhibitor batimastat, receptor 
binding increased not only in TCDD-treated cells but also in basal cells, arguing that a 
ligand(s) is modulating the number of cell surface receptors in both cell populations. 
Subsequent experiments with ligand-neutralizing antibodies showed that the elimination 
of all three ligands reduced receptor number in both basal and TCDD-treated cells.  This 
was somewhat surprising as we expected the removal of all the ligands to relieve receptor 
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down-regulation.  In fact, neutralizing either AREG or EREG in TCDD-treated cells 
partially restored biotin-EGF binding; however eliminating TGF-α intensified receptor 
loss, a response also observed in basal cells.  Although AREG predominates in basal 
cells, at 72 hours, TGF-α is elevated in basal cells and markedly enhanced in TCDD-
treated cells, suggesting that TGF-α may maintain a pool of EGFRs at the cell surface in 
both basal and TCDD-treated cells.  This would be consistent with the ability of TGF-α 
to bias EGFRs to the cell membrane [47,50]. In fact, our observation that exogenous 
TGF-α increases EGFR binding at the cell surface supports this role of TGF-α, although 
these data must be interpreted cautiously as exogenous addition of ligands does not 
reflect the impacts of autocrine secretion of EGFR ligands [36].  TGF-α-induced 
increases in cell membrane-associated EGFRs has also been observed in prostate cancer 
cells where the ligand stabilizes EGFR mRNA and enhances the de novo synthesis of the 
receptor [51].  Vassar and Fuchs [52] showed that there were no major differences in 
EGFR levels in TGF-α-overexpressing mice compared to normal, demonstrating that 
TGF-α does not promote the loss of EGFRs.  Together these results demonstrate that the 
combined effects of the three ligands is to maintain a reduced number of receptors on the 
cell surface by causing down-regulation (AREG, EREG, and TGF-α and promoting 
recycling (TGF-α).   
 Receptor down-regulation is typically thought of as a way to for cells to modify 
their responses to continued agonist presence.  Differences in signaling dynamics (signal 
intensity, frequency, and duration) can encode specific cellular responses [34], as 
exemplified by studies from Joslin et al., [36] who showed that the autocrine production 
of EGFR ligands leads to a persistent reduction in EGFR number but a sustained 
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elevation in ERK activity that mediated an enhanced migratory response compared to that 
produced by exogenous EGF.  Likewise, we show that the TCDD-induced down-
regulation of EGFRs in NHEKs was accompanied by an elevation in ERK activity that 
was significantly greater than that in basal cells and maintained by the autocrine 
production of AREG, EREG, and TGF-α. The production of EGFR ligands also 
maintained ERK activity in basal cells, consistent with the findings of Iordanov et al.. 
[48].  In addition, these data indicate that TCDD alters an autocrine loop already present 
in keratinocytes by reducing receptor number with AREG, EREG, and TGF-α and 
maintaining cellular responsiveness to secreted ligands by TGF-α-induced receptor 
recycling.    
  Increases in ERK activity mediate a host of cellular responses including 
proliferation [53].  Both basal and TCDD-treated cells grow in the absence of exogenous 
growth factors, reflecting the ability of locally produced EGFR ligands to activate ERK 
and maintain total cell number.   However, the total number of cells in basal- and TCDD-
treated cultures were not significantly different. This result was not surprising as our 
monolayer cultures are post-confluent and more reflective of intact skin.  Neutralizing 
individual ligands had modest impacts on cell number in basal or TCDD-treated cells, but 
in both basal and TCDD-treated cells the response was greatest in cells treated with 
AREG antibodies, consistent with AREG being the most abundant and efficacious 
regulator of keratinocyte growth [22].  Cell number was significantly reduced in basal 
and TCDD-treated cells when all three ligands were neutralized. Since NHEKs stratify in 
this culture system, our data suggest that the EGFR ligands are required for the 
homeostatic replacement of cells lost to sloughing during the culture period in both basal 
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and TCDD-treated cells.  However, the complement and concentrations of EGFR ligands 
produced by basal and TCDD-treated cells was different, with TCDD causing a much 
larger increase in TGF-α production than observed in basal cells and stimulating the 
production of EREG.  Since hyperproliferation is a well-described response to TCDD in 
vitro [25,26,49] and in vivo [44], we asked whether or not  the TCDD could enhance the 
number of proliferating cells in the culture.  EdU labeling of basal and TCDD-treated 
cells indicated that both populations required a functional EGFR to maintain a small pool 
of proliferating cells.  In addition, TCDD-treated cells, which have a higher concentration 
of secreted TGF-α compared to control cells and produce EREG, show a greater 
percentage of EdU positive cells, indicating that these cultures have a greater 
proliferative capacity.  These data support the idea that the hyperproliferative effect of 
TCDD in NHEKs is the result of producing a larger population of proliferative cells 
within a differentiating epidermis.  Maintenance of this proliferative pool in basal cells 
reflects the ability of AREG to promote proliferation while the small amounts of TGF-α 
produce by these cells maintains receptor number and ligand responsiveness.  AREG and 
TGF-α would serve the same purpose in TCDD-treated cells, but the enhanced 
production of TGF-α and EREG is responsible for the increased size of the proliferative 
pool of cells in these cultures.   
In summary, our data indicate that TCDD alters an autocrine loop present in 
keratinocytes by enhancing the production of EGFR ligands and modifying EGFR 
trafficking to maintain the cells’ responsiveness to locally produced growth factors.  The 
alteration in EGFR number in TCDD-treated cells required AREG, EREG, and TGF-α 







Fig. 9.  TCDD alters the EGFR/ligand autocrine loop present in 
keratinocytes.  (A). TCDD-induced EGFR internalization in NHEKs 
reflects the combined effects of AREG, EREG and TGF-α, while TGF-α 
promotes EGFR recycling. This receptor pool preserves the cell’s ability to 
respond to the local production of AREG, EREG, and TGF-α leading to a 
sustained elevation in ERK activity compared to basal cells.  (B) The 
enhanced production of TGF-α and EREG enhances the proliferation of a 
small subset cells in the basal or suprabasal layers of the skin that serve to 





receptors at the cell surface. This receptor pool preserves the cell’s ability to respond to 
the local effects of AREG, EREG, and TGF-α leading to a sustained elevation in basal 
ERK activity and the maintenance of a pool of proliferating cells that can quickly respond 
to disruption of the culture and replace cells lost to sloughing of the stratifying  culture 
(Fig. 9).   
5. Conclusion 
  TCDD treatment of NHEKs produces a ligand-dependent decrease in EGFR 
number that is limited by the ability of TGF-α to promote receptor recycling.  These 
ligands and receptor changes enhance the activity of the autocrine loop that sustains the 
monolayer with TGF-α promoting EGFR recycling and upregulation as well as sustained 
levels of ERK activity that promote homeostatic replacement of cells during the culture 
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Conclusions and recommendations for future work 
Concluding remarks 
 
The role of EGFR in keratinocyte differentiation becomes increasingly complex 
as our understanding of receptor signaling dynamics and down-regulation evolves. But 
this work is not the first that argues EGFR plays a role in physiological or 
pathophysiological keratinocyte differentiation. Previous studies have shown that Ca-
induced inactivation of EGFR signaling is a result of PKC-dependent receptor 
phosphorylation (1)—a process in which activated EGFR create a negative feedback loop 
which leads to EGFR silencing (1) and is observed in migrating and differentiating 
keratinocytes both in vitro and in the upper layers of the epidermis in vivo (2, 3).  
TCDD similarly produces EGFR down-regulation and its signaling, a response 
which is correlated with keratinocyte differentiation. TCDD induces processes typically 
associated with keratinocyte differentiation, such as accelerated expression of markers o 
differentiation  and  lipid biosythetic genes in the epidermal differentiation complex (4-6) 
as well as increased functional markers of differentiation such as increases in percentage 
of cornified envelopes in vitro (4, 5, 7) and acceleration of epidermal barrier formation in 
utero (8, 9). These TCDD-induced phenotypes have been shown to be both inhibited by 
EGF and dependent upon the AhR (5, 6, 8). However, TCDD is also considered to be 
pro-proliferative, though these claims are more subject to experimental conditions 
endpoints (7, 10, 11) or suggest that TCDD functions in a proliferative capacity on subset 
of keratinocyte populations (12). However, the ability of TCDD to induce proliferation is 
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influenced by multivariate experimental cell culture conditions, timepoints, and cell 
lineages which complicate cross-study comparison which might otherwise suggest a 
mechanism. 
While TCDD and Ca both induce keratinocyte differentiation, the nature of the 
changes in gene expression and barrier function are distinct.  In this study, we address the 
ambiguity by examining Ca and TCDD effects in a single type of keratinocyte utilizing 
the same timepoints and downstream targets for EGFR regulation.  What is perhaps most 
novel about this work is that, by bringing together and expanding upon experiments 
performed over the years in differing cell lines, culture conditions, and over varying time 
courses (Table 1.7), we are able to directly compare how Ca and TCDD-treatment alter 
EGFR signaling relative to one another and provide insight into mechanistic differences 
in between the two that can be applied to future work investigating TCDD-treatment in 
high Ca.   
Loss of surface associated [
125
I]-EGF binding observed in Ca- and TCDD-treated 
cells and the extent of this down-regulation differed. More importantly, the ability to 
reverse downregulation differed by treatment. In our work, Ca-treated cells still had 41% 
of the surface-associated EGFRs observed in basal cells (Figure 2.1), a number similar to 
observations in literature (13, 14), and this appears to be sufficient for EGFR-dependent 
barrier formation and wounding response. However, TCDD-treated cells maintained 78% 
of surface associated EGFRs suggesting a much less pervasive down-regulation (Figure 
3.2). In both cases, the loss of EGFR was accompanied by elevated levels of EGFR 
ligands though the complement of secreted ligands differed. Denning et al. showed that 
Ca increased TGF-α mRNA nearly 30-fold--though did not look at protein (1). Our work 
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expands on this to show that TGF-α protein increased following not only treatment with 
high Ca (Figure 2.2) , but also TCDD in low Ca conditions (Figure 3.4) which had been 
suggested though not directly shown in keratinocytes (15, 16).  In this work, Choi et al. 
(16) identified TGF-α in keratinocyte-conditioned medium but tested EGFR down-
regulation through the use of EGF. Additionally, explaining this down-regulation of 
EGFR as entirely TGF-α-dependent fails to recognize the contribution of other EGFR 
ligands: AREG and EREG which were not investigated (or in EREG’s case, known) at 
the time. We found that TCDD-treated cells secreted elevated levels of EREG (Figure 
3.4) while AREG secretion increased in all cells, including basal cells over time in 
culture. While the presence of secreted ligand in basal cells provides a clear mechanism 
of EGFR activation, in differentiating cells, ligand secretion creates a seemingly 
paradoxical environment where surface associated EGFR is reduced in the presence of 
elevated receptor ligands.  
This offers some insight into mechanisms of epidermal plasticity. Even within the 
differentiated, intact epidermis, an extracellular environment rich in proliferative ligands 
facilitates epidermal migration and re-epithelialization in response to wounding or UV 
damage (17-19) as well as promotes neoplasia and hyperproliferative disease states (3, 
20).  In the differentiated epidermis, EGFR occupancy by juxtacrine EGFR ligands is an 
important maintenance and anti-anoikos signal for the intact epidermis (21).  Its 
disruption in wounding or disease leads to ligand shedding and the release of EGFR for 
ligand binding and internalization (22, 23). Soluble AREG leads to activation of the pro-
proliferative ERK signaling pathway (22, 24) which is inhibited by Dsg1 at the intact 
desmosome (25). Without disruption, membrane-associated AREG prevents 
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internalization and signals through the anti-apoptotic PI3K at the cell membrane  (26, 27) 
or the EGFR silencing PKC (21, 28, 29) which colocalizes to the desmosome (30).  
Cleavage of membrane–associated pro-EGFR ligands, important in wound 
healing, maintains a proliferative capacity in confluent cell populations (31). In the 
differentiating epidermis, MMP-dependent EGFR-ligand shedding is critical to the 
maintenance of the epidermal barrier. ADAM17 -/- null mice develop barrier defects 
after birth and chronic dermatitis as adults and resemble mice with targeted epidermal 
knockout of EGFR (29).   Similar to the aforementioned knockout phenotype, EGFR 
down-regulation within the differentiating epidermis is not complete.  In fact, prolonged 
exposure to low level ligands is a mechanism for spatial and temporal regulation of 
receptor signaling (32). 
It was found, when neutralizing these ligands, that TCDD-induced loss of surface 
associated EGFR was reversible following removal of AREG or EREG by neutralizing 
antibodies of ligand cleavage through the use of a broad spectrum MMP inhibitor 
(Figure 3.6). However, neutralization of ligands in any combination in Ca-treated cells 
showed EGFR binding loss to be ligand independent (Figure 2.4). Signaling capacity of 
cells under these two conditions proved to be different as well: ERK signaling in Ca-
treated cells was ~55% that of basal cells at 72 hours, and neutralization of EGFR ligands 
was unable to restore it to basal levels (Figure 2.3). Conversely, TCDD-treated cells, 
with 22% fewer surface-associated EGFRs than the basal cells, had elevated ERK 
activity that was attenuated by the use of batimastat or neutralization of all three ligands 
(TGF-α, EREG, and AREG) (Figure 3.7).  
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Figure 1. Comparison of endpoints for Ca- and TCDD-treated cells.Summarizing 
findings relating to EGFR down-regulation, EGF-like ligand secretion, basal ERK 







Finally, the impact of Ca and TCDD on cellular proliferation was also distinct. 
Ca-treated cells showed a decrease in total cell number (Figure 2.5), TCDD-treated cells 
had similar number to control cells (that was reduced in a ligand-manner (Figure 3.8) as 
well as showed a higher proliferative capacity as measured by EdU labelling. Still, 
neutralization of EGFR ligand secretion in all treatments led to a significant and marked 
decrease in proliferative capacity, suggesting that EGFR signaling, even in differentiating 
cells is an essential part of this system. The continued presence of the EGFR may allow 
Ca-dependent cells to maintain a proliferative population and in TCDD-treated cells, 
where EGFR down-regulation is ligand-dependent, explain how TCDD can 
simultaneously mimic portions of epidermal differentiation while simultaneously 
maintain proliferative-capacity.   
Marked differences (Figure 1) in ability of ligands to account for changes in 
EGFR down-regulation, signaling, and proliferation observed following Ca- and TCDD-
treatment  suggest that Ca-induced alterations to EGFR localization and signaling are to a 
large degree, ligand-independent and therefore mechanistically distinct to the changes 
observed following TCDD exposure and therein may lie the difference in Ca- versus 
TCDD-induced keratinocyte differentiation. Cell number, while maintained by EGFR 
dependent proliferative capacity which maintained by a small portion of NHEKs is in 
both cases ligand-dependent, however, it the complement of ligands which impact how 
strongly this effect is.  
Taken together, our data lead us to two important conclusions on Ca- and TCDD-
induced differentiation.  
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1. That EGFR down-regulation observed in both Ca and TCDD-treated cells 
does not correlate with a loss of proliferative capacity though its effects on 
ERK activation  and cell number differ.  
2. Down-regulation observed in Ca- versus TCDD-treated cells is 
mechanistically different: neutralization of EGFR ligands leads to reversal of 
EGFR binding and altered ERK activation in TCDD-treated cells, while 
down-regulation in Ca-treated  cells is ligand independent 
 
 However, the difference may not be so clearly defined as physiological versus 
pathophysiological differentiation. The difficulty of exploring the contradictory 
proliferative and differentiating role of TCDD in the epidermis through the use of 
monolayer keratinocyte culture of keratinocytes pidermally, Ca is not present in the 
dichotomous form of “high” or “low” within the epidermis. Instead, Ca represents a 
complex gradient with low Ca basally and higher Ca suprabasally (37, 38).  Comparison 
of high Ca and TCDD compares cells under pro-differentiating and pro-proliferating, low 
Ca conditions respectively.   
It is difficult therefore, to parse whether the ability of TCDD treated cells is due to 
the fact that cells in low Ca better replicate the effects of TCDD on basal cells compared 
to high Ca better representing the Suprabasal layers of the epidermis. This work performs 
the necessary examinations into the differing role of Ca and TCDD on EGFR down-
regulation, and and signaling within the epidermis which paves the way for deeper 
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Fig. A1. HB-EGF in NHEK-conditioned medium is below detectable 
limits. NHEKs were treated for increasing times with Ca (1.8 mM) and 
culture medium was collected.  HB-EGF (A) standard curve and (B) medium 
concentration were determined by ELISA assay. Standard curve represents 
means of one assayed in duplicate. In both control and Ca-treated NHEK-
conditioned medium, HB-EGF concentration was below detectable levels in 
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Fig. A2. Reducing EREG availability has no further effect on Ca-
induced EGFR down-regulation. NHEKs were treated with or without Ca 
(1.8 mM) for 72 h in the absence or presence of neutralizing antibodies for 
AREG (15 µg/ml), EREG (5 µg/ml), TGF-α (5 µg/ml), or all three growth 
factors (anti-all-GF) for 72 h. The measurement of biotin-EGF binding was 
then determined as described in the Material and methods section. Basal 
refers to medium (K-SFM) without Ca; control refers to treatments in the 
absence of neutralizing antibodies. Data are means + SEM of three 
experiments assayed in triplicate, normalized to crystal violet staining, and 
reported as the % biotin-EGF bound in basal control cells.  (a)  indicates 
significantly different from the basal control at p (< 0.05). * indicates 
significantly different from the within treatment control (p <0.05) and 
indicates that anti-EREG together or separately do not have a significant 









Cells were grow and  treated as described in the body of this Dissertation unless 
otherwise mentioned.  Briefly, fifth passage NHEKs were grown to confluence, switched 
to basal K-SFM for 48 hours then treated with K-SFM with 1.8 mM Ca, 10 nM TCDD, 
or both 1.8 mM Ca and 10 nM TCDD. Neutralizing antibodies and inhibitors were used 
at the same concentrations described in text and figure legends.  
Protocols for [
125
I]-EGF binding, PACE assays, biotin-EGF binding, and EdU 
labelling were performed as addressed in the body of this work.  
Determination of cell number 
In lieu of double stranded DNA analysis, relative cell number was determined via 
crystal violet staining as described by Kueng et al (1989). Briefly, formaldahyde fixed 
cells were washed and stained with 0.04% crystal violet (Sigma Aldrich, St. Louis, MO) 
(w/v) in 4% ethanol  (Kueng, et al., 1989; Kramer, et al., 2008) . Cells were lysed 
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Figure 1.  TCDD/Ca caused sustained  [
125
I]-EGF binding loss. NHEKs were 
grown as described in the body of this Dissertation then (A) treated for the times 
indicated with EGF (100 ng/ml) or TCDD/Ca (10 nM/1.8 mM) for 4-72 h then 
[
125
I]-EGF binding was determined as described in . Data are expressed as the % 
time-matched control (TMC) and reported as the means + SEM of three experiments 
assayed in triplicate.  (B) TCDD/Ca co-treatment reduces [
125
I]-EGF binding below 
beyond TCDD or Ca alone. NHEKs were treated for 72 h with 1.8 mM Ca, 10 nM 
TCDD, or TCDD/Ca then [
125
I]-EGF binding was determined.  Data are expressed 
as the % TMC and represent means + SEM of three experiments assayed in 
triplicate. The dashed line in (A) and (B) indicates 100%. * indicates significantly 
different from time-matched control (TMC) (p<0.05), a indicates significantly 
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Figure 2.  The effect of TCDD, Ca, and TCDD/Ca on TGF-α and AREG 
secretion. NHEKs were treated for 4, 24, or 72 h with TCDD/Ca (10 nM/1.8 mM), 
and conditioned medium was collected. (A) TGF-α or (B) AREG content were 
determined by ELISA as described in the body of the Dissertation.  Data are means 
+ SEM of three experiments assayed in duplicate. EREG has not been investigated 









b a s a l T C D D /C a
0
c o n t
b a t
































Figure 3.  The effect of TCDD/Ca on ERK activation. NHEKs were treated for 72 
h with TCDD/Ca (10 nM/1.8 mM) in the presence or absence of batimastat (bat; 3 
M) or the EGFR inhibitor, PD153035 (300 nM) and basal ERK activity was 
measured at 72 h via PACE assay as described in the body of this Dissertation. (A) 
TGF-α or (B) AREG content were determined by ELISA as described in the body of 
the Dissertation.  Data are means + SEM of three experiments assayed in triplicate 
normalized to basal control cells, though PD153035 represents duplicate 
experiments.. *,** indicates significantly different from the within treatment control 
(p<0.05 and p<0.01, respectively). † indicates significantly different from the basal 
control (p <0.05).  The dashed line indicates the basal control. Role of individual 
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Figure 4.  Reducing TGF-α availability modifies EGFR down-regulation. 
NHEKs were treated with or TCDD/Ca (10 nM/1.8 mM) for 72 h in the absence or 
presence of batimastat (bat; 3 μM) or neutralizing antibodies for TGF-α (5 μg/mL), 
AREG (15 μg/mL), or both for 72 h followed by the measurement of biotin-EGF 
binding as described in the body of this Dissertation. Basal refers to K-SFM without 
TCDD/Ca; control refers to treatments in the absence of batimastat or neutralizing 
antibodies. Data are means + SEM of six experiments assayed in triplicate, 
normalized to crystal violet staining, and reported as the % biotin-EGF bound in 
basal cells.  a indicates significantly different from the within treatment control (p 
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Figure 5:  Inhibiting EGFR activity or reducing TGF-α availability have 
distinct effects on DNA synthesis and cell number. NHEKs were grown to 
confluence in glass chamber slides and then treated for 72 h with TCDD (10 nM), 
Ca (1.8 mM), or TCDD/Ca (10 nM/1.8 mM) in the presence or absence of 
PD153035 (300 nM), an EGFR inhibitor. During the last 16 h they were incubated 
with 10 mM EdU and labeled as described in the body of this Dissertation. (A) 
Representative confocal images of total (DAPI; 405 nm, blue) and EdU-staining 
nuclei (647 nm, pink) at 20x magnification.  (B) Proliferative index of Edu positive 
nuclei per field (EdU labeled/DAPI labeled).  Data are means + SEM from 
quantifications of five fields from three separate experiments. * indicates 
significantly different from the within treatment control (p<0.05 and p< 0.01 
respectively). (C) NHEKs were grown to confluence and then treated for 72 h with 
TCDD, Ca, or TCDD/Ca in the presence or absence of neutralizing antibodies for 
TGF-α (5 μg/mL), AREG (15 μg/mL), or both.  After treatment, cells were fixed in 
4% formaldehyde and stained with 0.04% crystal violet as described in the 
Supplemental Methods. Data are means + SEM of three separate experiments 
assayed in triplicate and reported as percentage of time-matched control. a  indicates 
significantly different from the basal control (p<0.05). The dashed line indicates 
100%. 
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Table 1. Comparison with TCDD and Ca treatments 
Characteristic TCDD Ca TCDD/Ca 
EGFR down-regulation Ligand-
dependent 
Ligand-independent Ligand-dependent (?) 











Cell number Reduced  No change Increased (crystal violet) 









 sandwich ELISA-based arrays as a screen for NHEK-secreted 
ligands, changes in ErbB receptor complement, and ErbB phosphorylation At 
common sites 
 
EGFR ligands in NHEK conditioned medium 
Design and methology  
Before pursuing whether EGFR down-regulation occurred through a ligand-
dependent or independent mechanism, we first needed to know whether or not EGF-like 
ligands recognized by the EGFR were available at our experimental timepoints. In order 
to assess which if any EGFR ligands were available in NHEK-conditioned medium, we 
designed a custom ligand array from RayBiotech (Norcross, GA). Ligands were selected 
via TCDD-induced fold change in a keratinocytes microarray (1), literature search, and 
ligand availability. Literature was searched alongside Raybiotech antibody availability by 
utilizing PubMatrix (2), an NCBI literature mining tool.  At the time, available ligands 
(n=292) were searched in pubmed against the terms: epidermis, keratinocyte, epidermal 
differentiation, skin, psoriasis chloracne, TCDD, epidermal disease, EGFR, calcium, and 
EGFR transactivation. Ligands were then ranked on a scale of 0-6 in each search wherein 
0 was no results 1 < 10 related articles, 2 < 25 related articles, 3 < 50 related articles, 4 < 
100 related articles, 5 < 500 related articles, and 6 < 1000. Within the top 100, we found 
TGF-α (ranked 5
th
), AREG (ranked 44
th
), HB-EGF (ranked 24
th




Capture antibodies for custom arrays were pre-dotted on nitrocellulose paper. 
Upon receipt, samples were incubated for 30 minutes at room temperature with 
proprietary blocking buffer before being incubated with 1 mL of cell culture conditioned 
medium for two hours at room temperature. Membranes were then washed five times 
with two proprietary washing buffers and incubated for one hour at room temperature 
with a mixture of biotin-conjugated anti-cytokine antibodies, washed again, and 
incubated for two hours with HRP-conjugated streptavidin. Membranes were then 
washed and developed via enhanced chemiluminescence on x-ray film. Film was scanned 
and spots quantitated using ImageJ software. Values are reported as arbitrary units (AU) 
that have been background subtracted and normalized to positive controls. Each 
membrane contained duplicate spots for each ligand and due to cost and the fact that this 
experiment served as a screening tool, each treatment x timepoint was performed on one 
membrane. 
Identification of NHEK-secreted ligands  
 We found that TGF-α, HB-EGF, and AREG were secreted in cells under our 
treatment conditions (Figure 1). BTC had significant background even on the negative 
control membrane (incubated with basal K-SFM), suggesting it reacted to a component of 
the media. Regardless, no BTC effect was found. TGF-α increased 1.58-fold over basal in 
Ca treated cells, 2.49-fold in TCDD-treated cells, and 2.95-fold in TCDD/Ca-treated cells 
comparable to the 2.83-fold and 3.22-fold observed in Ca and TCDD-treated cells via 
ELISA (Figure 1). However, HB-EGF increased 1.97-fold, 2.58-fold, and 2.86-fold in 
Ca, TCDD, and TCDD/Ca-treated cells however was not detected in a ELISA for human 
HB-EGF with a lower detection limit of 6.55 pg/mL. AREG increased 1.18, 1.81, and 
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1.97-fold in Ca, TCDD, and TCDD-treated cells.  EREG was not examined as it was not 
available at the time of this screen, however an ELISA assay became available after this 
initial screening and EREG was also analyzed. ERK activation or binding loss in TCDD-
treated cells.  
Changes in phosphorylation of common sites on EGFR, ErbB2, and ErbB3 in 
NHEKs  
Design and methology 
To investigate how EGFR phosphorylation was altered, we first examined 





 Figure 1. EGFR ligands increased in NHEK-conditioned medium. NHEKs were 
grown as described in Methodology TGF-α, HB-EGF, and AREG were assayed on a 
custom sandwich ELISA-based array. Antibody arrays were developed via (A) 
autoradiography and (B) quantitated via ImageJ. Data are representative of one 
experiment assayed in duplicate and background subtracted. Betacellulin (BTC) was 
also assayed but due to high non-specific binding on the control blot, we were unable to 






Table 1. Fold change in phosphorylation of tyrosine, serine, and threonine residues 






















Y845 Phosphorylated by Src.  
Activates Ras and Stat5 
48.92 ND +2.15 -1.39 +3.63 
Y992 Phosphorylated by EGFR/ErbB2. 
Activates STAT3, PKC, Erk, Vav2 
31.11 ND +1.46 -1.52 +9.64 
Y1045 Phosphorylated by EGFR/ErbB2. 
Recruits c-Cbl for ubiquitinylation 
31.67 -ND +1.79 -2.71 +9.66 
Y1068 Phosphorylated by EGFR/ErbB2 
Ras, STAT3, c-Jun, AP-1  
14.86 ND ND ND ND 
Y1086 Phosphorylated by ErbB receptors, 
Activates Ras, STAT3, c-Jun, and 
AP-1 
ND ND ND ND ND 
Y1148 Unknown phosphorylation 
mechanism. Activates MAPK, 
STAT1, and AP-1 
30.27 ND ND ND - 9.01 
Y1173 Autophosphorylated.  
Activates MAPK, PLCγ, Shp2 
25.92 ND ND ND +3.09 
S1046 Phosphorylated by Cam Kinase II. 
Causes c-Cbl-independent 
internalization/ubiquitinylation 
22.02 ND ND ND +5.62 
S1070 Phosphorylated by Cam Kinase II. 
Causes c-Cbl-independent 
internalization/ubiquitinylation 
ND ND ND ND ND 
ErbB2 
phospho-site 
Function Basal EGF Ca TCDD TCDD/Ca 
Y887 Phosphorylated by Src  
Activates STAT3 and PKA 
2.46 ND ND ND ND 
Y1112 Phosphorylated by EGFR/ErbB2. 
Recruits c-Cbl for ubiquitinylation 
ND ND ND ND ND 
Y1221 Shc, ErbB2 3.53 ND ND ND ND 
Y1248 Phosphorylated by unknown 
mechanism.  
Activates Shc and ErbB2 
11.46 ND +6.95 +3.61 ND 
T686 Phosphorylated by PKC.  
Leads to internalization 
ND ND ND ND ND 
S1113 Phosphorylated by Cam Kinase II.  
Unknown function 




Function Basal EGF Ca TCDD TCDD/Ca 
Y1299 Phosphorylated by an unknown 
mechanism.  
Activates PI3K 




Raybiotech, we assayed changes in the phosphorylation of thymine, serine and threonine 
residues. 
Capture antibodies were pre-dotted on nitrocellulose paper for phosphosites on 
ErbB1, ErbB2, and ErbB3.  Upon receipt, NHEKs grown for 72 hours in the presence of 
EGF (100 ng/mL), Ca (1.8 mM), TCDD (10 nM), or TCDD with 1.8 mM Ca (TCDD/Ca) 
were lysed in proprietary lysis buffer and quantitated using a Micro-BCA assay (Pierce 
Biotechnology, Rockford, IL) and equal amounts of protein were incubated for 2 hours at 
room temperature on membranes that had been pre-blocked for 30 minutes at room 
temperature with proprietary blocking buffer. Membranes were then washed five times 
with two proprietary washing buffers and incubated for one hour at room temperature 
with a mixture of biotin-conjugated anti-cytokine antibodies, washed again, and 
incubated for two hours with HRP-conjugated streptavidin. Membranes were then 
washed and developed via enhanced chemiluminescence on x-ray film.  
 Film was scanned and spots quantitated using ImageJ software. Values are 
reported as arbitrary units (AU) that have been background subtracted and normalized to 
positive control. Each membrane contained duplicate spots for each ligand and due to 
cost and the fact that this experiment served as a screening tool, each treatment x 
timepoint was performed one membrane. 
Identification of ErbB phosphorylation sites 
We found that most altered sites following Ca, TCDD, or TCDD/Ca were on 
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Figure 2. Phosphorylation sites on the EGFR at 72 hours.  Keratinocytes 
were treated for 72 hours with EGF (100 ng/mL), Ca (1.8 mM), TCDD (10 
nM), or TCDD/Ca. Not shown, Y1068, which had no detectable result. Data 
represent one experiment with duplicate spots. Data are background 
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